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Parkinson’s disease is a neurodegenerative disease that affects 
approximately 1% of people over the age of 60. In the rapidly aging 
population of the Western world, this represents an increasingly heavy 
social and economic burden. Along with related synucleinopathies, 
Parkinson’s disease is genetically and pathologically linked to the 
presynaptic protein alpha-synuclein, which aggregates in 
intraneuronal Lewy bodies in patients. Aside from its interaction with 
synaptic vesicles, which implicates alpha-synuclein in regulation of 
synaptic vesicle exocytosis, the normal function of this protein is not 
well understood. In dilute aqueous solution, alpha-synuclein contains 
no stable secondary or tertiary structure, making it a member of the 
class of intrinsically disordered proteins; however, much of alpha-
synuclein undergoes a disorder-to-helix transition when binding to 
lipid membranes. Alpha-synuclein is also post-translationally modified 
in vivo, in the form of ubiquitous and permanent N-terminal amine 
acetylation and transient phosphorylation on several serine and 
tyrosine residues. How these modifications play into the role of alpha-
synuclein is also unclear. The effects of N-terminal acetylation and 
phosphorylation of tyrosines 39 and 125 on alpha-synuclein structure 
in the free state were assessed using NMR and CD spectroscopy, as 
were the effects on binding to synthetic lipid vesicles and membrane-
  
mimetic detergent micelles. N-terminal acetylation increases helicity at 
the very N-terminus of alpha-synuclein in the free state; this effect 
propagates into the membrane-bound state, with the acetylated 
protein displaying stabilized helicity at the N-terminus and tighter 
binding to more curved lipid vesicles with lower, more physiologically-
relevant proportions of negatively-charged lipids, similar to synaptic 
vesicles. The modified protein binds to β-octyl-glucoside micelles in a 
previously unknown, partly helical conformation that may serve as a 
model for in vitro studies of pathogenic intermediates. In contrast, 
phosphorylation at tyrosine 39 has minor effects on the disordered 
state but greatly perturbs the lipid-bound protein, with the C-terminal 
half of the lipid-binding domain detaching from the membrane. This 
phosphorylation event may thus control rearrangements of alpha-
synuclein molecules bound to membrane surfaces at the synapse, and 
play an important role in the native function of alpha-synuclein, 
knowing which is key to making progress in understanding 
Parkinson’s disease. 
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I. Introduction 
 
In biological systems, proteins rarely act alone. On the contrary, 
they typically interact directly with other proteins, nucleic acids, lipids 
and/or small molecule ligands in order to carry out their biological 
functions. Usually, the physicochemical peptide properties combined 
with the native fold of a protein determine the type and strength of a 
protein’s interactions with its binding partners. In an additional level 
of regulation, these interactions are frequently modulated by post-
translational modifications, some static and others dynamically added 
and removed in a spatiotemporally-controlled manner. Thus, the 
specific cellular context of a protein can have a pivotal effect on its 
conformational state and can direct its interactions with binding 
partners. In addition to protein properties and modifications, the 
environment a protein inhabits can also play a role in modulating the 
interactions the protein undertakes. One very important and 
commonly encountered environment is the interface between the cell 
cytosol and a bounding lipid membrane. Many protein-protein 
interactions, enzymatic reactions, and signaling events occur in this 
environment and are profoundly affected by it in many ways yet to be 
fully elucidated. My thesis work addresses a small subset of these 
membrane-mediated interactions, specifically in the case of the 
Parkinson’s disease-associated protein alpha-synuclein. 
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I.a. Parkinson’s disease 
 
Parkinson’s disease (PD) is a neurodegenerative disease, 
affecting most notably the dopaminergic neurons of the substantia 
nigra pars compacta, that affects approximately 1% of people over the 
age of 60 [1]. In the rapidly aging population of the Western world, this 
high incidence represents a heavy social and economic burden that 
will only get worse with time. The loss of dopaminergic neurons affects 
the neuronal connections between the substantia nigra and striatum, 
which eventually innervates the motor cortex, thus being responsible 
for the motor dysfunctions evident in PD [2]. The majority of PD cases 
are idiopathic, usually arising in an age-dependent manner, but also 
showing some correlation to environmental factors [3]. One of the 
pathological hallmarks of idiopathic PD is the appearance of Lewy 
bodies, intra-neuronal aggregates containing several proteins, the 
most abundant of which is alpha-synuclein, in the brain [4,5]. The 
majority of the alpha-synuclein protein in Lewy bodies exists in highly-
structured, beta-sheet-rich aggregates known as amyloid fibrils [6–8]. 
Additionally, five point mutations (in order of discovery: A53T, A30P, 
E46K, H50Q, G51D) [9–13] in and duplications [14] or triplications [15] 
of the alpha-synuclein gene (SNCA) have been linked to familial, early-
onset, autosomal dominant forms of Parkinson’s disease and other 
neurological diseases termed “synucleinopathies.” These results, 
supported by recent GWAS studies [16,17], suggest a connection 
between alpha-synuclein and the etiology of PD. 
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Although the genetic link between alpha-synuclein and PD is 
quite strong, the precise nature of this link is unclear. Appearance of 
Lewy bodies seems to correlate with disease; however, there has been 
debate as to whether the mature amyloid fibrils found in Lewy bodies 
are toxic [7] or relatively benign endpoints for the actually toxic proto-
fibrils or amorphous aggregates formed during the aggregation of 
monomers into mature fibrils [18,19]. Adding to the confusion, the 
primary biological function of alpha-synuclein is not well-established; 
therefore, it is as of yet impossible to determine whether a loss of 
native synuclein function or a toxic gain of function of the aggregates 
is the leading cause of PD. 
 
I.b. Alpha-synuclein overview 
 
Alpha-synuclein has been studied in biochemical and cell-based 
assays for many years since its discovery and subsequent association 
with neurodegenerative disease. The first synuclein was discovered in 
the electric organ of the electric ray Torpedo californica, and soon rat 
homologues were isolated [20,21]. The name “synuclein” derived from 
its originally observed localization to synapses and the perinuclear 
region of neurons. In the next few years, synucleins in various 
organisms were “discovered” as either brain-expressed 
“phosphoneuroproteins” [22,23], precursors of amyloid fibril 
components [24,25], or, in one study, as a protein downregulated 
during song learning in the zebra finch [26]. Eventually, these early 
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data were synthesized to reveal a family of synuclein proteins: alpha-
synuclein – mostly expressed in the brain and involved in PD; beta-
synuclein – mainly expressed in the brain and reportedly protective 
against aggregation; and gamma-synuclein – mainly expressed in the 
peripheral nervous system and brain but present in many other 
tissues, with a later link to cancer [27–33]. 
 
Figure 1.1: Primary sequence of human alpha-synuclein. The 
consensus KTKEGV repeats are bolded. Positively-charged and 
negatively-charged residues are in blue and red, respectively, while 
aromatic residues are in magenta. PD-linked point mutations are in 
green above the wild-type sequence. The C-terminal tail and 
hydrophobic non-almyloid component (NAC) region are marked. 
One of the earliest observations about the alpha-synuclein 
primary amino-acid sequence was the existence of seven imperfect 11-
residue repeats, containing the consensus sequence KTKEGV, in the 
N-terminal region (Figure 1.1). These repeats were noted to be similar 
to those of the exchangeable apolipoproteins, which form amphipathic 
helices and mediate reversible lipid interactions [34–36], leading to the 
hypothesis that alpha-synuclein binds membranes as part of its 
cellular function [26]. Indeed, early cell biological and biochemical 
studies revealed an association with synaptic terminals and 
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synaptosomes [21–23,26,37–39]. At around the same time, single point 
mutations in the alpha-synuclein gene were discovered in patients 
with genetic, early-onset forms of PD. The first mutation discovered 
was A53T, quickly followed by A30P. The A30P mutation was found to 
abrogate membrane binding of alpha-synuclein, suggesting a possible 
pathway of pathogenesis of the mutant; however, in the same study, 
the A53T mutant did not show any decrease in vesicle binding, 
indicating that the mutations either cause disease through different 
pathways, or that membrane binding perturbations are not on-
pathway to the disease state [39]. 
Another interesting feature of alpha-synuclein discovered in the 
first decade of study was its apparent lack of stable secondary or 
tertiary structure when isolated in dilute aqueous solution, making it 
one of the first of a class of proteins originally termed “natively 
unfolded” and now referred to as “intrinsically disordered” [40,41]. 
Despite its deposition in an aggregated form in diseased brains, the 
isolated recombinant protein was determined to be monomeric, 
although it appeared as a larger species by SDS-PAGE gel (~19 kDa) 
and size exclusion chromatography (~70 kDa). This large apparent size 
was attributed to its disordered and dynamic nature [40,41]. 
 
I.c. Alpha-synuclein free-state properties 
 
Given the unexpected intrinsically disordered nature of alpha-
synuclein, much of the next decade was dedicated to examining any 
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indications of transient or residual structure in the free monomer of 
alpha-synuclein. Given its ability to query structural and dynamical 
properties in a residue-specific manner, NMR spectroscopy emerged as 
a valuable tool in the study of alpha-synuclein as well as many other 
intrinsically disordered proteins. Using NMR approaches that had 
been developed for structured proteins, several research groups 
reported weak but detectable helical propensities near the N-terminus, 
most notably between residues 20 and 30, in the dynamic ensemble of 
conformations adopted by free alpha-synuclein [42,43]. The disease-
associated A30P mutation was shown to decrease this helical 
propensity, but no clear link between local transient structure and 
aggregation propensity has emerged [43–46]. 
Additionally, transient intramolecular contacts between the 
positively-charged N- and negatively-charged C-terminal regions, likely 
mediated by electrostatics, were detected by paramagnetic relaxation 
enhancement (PRE) NMR experiments [28,47,48]. These transient 
contacts were originally hypothesized to be protective against 
aggregation and thought to be lost in the disease-linked mutants A30P 
and A53T [48,49]. However, a more careful comparison of these 
contacts in wild-type and mutant alpha-synuclein showed that the 
A30P and A53T mutations do not alter transient N- to C-terminal 
contacts in alpha-synuclein, and the E46K mutation actually slightly 
enhances them [44]. Moreover, the effect of the disease-linked 
mutations on fibrillization rate is not the same, with A53T and E46K 
increasing it and A30P decreasing it [50,51]. It has been postulated 
that the disease-linked mutations may have similar effects on oligomer 
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formation rather than mature fibril formation [51]; however, there is 
presently no unified theory of the etiology of Parkinson’s disease that 
encompasses all known alpha-synuclein mutants. 
NMR can be used to measure dynamical properties and two of 
the most informative measures of backbone motions on the 
picosecond-nanosecond timescale are the R2 relaxation rate and the 
steady-state heteronuclear NOE. Alpha-synuclein in aqueous solution 
displays R2 (~4 sec-1) and heteronuclear NOE (~0.2) values consistent 
with a highly disordered polypeptide exhibiting a high degree of motion 
[43]. A slight peak in the R2 rate, corresponding to slightly more 
rigidity, was seen around residue 20, and a decrease in both R2 and 
steady-state heteronuclear NOE values, corresponding to greater 
mobility, was seen in the C-terminal half of the N-terminal region, 
which forms the fibril-forming core, generally considered to consist of 
approximately residues 30-100 [52,53]. Most of the NMR-based 
structural studies contributing to the intrinsically disordered view of 
alpha-synuclein have been performed on purified recombinant protein 
at dilute concentrations in aqueous buffer; however, there is evidence 
that alpha-synuclein adopts a very similar disordered conformation in 
live intact E. coli cells [54]. 
 
I.d. Alpha-synuclein binding to membranes 
 
Alpha-synuclein was shown to bind to synthetic phospholipid 
vesicles in vitro with a concomitant induction of helical structure [55–
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57]. The increased affinity of alpha-synuclein for vesicles containing 
phospholipids with negatively-charged headgroups was demonstrated 
both qualitatively and quantitatively [55,58–62]. For example, one 
quantitative fluorescence correlation spectroscopy study found 
apparent KD values of 1.7 mM and 100 μM, for alpha-synuclein 
binding to synthetic vesicles composed of 100% POPC and a 
combination of 50% POPC and 50% POPS, respectively [61]. The size of 
phospholipid headgroup, proposed to correlate with existence of lipid 
packing defects, and level of saturation of the acyl chains were also 
found to influence alpha-synuclein binding, with alpha-synuclein 
binding more tightly to membranes containing phospholipids with 
smaller headgroups, such as PE and PA, and to those containing 
unsaturated fatty acyl chains [59,61]. Finally, vesicle curvature also 
plays a role, with alpha-synuclein having a strong preference for more 
highly curved (and therefore smaller) vesicles, similar to synaptic 
vesicles [55,61,63]. For instance, alpha-synuclein displays apparent 
KD values of 170 μM and 6 μM for synthetic vesicles composed of 50% 
POPC and 50% POPS with diameters of 116 and 46 nm, respectively 
[61]. 
A tandem calorimetric and structural (CD) study revealed that 
binding of alpha-synuclein to vesicles containing lipids in a partially 
ordered gel state (DPPC) results in increased ordering of the lipids and 
a greater release of heat than can be explained by the disorder-to-helix 
transition that accompanies binding [59]. These results led to the 
hypothesis that alpha-synuclein can preferentially bind to defect 
structures that are present in the highly-curved, partially-ordered 
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membranes, resulting in “defect healing.” Lipid packing defects are 
structures arising from the exposure of hydrophobic regions of the 
lipid bilayer to the aqueous solution due to lipid molecules that do not 
conform to the canonical cylindrical shape [64]. Thus, defects are often 
associated with smaller lipid headgroups (such as PE and PA), 
“kinked” unsaturated acyl chains, and stress arising from high 
curvature. Membranes containing lipid packing defects are often found 
in the early secretory pathway, while “late membranes,” including the 
plasma membrane and secretory/synaptic vesicles, where alpha-
synuclein is expected to act, tend to contain more charged lipids and 
fewer packing defects, partially due to the increased concentrations of 
sterols, which improve lipid packing [64]. 
Alpha-synuclein has also been shown to localize to various 
membrane structures in cultured cells and other cellular systems. 
When alpha-synuclein was originally isolated, it was found to localize 
to presynaptic nerve terminals, specifically clustered around (~70 nm 
diameter) vesicular structures, by immunogold staining and electron 
microscopy [21]. In an in vitro assay, alpha-synuclein (but not the 
A30P mutant) was shown to bind to isolated synaptic vesicles from rat 
brain [39]. Additionally, a significant proportion of alpha-synuclein 
(~15%) co-fractionated with membranes in a differential centrifugation 
scheme on rat brain homogenates [65]. In cultured cells pre-loaded 
with high concentrations of fatty acids, alpha-synuclein (but not the 
A30P mutant) localized to lipid droplets as well as the plasma 
membrane [66]. When heterologously expressed in yeast, alpha-
synuclein localizes to the plasma membrane as well, although 
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increased copies of the alpha-synuclein plasmid result in punctate 
cytosolic staining [67]. These cytosolic puncta of alpha-synuclein also 
stain for yeast Ypt1, a Rab1 homolog that localizes to ER-to-Golgi 
transport vesicles in yeast, suggesting that these transport vesicles 
present a binding surface similar to that of synaptic vesicles for alpha-
synuclein [68]. In hippocampal neurons cultured from rats 
overexpressing human alpha-synuclein, the protein co-localizes with a 
marker of synaptic vesicles (vGLUT-pHluorin) [69]. These data, when 
taken together, strongly implicate alpha-synuclein in binding to “late 
membranes,” such as the plasma membrane, late transport vesicles, 
and synaptic vesicles, in a host of cellular environments. In addition, 
the evidence suggests that this binding is involved in alpha-synuclein 
function. 
At the same time, biochemical and spectroscopic studies 
elucidated the molecular details of alpha-synuclein binding to 
membranes. The binding was localized to the N-terminal region of the 
protein (approx. residues 1-100) by virtue of those peaks disappearing 
in a 1H-15N HSQC NMR spectrum due to the large effective size and 
slow tumbling rate of regions of the protein immobilized on the vesicle 
surface [42]. However, because the vesicle-bound protein is NMR-
invisible, it is difficult to determine its structure at high resolution. 
Following strategies employed in early studies of apolipoprotein 
structure[70], micelles composed of the anionic detergent sodium 
dodecylsulfate (SDS) were used to mimic the membrane surface at a 
much smaller size (approximately 0.5 nm in diameter as opposed to 40 
and 120 nm for small and large vesicles, respectively) [42,71,72]. In 
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much the same way as with apolipoproteins, addition of SDS at 
micellar concentrations was found to induce a similar amount of 
helical structure in the N-terminal region as anionic phospholipid 
vesicles, as measured by CD spectroscopy, and to cause similar peaks 
to disappear from the HSQC spectrum. As a result, SDS micelles were 
deemed a suitable mimic for membrane surfaces in the case of alpha-
synuclein. 
In the presence of SDS micelles, alpha-synuclein adopts a 
“broken-helix” conformation, in which the N-terminal 90-100 residues 
form an amphipathic α-helix, with a break around residue 42-44 [71–
73] (Figure 1.2A). The helical structure (and break) was confirmed by 
measuring secondary shifts of the alpha-carbons and i,i+1 amide-
amide NOE cross-peaks. Interestingly, the helical region seems to be 
bounded by the aromatic side-chains present in phenylalanines 4 and 
94 and tyrosine 39. The helical structure was found to exhibit an 
atypical 11/3 periodicity that aligns well with the 11-residue repeats of 
alpha-synuclein and thereby eliminates a super-helical twist of the 
hydrophobic moment, allowing the hydrophobic face of the helices to 
remain oriented towards the hydrophobic membrane or micelle interior, 
while the lysine residues lining the interface between the hydrophobic 
and hydrophilic faces ostensibly interact with the negatively-charged 
lipid headgroups. 
A high-resolution model of the SDS-bound state of alpha-
synuclein was reported, integrating NMR-derived secondary structure 
information, NOEs, residual dipolar couplings, and PRE distance 
constraints in a molecular fragment replacement framework (PDB ID: 
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1XQ8) [74]. This structure illustrates the broken-helix conformation 
that alpha-synuclein adopts in the presence of spheroidal SDS  
 
Figure 1.2: Structures of alpha-synuclein on membrane surfaces. 
(A) Broken-helix state on spheroidal SDS micelles. (B) Splaying apart 
of helices on micelles of increasing size, leading to extended-helix state. 
(C) Interconversion between broken- and extended-helix state on small 
vesicles. 
 13 
 
micelles. In this structure, the N-terminal domain of alpha-synuclein 
consists of two curved, antiparallel α-helices: helix-1, composed of 
residues 3-37, and helix-2, comprising residues 45-92. Connecting 
these two helices, which have no inter-helix contacts, is a non-helical 
but structured linker, which contains the tyrosine at position 39. The 
N-terminal 2 residues are disordered and the remaining C-terminal 
residues are in a slightly extended conformation. Dynamical and 
secondary structural parameters indicate that the regions around 
residues 30-35, 66-67, and 88 display “weaker” helical structure, 
indicative of some fraying, kinking, or flexibility in the helices at those 
positions [74,75]. 
The main advantage of using SDS micelles as a model for 
membrane binding is the small size of the resultant particles, which is 
amenable to high-resolution structural studies by NMR. However, the 
possibility exists that this small size and high curvature of SDS 
micelles is itself affecting the conformation of alpha-synuclein. In fact, 
the inter-helix distance in the broken-helix state was found to be very 
close to the expected size of a spheroidal SDS micelle. This match 
between the protein and micelle sizes led to the hypothesis that the 
broken-helix conformation is constrained by the topology of the SDS 
micelle. ESR (electron spin resonance) can be used to provide 
structural and dynamical information about sites labeled with 
paramagnetic spin-labels and is less limited by size than solution NMR; 
additionally, pulsed dipolar ESR can be used to measure distances 
between two spin-labeled sites. Therefore, this technique has been 
used extensively to characterize the conformational state of alpha-
 14 
 
synuclein on larger membrane surfaces. For example, continuous-
wave ESR measurements at each site throughout the length of the N-
terminal domain of alpha-synuclein in the presence of phospholipid 
vesicles suggested that the entire region may form a continuous, 
ordered 11/3 helix [76,77]. 
These results led to the hypothesis that a larger micelle might 
allow the two antiparallel helices to fuse into a single continuous helix. 
Supporting this, pulsed dipolar ESR studies using longer-chain 
lysophospholipid micelles, reported increased inter-helix distances 
compared to those observed using SDS micelles [78], indicating a 
splaying apart of the two helices of the broken-helix state on a larger 
surface (Figure 1.2B). Subsequently, pulsed ESR studies using binding 
partners of increasing sizes, including rod-like micelles, phospholipid 
bicelles, and lipid vesicles, yielded longer inter-helix distances that 
confirmed an “extended-helix” conformation in which the two helices 
are fully fused [79]. The application of other techniques, such as 
molecular dynamics simulations using ESR-derived distance restraints 
[77] and single molecule Förster resonance energy transfer (smFRET) 
spectroscopy [80,81] provided further evidence for the extended-helix 
conformation of alpha-synuclein in the presence of lipid vesicles. 
Interestingly, other contemporaneous ESR studies suggested that a 
broken-helix conformation persists in the presence of vesicles [82,83]. 
While the Bortolus et. al. study likely results from a misinterpretation 
of the data, the Drescher et. al. study, along with data in the original 
ESR distance measurements, suggests the possibility of 
interconversion between the extended-helix and broken-helix forms of 
 15 
 
alpha-synuclein on the membrane surface (Figure 1.2C). Due to the 
substantial difference in surface curvature and hydrophobic chain 
packing between SDS micelles and lipid vesicles, this confirmation of 
similar helical structures of alpha-synuclein on lipid vesicles as on 
SDS micelles suggests strongly that these helical conformations are 
encoded in the alpha-synuclein sequence and can be induced by 
different lipid environments. 
Further ESR studies of the conformation of alpha-synuclein in 
the presence of SDS showed a co-existence of the broken- and 
extended-helix states, and that the relative populations of the two 
conformations depend not only on absolute detergent concentration 
(which in the absence of protein determines micelle topology) but also 
protein:detergent ratio [84]. SDS concentrations were increased from 
those at which spheroidal micelles are expected to dominate to those 
at which rod-like micelles begin to form spontaneously with the 
expected switch from mostly broken-helix to mostly extended-helix 
alpha-synuclein. However, even at relatively low SDS concentrations, 
at which micelles are still expected to be spheroidal, extended-helix 
conformations of alpha-synuclein began to dominate when the 
detergent:protein concentration exceeded ~500. These data suggested 
that alpha-synuclein does not passively adapt its conformation to a 
presented lipid or detergent topology, but rather can remodel 
membrane-like surfaces to promote binding of a certain conformation. 
These findings were in agreement with sporadic previous and 
subsequent reports of alpha-synuclein remodeling membrane surfaces 
[57,63,85–89]. The remodeling of membranes into micelles or tubules 
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by alpha-synuclein seems to be a consequence of the amphipathic 
helix inserting to some extent into the membrane bilayer; in fact, 
similar tubulation has been observed for apolipoprotein A-1, which 
forms amphipathic helices very similar to those of alpha-synuclein [89]. 
Interconversion between the broken- and extended-helix states was 
suggested to contribute to the putative functions of alpha-synuclein at 
the presynaptic membrane, which presents a variety of membrane 
topologies to the protein. Specifically, broken-helix alpha-synuclein 
was envisioned to bridge two closely apposed membrane surfaces, 
such as a fusing or budding synaptic vesicle at the synaptic plasma 
membrane, while extended-helix alpha-synuclein, which is unable to 
form such a bridge, may exist as a reservoir for the active broken-helix 
form [84,90] (Figure 1.3). 
 
Figure 1.3: Proposed model of functional interconversion between 
alpha-synuclein states on membranes at the synapse. 
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As the above-referenced studies reveal, it has been difficult to 
obtain high-resolution structural information on the vesicle-bound 
form of alpha-synuclein, which, based on the association of alpha-
synuclein with vesicles in vivo, is expected to be the functionally-
relevant form. X-ray crystallography has not been productively applied 
to membrane surface associated proteins, solution-state NMR is 
hampered by the large size of the vesicles, and cryoelectron 
microscopy does not offer sufficient resolution for smaller, asymmetric 
assemblies. Structural information in the context of lipid vesicles has 
thus been largely limited to inferences from solution-state NMR 
methods [91,92], distance constraints measured by ESR and smFRET 
[80,81,83], and CD spectroscopy [93–95], although recently solid-state 
NMR was able to directly observe a small portion of the membrane-
associated alpha-synuclein protein [96]. 
 
I.e. Alpha-synuclein aggregation and membranes 
 
Interestingly, several studies of membrane-associated alpha-
synuclein have suggested that binding to membranes or lipid 
molecules may play a role in facilitating alpha-synuclein aggregation, 
implicating a transient partly-helical state in that process. Evidence 
for a partially-folded state of alpha-synuclein and its potential 
implication in fibrillogenesis cropped up in early spectroscopic studies 
of alpha-synuclein [97–100]. Several environmental factors, such as 
low pH (~3), heavy metal ions (e.g. Cu2+ and Fe3+), the pesticides DDC 
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and dieldrin, and high temperature, result in both a partly folded 
structure and a shorter lag phase for fibrillogenesis. A similar partly-
folded CD signature was observed for alpha-synuclein in the presence 
of low concentrations of alcohols, in which fibril formation was 
enhanced [94]. Mixtures of water with alcohols, particularly 
fluorinated alcohols, have been used extensively as a membrane model 
for alpha-synuclein, building off previous protein folding studies that 
used such mixtures to recapitulate the low dielectric constant 
conditions expected to exist at the cytosol-membrane interface 
[101,102]. These results suggest that, in addition to other external 
factors, the membrane-water interface may induce partial folding of 
alpha-synuclein, which is correlated to fibril formation, and thus to 
dysfunction and disease. 
At approximately the same time, early in vitro studies showed 
conflicting effects of the presence of lipid molecules on alpha-synuclein 
aggregation. Many studies found that the presence of various lipids 
and detergents increased the aggregation and fibrillization rates of 
alpha-synuclein [65,85,103,104], while a few found the opposite effect 
[105,106]. A synthesis of these disparate results suggests that high 
lipid:protein concentrations inhibit fibril formation and low 
lipid:protein ratios promote fibrillzation [107]. As a result, it has been 
proposed that lipids promote alpha-synuclein aggregation by two 
possible mechanisms: by increasing the local concentration of protein 
as a result of confining alpha-synuclein molecules to a smaller area or 
by promoting a fibrillogenic folding intermediate [107,108]. In the first 
model, an increase in local alpha-synuclein concentration would not 
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be seen at higher lipid concentrations, since alpha-synuclein 
molecules would not be confined to a small area. In the second model, 
the concentration of the fibrillogenic intermediate would be more dilute 
at higher lipid concentrations. Thus, both models lead to the 
conclusion that lipid-mediated aggregation would only occur at low 
lipid:protein ratios. 
Much of the early evidence for the fibrillogenic intermediate 
model was circumstantial, consisting of the observation that 
concentrations of membrane-mimetic detergent that promoted alpha-
synuclein aggregation also induced partly helical conformations of 
alpha-synuclein [109–111]. One such correlative study used CD 
spectroscopy to infer the structure of alpha-synuclein in the presence 
of different concentrations of trifluoroethanol (TFE). At intermediate 
concentrations of the fluorinated alcohol, where, like in the presence of 
intermediate concentrations of lipids or detergents, alpha-synuclein 
formed fibrils more readily, the protein was found to populate a folding 
intermediate [95]. When the CD spectrum of this state was 
reconstructed, it revealed a partly helical conformation, with helical 
content of ~24 residues. These results suggested that at least some of 
the previously reported partially folded states correlating with 
enhanced fibril formation are a partly helical conformation in which 
part, but not all, of the N-terminal membrane binding domain forms 
an α-helix. Other structural studies have detected N-terminal partly 
helical states of alpha-synuclein on membrane bilayer surfaces. For 
example, site-directed spin-labeling and continuous wave ESR 
detected a binding mode of alpha-synuclein in which (at least) the N-
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terminal 18 residues were bound to a vesicle surface, while residues 
C-terminal to position 69 (at least) were detached [83]. This binding 
mode was especially prevalent on vesicles with low (below 40% PG 
headgroups) negative charge content. 
Although solution-state NMR cannot directly observe the lipid 
vesicle-bound state of alpha-synuclein due to size constraints, NMR 
experiments can indirectly provide information about the extent of 
binding of different regions. This residue-specific resolution is one of 
the major advantages of NMR spectroscopy in the study of protein 
interactions. For instance, loss of signal due to immobilization on the 
vesicle surface has been used to quantify extent of binding in a 
residue-specific manner [58,91,92]. This method is especially useful 
for detecting partially bound states, in which the unbound regions of 
the protein retain their flexible and dynamic character while only the 
regions that are bound (or those nearby) are affected. Using this 
approach, it was shown that at low lipid:protein ratios, alpha-
synuclein did not bind uniformly to the vesicles along the length of the 
polypeptide chain [91]. Specifically, while the N-terminal 90-100 
residues all bound to some extent, the very N-terminus of the protein, 
consisting of approximately 20-30 residues, displayed relatively more 
binding than the remainder of the protein. Increased binding for that 
region was also indicated by stronger lipid-to-protein NOEs detected 
by NOE transfer experiments. These data suggest that a subset of the 
bound alpha-synuclein exists in a conformation in which only the N-
terminal ~25 residues are bound to the vesicle, presumably in an α-
helical conformation. 
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The nonuniform binding profile of alpha-synuclein can provide 
quantitative estimates of the relative populations of different binding 
modes. Interestingly, the fractional population of the N-terminal 
partially bound state was found to be higher for the A30P, E46K, and 
A53T Parkinson’s disease-associated mutants, despite their different 
effects on total binding [92]. This finding bolstered the hypothesis that 
a partially bound, partly helical conformation of alpha-synuclein, 
which prevails at low or limiting concentrations of membrane binding 
sites, enhances the aggregation of the protein, perhaps by bringing 
amyloidogenic regions closer together. Additionally, these studies 
localized the likely region of partial folding to the N-terminal ~25 
residues, which closely matches the number of residues predicted to 
be helical in the partly helical folding intermediate indirectly observed 
in the presence of intermediate concentrations of TFE. A CD 
spectroscopy and ITC study looking at binding of overlapping alpha-
synuclein peptides to lipid vesicles also concluded that the N-terminal 
~25 residues trigger binding and folding of the entire N-terminal 
domain, also positing the existence of a partly helical state on vesicles 
[112]. Interestingly, this N-terminal section of the protein has also 
been implicated in protein-protein interactions, specifically calmodulin 
binding [113]. However, none of these studies were able to directly 
observe the hypothesized, aggregation-prone, partly helical state at 
high resolution. 
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I.f. What is the functional state of alpha-synuclein? 
 
The paradigm of alpha-synuclein existing mostly as a dynamic, 
disordered monomer in cells, with a small population of various lipid 
membrane bound states, has recently been challenged. Although 
alpha-synuclein was originally purified using standard methods used 
for natively folded proteins, its apparent disorder and heat-stability 
soon led to the proliferation of denaturing steps in the purification 
schemes. Currently, recombinant alpha-synuclein produced in E. coli 
(which is used for most structural studies) is usually purified using 
either a boiling step or a reverse-phase HPLC procedure. Both of these 
methods can be expected to break up any tertiary or quaternary 
structure that the native protein may adopt; in addition, the 
heterologous expression system and overexpression can also affect 
protein folding in the E. coli cells. In order to examine the effects of 
these relatively harsh expression and purification conditions on the 
native structure of alpha-synuclein, Selkoe and coworkers purified the 
protein using gentle, nondenaturing methods from an endogenous 
source [114]. An easily obtainable source with sufficient alpha-
synuclein expression was found: human red blood cells, which have 
been shown to express significant amounts of the protein though the 
functional consequence of alpha-synuclein in this context is still 
unclear [115,116]. The protein purified from red blood cells (as well as 
neuroblastoma cell lines) using ammonium sulfate precipitation, 
hydrophobic interaction chromatography, and gel filtration exhibited a 
 23 
 
size consistent with a tetramer (~60 kDa) by analytical 
ultracentrifugation and native-PAGE, and displayed helical character 
similar to vesicle-bound recombinant monomer by CD spectroscopy. In 
addition, the tetrameric species was shown to bind to synthetic lipid 
vesicles and to fibrillize more slowly than the monomer. This finding 
lent itself to an attractive dichotomous model: a native, functional 
helical tetramer and a fibrillogenic, unfolded monomer. 
Further studies offered more evidence of a tetrameric form of 
alpha-synuclein. For instance, an alpha-synuclein construct 
containing a 10-residue N-terminal addition purified from E. coli under 
nondenaturing conditions was analyzed by NMR and other methods 
and showed some characteristics consistent with a helical tetramer 
[117]. Additional studies suggested that N-terminal acetylation (see 
section I.g) and purification in β-octyl glucoside was necessary to 
observe the tetrameric form of alpha-synuclein [118]. In contrast, 
several studies showing that alpha-synuclein exists primarily as a 
monomer when purified from multiple native and nonnative sources, 
and even in intact E. coli cells were published [119–121]. Currently, it 
is thought that alpha-synuclein exists in equilibrium between several 
forms in vivo: a majority of monomeric species, with some helical 
tetrameric and potentially amyloidogenic oligomeric forms as well [122]. 
Despite the controversy over the physiologically relevant, 
functional form of alpha-synuclein, the actual function of the protein 
is not well-established. Mice with alpha-synuclein knocked out have 
been generated and studied; however, the observed phenotypes were 
not consistent from study to study and depend on what the study was 
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designed to look at. For example, some studies specifically examined 
the effects on dopamine signaling in the brain and found a slight 
increase in dopamine release with a concomitant drop in overall 
dopamine levels upon loss of alpha-synuclein [123,124]; other studies 
looked at the effects on pools of synaptic vesicles in neurons in general 
and found a loss of undocked, or “reserve” synaptic vesicle pools [125]. 
Thus, alpha-synuclein plays a role at neuronal synapses in general 
and potentially a (different?) role in dopaminergic neurons. In cultured 
neurons, alpha-synuclein was shown to localize to presynaptic 
terminals fairly late, after they had become well-established [126], 
while alpha-synuclein knockdown neurons also displayed a decreased 
“reserve” pool of synaptic vesicles [127] and a loss of potentiation of 
glutamatergic synaptic transmission [128]. A double-knockout of 
alpha- and beta-synuclein showed no major deficiencies in synaptic 
function, aside from a decrease in complexin and 14-3-3 protein levels 
and decrease in brain dopamine levels [129]. While these findings 
implicate alpha-synuclein in regulation of synaptic vesicle exocytosis 
in general, they do not elucidate any coherent specific function for the 
protein. 
One clue to a possible function of alpha-synuclein was 
discovered in mice lacking the synaptic chaperone CSPα [130]. These 
mice display loss of SNARE complex formation and rapid 
neurodegeneration that is ameliorated by the overexpression of alpha-
synuclein. SNARE proteins are the machinery that drives vesicle 
fusion in cells, with a specific subset responsible for synaptic vesicle 
exocytosis in neurons [131]. The generation of alpha-, beta-, and 
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gamma-synuclein triple-knockout mice [132,133] implicated 
synucleins further in SNARE complex regulation. These mice displayed 
an age- and activity-dependent neurodegenerative phenotype. On a 
molecular level, the mice showed decreased neuronal SNARE complex 
assembly, which was remedied by expression of alpha-synuclein in 
cultured triple-knockout neurons and other cell lines [133]. These 
findings suggest that different synuclein proteins may have redundant 
functions in the brain, at least in terms of chaperoning the SNARE 
complex. A connection between alpha-synuclein and the neuronal 
SNARE complex is further supported by observed SNARE protein 
accumulation at synapses of mice expressing a truncated (1-120) form 
of alpha-synuclein, one of many animal models for PD [134]. However, 
this is only one putative function for alpha-synuclein, and a 
consensus on its in vivo function remains elusive. 
 
I.g. Alpha-synuclein post-translational modifications 
 
N-terminal acetylation, a very common protein modification, was 
first discovered in 1958 [135]. As much as 80% of cytosolic mouse 
proteins were found to be N-terminally acetylated [136], while more 
recently, proteomics analyses have found that 84% of human and 57% 
of yeast proteins are N-terminally acetylated [137]. N-terminal 
acetylation, which consists of the transfer of an acetyl group to the 
protein primary amine by one of a group of N-acetyltransferase 
enzymes (NatA-NatF) [137,138], is thought to happen while the 
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nascent peptide is still on the ribosome [139,140], together with 
initiator methionine cleavage [141,142]. Each N-acetyltransferase 
acetylates a subset of proteins depending on the sequence of the N-
terminal two or three residues [143,144]. Meanwhile, prokaryotes use 
an incompatible N-terminal acetylation system [145]; thus, eukaryotic 
proteins produced recombinantly in bacterial systems are not N-
terminally acetylated. 
Modification of the N-terminus of alpha-synuclein was originally 
observed when the protein purified from human brain was found to be 
N-terminally blocked [24]. However, the shift to recombinant protein 
for biophysical and biochemical studies prevented any further 
determination of the nature of the N-terminal modification until a 
study comparing modifications of cytosolic and Lewy body alpha-
synuclein by mass spectrometry found ubiquitous N-terminal 
acetylation [146]. Subsequently, members of the yeast NatB complex 
appeared in a screen looking for mislocalization of alpha-synuclein 
expressed in yeast [147]. When the NatB complex was knocked out, 
the usual plasma membrane localization of alpha-synuclein was lost, 
resulting in a diffuse, cytosolic signal. NatB is known to acetylate 
proteins with N-terminal Met-Asp and Met-Glu sequences [143], which 
includes alpha-synuclein; therefore, while N-terminal acetylation of 
alpha-synuclein by NatB was not directly detected, it was suggested 
that this modification is important for plasma membrane localization. 
More evidence of a potential role of N-terminal acetylation in alpha-
synuclein function was subsequently found, when several research 
groups reported the isolation of helical and tetrameric forms of alpha-
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synuclein. In all of the reports, the isolated protein was N-terminally 
modified, either by endogenous N-terminal acetylation [114,118] or by 
a peptide scar left over from a purification tag [117]. One of the studies 
suggested that N-terminal acetylation, along with use of a buffer 
containing the detergent β-octyl glucoside (BOG) was necessary to 
observe the helical tetramer [118]. These findings sparked an 
outpouring of interest in the structural and functional roles of N-
terminal acetylation of alpha-synuclein. 
Although N-terminal acetylation is almost ubiquitous in 
eukaryotic proteomes, protein phosphorylation is the most extensively 
studied post-translational modification since the 1950s [148]. 
Phosphorylation, which in eukaryotes consists of the transfer of a 
phosphate group to either a serine (86%), threonine (12%), or tyrosine 
(2%) residue, is reversible, unlike N-terminal acetylation [149,150]. 
Phosphorylation by a kinase and dephosphorylation by a phosphatase 
form a dynamic signaling system that can regulate cellular processes 
in space and time. Phosphorylation increases the variety of protein 
surfaces for protein-protein interactions without increasing the gene 
number, as well as allowing the cell to respond to environmental 
changes faster than gene transcription and protein translation [151]. 
Different kinases have been shown to phosphorylate alpha-
synuclein on a few serine and tyrosine residues [152–156]. The most 
common phosphorylated residue of alpha-synuclein is serine 129; this 
modification is found in cytosolic [157] and aggregated alpha-
synuclein [146,158,159]. The effect of phosphorylation of Ser-129 on 
PD progression is unclear and is most likely context-dependent. There 
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is evidence that phosphorylation at Ser-129 can inhibit alpha-
synuclein fibril formation in vitro [155] but also that it can increase 
fibril formation in vitro and aggregation in cells [158,160]. 
Phosphorylation of alpha-synuclein at another site, serine 87, was also 
detected in cell models [159]. Phosphorylation of alpha-synuclein at 
Ser-87 was demonstrated in vitro by the kinase Dyrk1A [161]. Also, 
alpha-synuclein phosphorylated at Ser-87 was found to be enriched in 
samples from PD patients and animal models of PD [154]. 
Eukaryotic proteins are also often phosphorylated on threonine 
and tyrosine residues. Despite containing 10 threonine residues due to 
the conserved KTKEGV repeat motif, alpha-synuclein does not seem to 
undergo phosphorylation on any of those residues. Tyrosine residues, 
on the other hand, have been shown to be phosphorylated. Studies in 
which alpha-synuclein was transfected into cell lines showed that 
tyrosine 125 could be phosphorylated [162,163]. Meanwhile, 
phosphorylation at tyrosines 133 and 136 was also detected, but at 
lower levels [162,164]. Alpha-synuclein phosphorylated at Tyr-125 was 
detected in human samples and animal models, decreasing in level 
with age [165]. However, the difficulty of producing pY125 alpha-
synuclein in vitro and lack of widely accepted phospho-tyrosine 
mimicking mutations has prevented further biophysical 
characterization of alpha-synuclein phosphorylated at Tyr-125 or 
other tyrosine sites (such as tyrosine 39). 
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I.h. Motivations and goals 
 
Inspired by the nascent studies of the effect of N-terminal 
acetylation on alpha-synuclein structure and function, this thesis 
contains work aimed at determining these effects in greater detail. 
Specifically, the impact of N-terminal acetylation on the structure and 
intramolecular contacts of disordered monomeric alpha-synuclein, 
both in cells and in a purified form, is determined. In addition, the 
effects of these structural changes on alpha-synuclein interaction with 
membrane mimics, such as micelles of different detergents, and 
synthetic lipid vesicles of different composition and curvature are 
examined. The goal is to structurally characterize N-terminally 
acetylated alpha-synuclein in a similar way to the heretofore studied 
unmodified recombinant form of the protein, and to compare these 
structural and lipid-interaction characteristics. Studying the effects of 
N-terminal acetylation on alpha-synuclein binding to lipid vesicles 
similar to synaptic vesicles, its most well-validated in vivo binding 
partner, is expected to give insights into the still poorly-characterized 
native function of alpha-synuclein. 
Analogously, the effects of another modification, tyrosine 
phosphorylation, are studied. Since a bevy of work has focused on 
serine phosphorylation in alpha-synuclein, this thesis focuses on the 
previously known phosphorylation site at Tyr-125 and the very 
recently discovered site at Tyr-39. The effects on free-state structure 
and membrane and detergent interactions are assessed. Due to the 
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location of Tyr-39 in the middle of the lipid-binding domain, 
specifically in the linker region, greater attention is paid to the effects 
of phosphorylation at that site on the membrane and micelle-bound 
structure of alpha-synuclein. The goal is to characterize the lipid 
membrane-bound state of phosphorylated alpha-synuclein in order to 
draw conclusions about the effect of phosphorylation on the function 
of the protein. 
In addition to post-translational modifications, PD-associated 
point mutations can affect the structural properties and membrane 
interactions of alpha-synuclein. Recently, two newly-discovered 
mutations in alpha-synuclein have come to the forefront: H50Q, 
identified in patients with late-onset PD [12,166], and G51D, identified 
in patients with early-onset PD and multiple system atrophy [9,167]. 
The discovery of these two mutations allows previously proposed 
hypotheses of mutation roles in alpha-synuclein dysfunction to be 
tested. As with N-terminal acetylation and tyrosine phosphorylation, 
the impact of these point mutations on the structural characteristics 
of the free-state and micelle- and membrane-bound states of alpha-
synuclein is assessed. 
Before tackling what goes wrong with alpha-synuclein in PD, it 
would be helpful to have a better grasp of what the normal function of 
the protein is. Since the in vivo studies of alpha-synuclein function 
have yielded the inconsistent and confounding results described above, 
a greatly simplified in vitro system focusing on the structure of the 
protein and binding to synaptic-vesicle-like synthetic liposomes can be 
useful. This binding is expected to be central to the still poorly-defined 
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function of the protein and involves the N-terminal region, which 
contains all of the abovementioned modifications. Thus, it is 
hypothesized that these modifications affect the function of alpha-
synuclein, and that studying their effects in this in vitro system will 
not only help determine their physiological effects, but also provide key 
information about the heretofore unclear function of alpha-synuclein. 
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II. Methodology 
 
In this work, the effects of various post-translational 
modifications on the structure of alpha-synuclein and on its 
interactions with membranes and membrane mimics were studied 
using NMR and CD spectroscopy. A wide variety of NMR experiments 
were applied to determine structural properties of different alpha-
synuclein constructs and samples at residue-specific resolution, in 
isolation and in the presence of lipid vesicles and detergents. 
Additionally, CD spectroscopy was applied to measure binding, as 
detected by secondary structure changes, when appropriate. All such 
measurements required sample preparation, including molecular 
biology (mutagenesis and cloning), recombinant protein overexpression 
in bacterial culture (including isotopic labeling), protein purification, in 
vitro phosphorylation where relevant, site-directed spin-labeling when 
necessary, and lipid vesicle preparation. The methods used, including 
data analysis protocols, will be discussed in this section. 
 
II.a. Cloning, Protein Expression, and Purification 
 
Molecular Biology – Human alpha-synuclein was expressed in E. 
coli under the control of a phage T7 promoter using a plasmid 
originally kindly provided by Dr. Peter T. Lansbury [40,42]. The 
plasmid also contained an ampicillin resistance marker. N-terminally 
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acetylated alpha-synuclein was produced in E. coli using a previously 
developed co-transformation method involving the yeast N-
acetyltransferase complex NatB (plasmid pNatB), kindly provided by 
Dr. Daniel Mulvihill (University of Kent, UK) via Dr. Elizabeth Rhoades 
(Yale University). [168,169]. The pNatB plasmid contains a 
chloramphenicol resistance marker for co-selection with the T7 alpha-
synuclein plasmid. Single-residue mutagenesis (PD mutants A30P, 
E46K, H50Q, G51D, and A53T; phosphomimic Y39E; cysteine 
mutants for spin-labeling S9C, E20C, E83C, and P120C; and C-
terminal truncation [1-102] N103stop) were generated using an 
Agilent/Stratagene QuikChange site-directed mutagenesis kit with the 
appropriate forward and reverse primers manufactured by Life 
Technologies/Invitrogen. PCR-amplified plasmids were transformed 
into E. coli XL1-Blue cells for MiniPrep amplification and purification. 
Plasmids were stored at -20 °C and amplified in E. coli NovaBlue cells 
when necessary. 
Protein Expression and Purification – All proteins were expressed 
in E. coli BL21 (DE3) cells. For production of N-terminally acetylated 
alpha-synuclein, the T7 alpha-synuclein plasmid and pNatB plasmid 
were simultaneously transformed into the bacterial cells, which were 
then plated on agar plates containing ampicillin (100 μg/mL) and 
chloramphenicol (34 μg/mL). Unmodified alpha-synuclein was 
produced by simply transforming the T7 alpha-synuclein plasmid into 
E. coli BL21 (DE3) cells followed by plating on ampicillin plates. For 
production of unlabeled (natural abundance of isotopes) protein for CD 
experiments, bacteria were grown in low volumes (100-400 mL) of LB 
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(Luria-Bertani) broth with appropriate antibiotics overnight, then 
transferred to larger volume cultures (1-4 L) for 2 hr at 37 °C. When 
the OD reached 0.6-1.0, protein expression was induced using ~1 mM 
IPTG and continued for 3-3.5 hr. A 1 mL sample was taken every 1 hr 
to check OD and saved to estimate protein expression using SDS-
PAGE. Cells were harvested by centrifugation at 6,000 rpm (6,900 x g) 
for 15 minutes and the pellet stored at -20 °C. Typical preparations 
utilized 4 L of bacterial culture for producing unlabeled protein. 
For production of isotopically-labeled protein for NMR studies 
(either 15N-labeled or 15N,13C-labeled), the “media swap” method was 
employed [170]. Transformed E. coli cells were grown in LB broth 
(usually 1 or 4 L) as for unlabeled proteins until an OD of 0.6-1.0 was 
reached, then centrifuged at 6,000 rpm (6,900 x g) for 15 minutes at 
24 °C and the pellet resuspended in either 0.25 or 1 L “wash medium,” 
consisting of M9 minimal medium without carbon or nitrogen sources 
and containing appropriate antibiotics. This resuspension serves as a 
wash step to remove any natural abundance carbon and nitrogen 
sources remaining from the LB broth. The resuspended cells were then 
centrifuged again at 6,000 rpm (6,900 x g) for 15 minutes at 24 °C and 
the pellet resuspended in M9 minimal medium, supplemented with 
BME vitamins, the appropriate antibiotics, and either 1 g uniformly 
labeled 15N ammonium chloride and 4 g natural abundance dextrose 
or 1 g 15N ammonium chloride and 2 g 13C glucose for the production 
of 15N-labeled or 15N,13C-labeled protein, respectively. After recovery at 
37 °C in minimal medium for 0.5-1 hr, protein expression was induced 
using ~1 mM IPTG and continued for 3-3.5 hr. A 1 mL sample was 
 35 
 
taken every 1 hr to check OD and saved to estimate protein expression 
using SDS-PAGE. Cells were harvested by centrifugation at 6,000 rpm 
(6,900 x g) for 15 minutes and the pellet stored at -20 °C or used 
immediately for in-cell NMR experiments. 
The purification scheme was the same for all recombinant 
alpha-synuclein proteins, regardless of mutation or acetylation, except 
that the scheme for purifying the N-terminal truncation alpha-
synuclein 1-102 involved a different ion exchange chromatography 
step. Protein purification was performed on ice or at 4 °C whenever 
possible. Frozen bacterial pellets (from 1 L culture for isotopically 
labeled protein or 4 L culture for natural abundance protein) were 
thawed on ice and resuspended in 50 mL lysis buffer (10 mM tris pH 
8.0, 1 mM EDTA, 1 mM DTT, 1 mM PMSF). The suspension was then 
homogenized using a Dounce homogenizer. The resultant homogenate 
was subjected to sonication by a tip sonifier (Branson) for 2 x 6 
minutes at a power setting of 6 with a duty cycle of 50%. The sample 
was stirred between the two applications of the sonifier. The lysed cell 
suspension was then subjected to ultracentrifugation at 40,000 rpm 
(145,000 x g) for 1 hr at 4 °C. A sample for SDS-PAGE was taken after 
each step (resuspension, homogenization, sonication, and 
ultracentrifugation [pellet and supernatant]). 
The ultracentrifugation pellet was saved at 4 °C while the 
supernatant (~45 mL), which contained the soluble fraction of lysed 
bacterial cells, was mixed with 1% w/v streptomycin sulfate (~0.45 g) 
and stirred at 4 °C for 30 min to precipitate nucleic acids. A white 
precipitate formed, and the resultant suspension was centrifuged at 
 36 
 
15,000 rpm (18,000 x g) for 20 min at 4 °C. The pellet was saved at 
4 °C and supernatant (~40 mL) used for the next step. The 
supernatant was subjected to two subsequent ammonium sulfate cuts. 
First, 0.116 g/mL of ammonium sulfate (~22% saturation) was added 
and stirred at 4 °C for 10 min. Usually, no precipitate formed, but if it 
did, the suspension was centrifuged at 15,000 rpm (18,000 x g) for 20 
min at 4 °C and the supernatant used for the next cut. For the second 
cut, 0.129 g/mL of ammonium sulfate (~42% saturation) was added 
and the solution was stirred for 1 hr at 4 °C. A precipitate, containing 
the alpha-synuclein protein, formed due to a salting out effect, and the 
resultant suspension was centrifuged at 15,000 rpm (18,000 x g) for 
20 min at 4 °C. The supernatant was saved at 4 °C and the pellet 
resuspended in 50 mL lysis buffer and set up to dialyze into 1 L of 25 
mM tris pH 8, 20 mM NaCl, 1 mM EDTA overnight. After each step, 
samples of the resultant pellet and supernatant were saved for SDS-
PAGE. 
After dialysis, the protein was applied to an ion-exchange 
column using an AKTA FPLC system (GE Healthcare). An anion-
exchange chromatography column (DEAE-cellulose, GE Healthcare) 
was used for full-length protein and a cation-exchange column (CM-
cellulose, GE Healthcare) for the truncated alpha-synuclein 1-102 
protein. The protein was eluted in buffer containing 25 mM tris pH 8, 
1 mM EDTA, with a gradient from 20 mM to 1 M NaCl. Full-length 
alpha-synuclein usually eluted at 220-320 mM NaCl and alpha-
synuclein 1-102 at 170-270 mM NaCl. Fractions of 0.5 mL were 
collected and protein was monitored by absorbance at 280 nm. 
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Samples from protein-containing fractions were taken for SDS-PAGE 
and the fractions pooled for dialysis into 5% acetic acid overnight. The 
dialyzed protein sample was applied to a reverse-phase preparative C4 
column (Vydec) for HPLC purification using a Waters 2690 Separations 
Module. The column was eluted with buffer A (99.9% dH2O, 0.1% 
trifluoroacetic acid [TFA]) and a gradient from 20% to 100% buffer B 
(90% acetonitrile, 9.9% dH2O, 0.1% TFA). The eluant was monitored 
for protein absorbance at 229 nm; alpha-synuclein usually eluted at 
~46% buffer B. Samples from HPLC peaks were taken for SDS-PAGE 
analysis, and protein-containing peaks were dried under vacuum to 
remove acetonitrile, then lyophilized for 2-3 days. For cysteine 
mutants of alpha-synuclein, the low pH during and after HPLC 
purification served to inhibit dimerization, and any covalent dimers are 
presumed to separate from monomeric protein on the column. The 
lyophilized powder was then stored at -20 °C. Purity was usually >90%. 
Phosphorylated Protein Samples – Alpha-synuclein protein 
phosphorylated on tyrosine 39 was produced by Dr. Bruno Fauvet in 
Dr. Hilal Lashuel’s lab (EPFL, Switzerland) for NMR experiments. 
Lyophilized alpha-synuclein protein was dissolved in buffer and 
incubated with the SH2-CD fragment of c-Abl and ATP. After the 
reaction was completed, the phosphorylated alpha-synuclein was 
purified by reverse-phase HPLC and lyophilized. 
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II.b. General NMR and CD Sample Preparation 
 
Protein Sample Preparation – For preparation of most protein 
samples for NMR and CD spectroscopy, lyophilized protein was 
dissolved in NMR buffer (10 mM Na2HPO4, 100 mM NaCl, pH 6.8). The 
pH was often low due to residual TFA from the HPLC step and was 
adjusted to around 6.8. The solution was then filtered through a 100 
kDa centrifugal filter to remove large aggregates. Protein concentration 
was estimated from the mass of lyophilized protein dissolved or the 
absorbance at 280 nm (using an extinction coefficient of 5960 M-1*cm-
1). For more accurate protein concentration determination, samples of 
the protein stock were run on an SDS gel along with samples of BSA 
with a predetermined concentration. The gel was stained, destained 
overnight, imaged, and the band intensity quantified using ImageJ 
software [171]. The band intensity was then correlated with 
concentration for the BSA samples, and concentration of alpha-
synuclein stock was calculated from the band intensity of those 
samples. This calculation usually resulted in a lower alpha-synuclein 
concentration than expected from mass of lyophilized protein. 
Protein stocks were then mixed with stocks of detergents (SDS, 
BOG) or lipid vesicles or with buffer to obtain desired concentration. 
Protein-containing samples were kept either at room temperature or 
4 °C, while those with lipid vesicles and BOG were kept exclusively at 
4 °C and those with SDS were kept at room temperature or higher so 
as to be above the Krafft point of SDS, below which SDS solutions 
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form a crystalline phase. Finally, 10% D2O was added to NMR samples 
to provide a deuterium signal for locking the NMR signal. Titrations 
were generally performed using separate, matched samples for 
titration points, although occasionally the titrant was added stepwise 
to the same sample to conserve material. 
NMR Sample Considerations – NMR experiments were usually 
run on samples dissolved in NMR buffer (10 mM Na2HPO4, 100 mM 
NaCl, pH 6.8, 10% D2O). This buffer composition has the advantage of 
having no extraneous NMR signals arising from the buffer components. 
However, the buffering strength of phosphate is not very robust 
around neutral pH, resulting in low pH (~3-4) after dissolving 
lyophilized protein, likely due to residual TFA from the HPLC buffers. 
While high pH is undesirable for NMR studies on disordered proteins 
due to increased amide proton exchange with the solvent, which leads 
to decreased NMR signal intensity for amide protons that are not 
protected (usually by hydrogen bonds), low pH induces a collapsed 
state in alpha-synuclein due to the neutralization of the many charged 
residues in the C-terminal tail [172]. As a result, pH was adjusted to 
slightly below neutral (pH 6.8) for most NMR experiments, to decrease 
the effects of amide proton exchange, or to slightly above neutral (pH 
8.4) for those experiments in which increased amide proton exchange 
at high pH was harnessed to determine the extent of protection for 
amide protons. This pH adjustment could result in the addition of 
significant and unknown amounts of sodium and chloride ions to the 
sample. 
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High salt concentration increases the conductivity of the sample 
and requires input of higher power radio frequency pulses in NMR 
experiments, in addition to potentially modulating intermolecular 
interactions. To avoid the addition of extraneous salt and the 
formation of potentially insoluble salts with divalent metal cations, 
PIPES, which has a greater buffering capacity around pH 6, was used 
in certain samples. The “PIPES NMR buffer” consisted of 20 mM PIPES 
and 100 mM NaCl (salt concentration varied by experiment) at pH 6.8. 
Routine HSQC experiments with SDS or BOG detergents used natural 
abundance detergent; however, deuterated SDS was used for 
multidimensional NMR experiments and deuterated BOG was used 
when high concentrations of BOG were required. Deuterated 
detergents not only have decreased proton signal arising from the 
detergent, but also reduce the loss of magnetization through spin 
diffusion between the protein and detergent micelle protons. 
Additionally, sample temperature can play a large role in the 
results of NMR experiments. High temperature, like high pH, is 
conducive to increased amide proton exchange with the solvent. On 
the other hand, high temperature decreases the viscosity of solvent 
and increases the tumbling rate of macromolecules, decreasing the 
loss of signal due to T2 relaxation (yup). This is especially 
advantageous for relatively large and slow-tumbling protein-micelle 
complexes. For this reason (as well as the tendency of SDS to 
transition to a crystalline phase below room temperature), all NMR 
spectra on samples containing SDS micelles were obtained at 40 °C.  
Spectra for which the observed signals originate from the free protein 
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were obtained at 10 °C, originally selected to minimize amide proton 
exchange, and subsequently used for consistency. 
NMR Equipment – Most multidimensional NMR experiments were 
collected on either a Varian INOVA 600 MHz spectrometer, equipped 
with a cryogenically-cooled triple-resonance z-gradient probe at Weill 
Cornell Medical College, or Bruker AVANCE spectrometers with 
cryogenically-cooled triple-resonance gradient probes with proton 
frequency ranging from 600 to 900 MHz at the New York Structural 
Biology Center (NYSBC). The vast majority of pulse sequences were 
either standard ones from Varian BioPack or Bruker library pulse 
sequences modified and optimized by NYSBC staff. One-dimensional 
(mostly proton) spectra, as well as diffusion experiments, were usually 
collected on a Bruker AVANCE 500 MHz spectrometer with a room 
temperature broadband probe at Weill Cornell Medical College. All 
probes were 5 mm, and 5 mm NMR tubes, mostly thin wall precision 
NMR sample tubes from Wilmad-LabGlass, were used. On occasion, 5 
mm solvent-matched Shigemi cells were used for low-volume or high-
field applications. 
 
II.c. HSQC Experiments 
 
HSQC (heteronuclear single quantum coherence) experiments 
use scalar couplings to correlate two different, chemically bonded, 
NMR-active nuclei, such as 1H and 15N or 1H and 13C [173]. This pulse 
sequence results in a two-dimensional spectrum with cross-peaks 
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corresponding to every H-N or H-C group in the sample, with the 
chemical shift of the proton on one axis and that of the heteronucleus 
on the other. The 1H,15N-HSQC is considered the “fingerprint” 
spectrum of a protein, since it contains a diagnostic peak for (the 
amide group of) each residue of the protein, except the proline 
residues, which lack an N-H. The peak position (i.e. amide proton and 
nitrogen chemical shifts) is very sensitive to the many factors that 
influence the electrochemical environment of the amide group, and 
thus can report on structural changes, binding interactions, nearby 
protonation states, phosphorylation, etc. Thus, 1H,15N-HSQC 
experiments are often used to monitor titrations of a binding partner, 
such as lipid vesicles, detergents, or metal ions, in the case of alpha-
synuclein. Plots of chemical shift perturbations/differences versus 
protein primary sequence can help to localize interacting regions, 
especially for proteins with no well-defined tertiary structure. In this 
work, amide chemical shift differences were quantified as follows: 
])5/([)2/1( 2
2
NHNavg          (1) 
where ∆δHN and ∆δN are the amide proton and amide nitrogen chemical 
shift differences, respectively (the latter is scaled by 5 due to the larger 
chemical shift values of amide nitrogen nuclei). For HSQC experiments 
used for titrations, it is important to use samples that are as closely 
matched as possible (protein and salt concentration, pH, etc). 
Lipid vesicle binding measurements are a special case, since the 
vesicle-bound protein tumbles too slowly and is invisible by NMR, so 
the proportion of the protein that is bound does not give rise to NMR 
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signals. This logic can also be applied to any sufficiently large particle, 
such as microtubules or LPS aggregates. In this case, signal intensity 
changes, rather than peak position changes, are used to monitor 
binding; therefore, protein concentration (which scales linearly with 
signal intensity) and receiver gain settings, must be the same between 
samples. Binding to paramagnetic metal ions, which decrease NMR 
signal intensity in a distance-dependent manner, can also be 
monitored by relative intensity ratios, rather than chemical shift 
changes. 
Phosphorylation of alpha-synuclein by c-Abl was followed by 
incubating wild-type alpha-synuclein with and the catalytic truncation 
SH2-CD c-Abl and collecting successive 1 hr 1H,15N-HSQC 
experiments. A spectrum was also collected on a matched alpha-
synuclein sample with no c-Abl to serve as a zero timepoint. The 
relative intensity of each phosphorylated peak was calculated and 
plotted versus time. 
1H,15N-HSQC experiments were usually collected with 1024 
points and an acquisition time < 100 msec (resulting in 14-20 ppm 
spectral width)  in the direct dimension (proton) and at least 64 
complex pairs (up to 512 complex pairs) in the indirect dimension 
(nitrogen), with a spectral window of around 104-128 ppm for SDS-
containing samples and around 107-132 ppm for all others. Number of 
transients collected for each increment in the indirect dimension was 
optimized for each sample to obtain a sufficient signal to noise ratio. 
The spectra were processed with NMRPipe [174] using standard 2D 
processing scripts including a solvent filter in the direct dimension, 
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zero-filling and cosine-bell apodization in both dimensions, and 
polynomial baseline correction in the direct dimension, applied after 
Fourier transform of both dimensions. Linear prediction was generally 
not employed; thus number of complex points correlated directly with 
resolution in the indirect dimension. All NMR spectra were visualized 
and analyzed in NMRViewJ [175]. 
 
II.d. Lipid Vesicle Binding Studied by NMR 
 
Lipid Vesicle Preparation – All lipids were purchased from Avanti 
Polar Lipids as solutions in chloroform and kept at -20 °C. A pre-made 
5:3:2 mix of DOPE:DOPS:DOPC (“coagulation reagent I”) was used as a 
starting point for many lipid composition mixtures. Synthetic lipid 
vesicles of defined composition and different size distributions were 
made by sonication (SUVs) or extrusion (LUVs). In both cases, the 
appropriate volumes of each lipid type (coagulation reagent I, DOPC, 
DOPS, etc) were mixed in a glass tube. Frequently used lipid 
compositions were 15% DOPS 25% DOPE 60% DOPC (1:1 coagulation 
reagent I:DOPC) and 50% DOPS 15% DOPE 35% DOPC. The 
chloroform was removed by drying under nitrogen at 50 °C, followed 
by drying under vacuum. The dried lipid film was resuspended by 
pipetting up and down in the appropriate buffer (usually NMR buffer) 
and vortexing. SUVs were prepared by sonicating the multilamellar 
vesicle suspension in a bath sonicator 4 times for 3 min. The 
suspension became clearer as vesicles became smaller. The 
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suspension was then centrifuged at 60,000 rpm (160,000 x g) at 4 °C 
for 2 hr to remove larger vesicles. The supernatant was used as SUV 
stock. LUVs were prepared by freezing (in liquid nitrogen) and thawing 
(in room temperature water) the multilamellar vesicle suspension 10 
times, then passing 21 times through a 400 nm membrane and 21 
times though a 100 nm membrane using an Avanti mini-extruder. 
While lipid vesicles occupy wide size distributions, SUVs prepared by 
sonication have a distribution centered around a diameter of ~40 nm, 
while LUVs extruded through a 100 nm filter have distribution 
centered around a diameter of ~120 nm, based on dynamic light 
scattering data acquired for similarly prepared vesicles [176]. 
Lipid Vesicle Titrations – Lipid vesicle binding measurements 
were performed using concentration-matched samples with and 
without lipid vesicles. Since the vesicle-bound protein tumbles too 
slowly and is invisible by NMR, peak intensity is proportional to the 
fraction of protein in which that region is not bound to the vesicle. 
Thus, signal intensity changes were used to monitor binding. In a 
flexible and disordered protein like alpha-synuclein, regions of the 
protein that are not bound to the vesicle retain their disordered 
character, allowing for a nonuniform binding profile in which different 
regions of the protein that bind as a unit can be resolved. Peak 
intensity can be averaged over each such region to extract bound 
fractions of specific binding modes: “all bound states,” representing all 
states in which any (N-terminal) region is bound; “fully helical states,” 
representing the state in which the entire N-terminal domain (residues 
~1-100) is bound and presumably helical; and “partly-helical states,” 
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the difference between the two, representing states in which only part 
of the N-terminal domain is bound, presumably in a helical 
conformation. As the C-terminal region is not expected to bind 
appreciably to lipid vesicles, the average intensity ratio of residues 
129-137 was used as a control for protein concentration or nonspecific 
effects on signal intensity. The average intensity ratio of residues 3-9 
and of residues 65-80 was divided by the average of residues 129-137 
and subtracted from 1 to calculate the population of “all bound states” 
and “fully-helical states,” respectively. 
Binding titrations were fit to equations derived from a simple 
bimolecular binding equilibrium using bulk lipid concentration [177]. 
This results in a quadratic equation with only one fitting parameter, 
an apparent KD (e.g. equation 2, below). This one-parameter model 
equates bulk lipid concentration with binding site concentration, 
effectively assuming that each lipid molecule provides one binding site 
for alpha-synuclein. A more nuanced model can be set up by adding a 
parameter for the number of protein binding sites per lipid molecule 
(Bmax). This parameter can be used to calculate the number of lipids 
per binding site (by taking the inverse) and to estimate the number of 
binding sites per vesicle. Thus, the two-parameter model allows one to 
compare not only binding affinity but also quantity of protein “binding 
sites” (e.g. packing defects) on the vesicle. However, due to the 
sparseness of titration data, the one-parameter quadratic model was 
used for most analyses. This quadratic formulation is more rigorous 
than a commonly used hyperbolic model [61], although in the case of a 
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large excess of lipids, the derived apparent KD values do not differ 
significantly. 
As mentioned above, the use of bulk lipid concentration for lipid 
vesicle binding measurements is a necessary oversimplification. 
However, when comparing lipid vesicles of different size, using total 
lipid concentration ignores the difference in accessible outer 
membrane lipid concentration. In a sample with the same total lipid 
concentration, more curved lipid vesicles, such as SUVs, have a 
greater proportion of lipids on the outer surface able to form binding 
sites for protein. Thus, using total lipid concentration would 
underestimate accessible lipid concentration in SUVs relative to LUVs. 
To overcome this, the proportion of outer surface lipids for both SUVs 
(~40 nm in diameter) and LUVs (~120 nm in diameter) was estimated 
as follows: assuming a bilayer thickness of 5 nm, the outer and inner 
radii for SUVs (20, 15 nm) and LUVs (60, 55 nm) were calculated and 
used to determine the surface areas of the outer and inner monolayers 
of each vesicle. Given an estimated lipid headgroup cross-sectional 
area of 0.7 nm2, the number of lipids in each leaflet of each vesicle was 
calculated from the surface areas. As a result, SUVs were found to 
have 64% of total lipid concentration in the outer leaflet, while LUVs 
have 54%. These percentages agree well with those used to calculate 
effective outer lipid concentrations in other studies [61]. 
Fitting of NMR-derived bound fractions for different binding 
modes was performed using both total lipid concentration and outer 
lipid concentration using a simple equation derived from a bimolecular 
 48 
 
binding equilibrium with or without a parameter for the number of 
binding sites per lipid molecule: 
    



  LK+P+LK+P+L=F tappDtappDtt 4P2P/1
2
,,B     
 (2) 
    



  max
2
,max,maxB 4P2P/1 BLK+P+BLK+P+BL=F tappDtappDtt  (3) 
where FB is the bound fraction of the given bound state, Pt is protein 
concentration, L is the lipid concentration, Bmax is the maximum 
number of binding sites per lipid molecule, and KD,app is the apparent 
dissociation constant. Fitting was done with the nonlinear curve fitting 
module in XMgrace and the curve_fit function in SciPy. Apparent 
dissociation constants were used to calculate selectivity for SUVs and 
“helix extension,” which is also the fraction of fully-helical bound 
protein, as follows: 
SUVappDLUVappD KKvitySUVselecti ,,,,       (4) 
tftvufvufullappDtotalappD CCCCCCCCKKextension  ,,,,    (5) 
where KD’s are apparent dissociation constants for the relevant 
binding modes and vesicles, Cu is unbound protein concentration, Cv 
is unbound vesicle concentration, and Ct and Cf are the concentrations 
of total bound protein and fully-helical bound protein, respectively. 
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II.e. In-Cell NMR Experiments 
 
NMR on intact E. coli cells has been applied to examine protein 
(mostly alpha-synuclein) structure in a biologically-relevant 
environment [120,178]. If the cells are grown in isotopically-labeled 
medium and the (overexpressed) protein is sufficiently mobile in the 
crowded intracellular milieu, many multidimensional protein NMR 
methods can be successfully applied to resuspended live cells, 
although cross-peak linewidths are significantly broader than for 
purified proteins in solution. The overexpressed protein signals usually 
dominate the spectra, although intense signals from bacterial 
metabolites and peptides are also present. An important control 
experiment is to examine the cell growth medium for evidence of 
protein leakage, to ensure that the signal in the in-cell NMR 
experiments actually arises from protein located within intact cells. It 
is also essential to quantify the protein concentration in the cell 
sample and compare to the apparent concentration observed in the 
NMR experiments to ascertain whether there is any significant NMR-
invisible population. Large protein complexes tend to tumble very 
slowly in cells and thus become NMR-invisible at an even smaller size 
than in dilute aqueous solution. Finally, NMR experiments can also be 
performed on freshly lysed cells, in which case line broadening is not 
as severe as inside the crowded cells. 
In this work, E. coli BL21 (DE3) cells were transformed with the 
T7 alpha-synuclein plasmid, the pNatB plasmid, or both. Cells 
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expressing solely the NatB complex served as a control, since the 
complex is over 100 kDa in size and should not give rise to detectable 
signals on an HSQC spectrum in either intact cells or cell lysates. 
Transformed E. coli cells were grown according to the media swap 
method in a lower culture volume and the pellet used immediately for 
in-cell NMR. The cell pellet was resuspended by adding NMR buffer 
and 500 μL was taken to serve as the in-cell NMR sample. The 
remainder of the slurry was diluted by addition of 2 mL NMR buffer 
and subjected to sonication. The lysed cell suspension was then 
centrifuged and 500 μL of the supernatant was used as the lysate 
NMR sample. The resuspended cell sample proved refractory to 
shimming, so shimming was performed on the volume- and length-
matched lysate sample. Both samples were analyzed by Varian 
BioPack standard HSQC experiments at 10 °C, with parameters as 
described above. The high concentration of protein the resuspended 
cells and cell lysates allowed for high signal-to-noise with only a few 
transients. 
 
II.f. Triple Resonance NMR Experiments 
 
Experiments for Backbone Assignments – While HSQC 
experiments provide a lot of data, they cannot be used to determine 
the connectivity between residues or reliably report on the local 
secondary structure. A suite of standard triple-resonance experiments 
on uniformly 13C,15N-labeled protein is usually used for these  
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Figure 2.1: Schematics of multidimensional NMR experiments 
used. Red circles and arrows indicate magnetization transfer. 
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applications. Triple-resonance experiments such as HNCA, HN(CO)CA, 
HNCO, HN(CA)CO, HNCACB, and CBCA(CO)NH use scalar coupling to 
correlate the chemical shifts of covalently-bonded nuclei in three 
dimensions [179–182]. Experiments such as HNCA and HNCACB 
correlate carbon nuclei in the i-1 and i residue to amide groups in the i 
residue, while HNCO and CBCA(CO)NH solely correlate i-1 carbons to i 
amides (Figure 2.1). Alpha and beta carbon chemical shifts (and 
carbonyl chemical shifts to a lesser extent) are well-correlated to 
residue type; thus, high quality, complete, and non-overlapped spectra 
from the standard suite of six triple-resonance experiments listed 
above can be combined with knowledge of the amino acid sequence to 
identify sets of dipeptide chemical shifts. These sets of chemical shifts 
can be extended in a step-wise protocol to unambiguously assign 
chemical shifts for the majority of backbone atoms (amide proton, 
amide nitrogen, carbonyl carbon, and alpha [and beta] carbon) (e.g. 
[183]). 
Amide chemical shifts obtained from this assignment protocol 
can be used to analyze HSQC spectra from binding titrations or other 
experiments. In addition, alpha, beta, and carbonyl carbon chemical 
shifts are highly sensitive to local secondary structure and are often 
analyzed in the form of secondary shifts, or differences between 
measured chemical shifts and sequence-calculated random-coil 
chemical shifts [184,185]. Positive (negative for beta carbon) secondary 
shifts reflect α-helix structure, while negative (positive for beta carbon) 
secondary shifts reflect extended structure, chiefly β-sheet/strand or 
polyproline type II helix. Plots of secondary shifts versus protein 
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primary sequence can reveal regions of stable or nascent secondary 
structure. Contiguous secondary shifts greater than +/- 2 ppm are 
indicative of stable helix or sheet structure, respectively [186].  For 
slightly modified protein constructs, such as point mutants and 
phosphorylated or acetylated versions of alpha-synuclein, an HNCA 
experiment with very high resolution in the alpha-carbon dimension 
can suffice to determine amide (and alpha-carbon) assignments 
starting from previously known wild-type alpha-synuclein assignments 
[42,71]. 
NOESY Experiments – Connectivity can also be determined using 
isotope-filtered NOESY experiments, which take advantage of the 
nuclear Overhauser effect (NOE) to transfer magnetization through-
space (as opposed to through-bond) using dipolar couplings between 
nuclei. Since the NOE is proportional to r-6, where r is the distance 
between two nuclei, the transfer is only efficient for nuclei within a 
short distance (typically < 5 Å) of each other. Different secondary 
structure elements are characterized by unique patterns of NOE 
connectivity between sequential residues. For example, an α-helical 
region displays strong i,i+1 amide proton-amide proton NOE cross-
peaks and i,i+3 and i,i+4 amide proton-alpha proton NOE cross-peaks, 
while a β-sheet is characterized by stronger i,i+1 amide proton-alpha-
proton cross-peaks and weaker i,i+1 amide proton-amide proton cross-
peaks as well as the appearance of cross-strand amide proton-alpha 
proton cross-peaks [187]. Proton-proton NOESY experiments had been 
used extensively to determine sequential residue connectivity for short 
peptide assignments [187]; however, this use has been superseded by 
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heteronuclear 2D and 3D NMR for larger proteins due to spectral 
crowding in the presence of so many protons. Isotope-filtered (13C or 
15N) NOESY experiments, coupled with known side-chain and 
backbone assignments, are now used to provide distance restraints for 
structure calculations. 
Further filtering, such as in a 1H,15N-HSQC-NOESY-HSQC 
experiment, can decrease spectral crowding even more [188]. In this 
experiment, cross-peaks arising from i,i-1 and i,i+1 pairs of amide 
protons are visualized. Since the magnetization transfer is due to an 
NOE mixing period rather than scalar coupling (through-space versus 
through-bond), only cross-peaks arising from regions of relatively rigid 
and collapsed secondary structure, such as α-helix, β-sheet, or turns, 
will be visible. This experiment can be used to confirm backbone 
amide assignments in structured regions or determine the existence of 
structured regions if assignments are known. This strategy has been 
used to delineate the break between the two antiparallel helices in the 
micelle-bound form of alpha-synuclein [71,72]. 
Multidimensional experiments were usually collected on 
spectrometers from 600 to 900 MHz. HNCA experiments had 50-72 
complex pairs in the nitrogen indirect dimension and 130-160 complex 
pairs in the carbon indirect dimension. HNCO experiments had 50-72 
complex pairs in the nitrogen indirect dimension and about 64 
complex pairs in the carbon indirect dimension. 1H,15N-HSQC-NOESY-
HSQC experiments were run using a pulse sequence adapted from a 
four-dimensional proton-nitrogen-nitrogen-proton experiment [189] to 
yield proton-nitrogen-nitrogen chemical shifts and collected with 96 
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complex pairs in the first nitrogen dimension and at least 128 complex 
pairs in the second nitrogen dimension to provide sufficient resolution 
to overcome peak overlap. The spectral windows for nitrogen were as 
described above for HSQC spectra, while alpha-carbon and carbonyl 
spectral windows were usually 44-70 and 170-180 ppm, respectively. 
Number of transients collected for each increment in the indirect 
dimensions was optimized for each sample to obtain a sufficient signal 
to noise ratio in a reasonable amount of time (1-3 days for HNCA or 
HNCO, 3-4 days for 1H,15N-HSQC-NOESY-HSQC). The spectra were 
processed with NMRPipe [174] using standard 3D processing scripts 
including a solvent filter in the direct dimension, zero-filling and 
cosine-bell apodization in all dimensions, and polynomial baseline 
correction in the direct dimension, applied after Fourier transform of 
the second dimension. As for two-dimensional experiments, linear 
prediction was generally not employed. All NMR spectra were 
visualized and analyzed in NMRViewJ [175]. 
 
II.g. Relaxation NMR Experiments 
 
Relaxation (R1 and R2) Experiments – Longitudinal (“spin-lattice,” 
relaxation time T1, relaxation rate R1) and transverse (“spin-spin,” 
relaxation time T2, relaxation rate R2) relaxation are properties of 
NMR-active nuclei that generally reflect the mobility or flexibility of the 
molecule in that region. R2 relaxation rates of amide nitrogen nuclei (or 
side-chain methyl groups) are often used to estimate flexibility of a 
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protein arising from motions on the picosecond-nanosecond timescale 
or slower conformational or chemical exchange processes on the 
millisecond timescale [190]. Residue-specific R2 relaxation rates can be 
measured by collecting a series of HSQC-like experiments with 
variable time delays inserted when the magnetization resides on the 
amide nitrogen and is transverse (in the x-y plane), with CPMG (Carr-
Purcell-Meiboom-Gill) refocusing pulses interspersed [191]. The signal 
intensity for each amide cross-peak is plotted as a function of the time 
delay and fit to a single exponential to extract the R2 relaxation rate. 
Relaxation time delays should be long enough to achieve at least a 
70% reduction in signal intensity at the longest time point in order to 
get accurate fits. Peak intensities as a function of delay time were fit to 
a single exponential decay function using internal NMRViewJ [175] 
fitting module. The equation used was: 
tR
eII 20
            (6) 
where I is the signal intensity at time t, I0 is the (fit parameter) 
intensity at time 0, R2 is the relaxation rate, and t is the relaxation 
time delay. 
The measured R2 rates of a sample undergoing slow exchange to 
an invisible bound state can be decomposed into the R2 rate of the un-
bound state and a contribution from the binding process. When the 
forward binding rate is similar to the intrinsic R2 rate (which is very 
slow for free alpha-synuclein), the binding rate constant can be 
estimated from R2 measurements. Assuming that the exchange is 
between only two states, the bound and un-bound, and that only one 
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state can be observed, measurement and subtraction of R2 rates in the 
presence and absence of binding partner (e.g. lipid vesicles) can yield 
the on-rate contribution [92], and, when adjusted for protein and 
binding partner concentration, the second-order binding rate constant 
kon in units of sec-1M-2. 
 
II.h. PRE NMR Experiments 
 
Spin-Labeling for PRE Experiments – To achieve site-directed 
spin-labeling of proteins, single cysteine mutants of alpha-synuclein 
were labeled with paramagnetic moieties using two different 
approaches. In one, a methanethiosulfonate (MTS)-functionalized 
nitroxide spin label (S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-
pyrrol-3-yl)methyl methanesulfonothioate, MTSL, Toronto Research 
Chemicals) was covalently linked to the cysteine residue using MTS 
chemistry resulting in a disulfide bond. The lyophilized desired 
cysteine mutant of alpha-synuclein was dissolved in NMR buffer 
(usually 10 mM Na2HPO4, 100 mM NaCl, pH 6.8, see below) and 10 
equivalents of MTSL (from a stock dissolved in DMSO and stored at -
80 °C) was added. The pH was adjusted to above 5 to facilitate 
disulfide bond formation and the reaction mixture incubated with 
rocking for 30 min at room temperature. Excess unbound spin-label 
was removed using two sequential hand-poured size-exclusion 
columns (2 mL, Sephadex G25 beads) equilibrated 3 times with 2 mL 
NMR buffer. The conjugated protein sample was split into two, and 2 
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mM (final concentration) DTT added to one (equivalent volume of 
deionized H2O to the other) to reduce off the conjugated spin-label. 
After addition of 10% (final concentration) D2O and, optionally, 
detergent, the DTT-free and DTT-containing samples were used as the 
paramagnetic sample and diamagnetic control, respectively. 
The second labeling method made use of a cysteine-linked EDTA 
(N-[S-(2-pyridylthio)cysteaminyl]-EDTA, CysEDTA, Toronto Research 
Chemicals) chelated with either a paramagnetic (Mn2+) or a 
diamagnetic (Ca2+) divalent cation [74]. The lyophilized desired cysteine 
mutant of alpha-synuclein was dissolved in PRE buffer 1 (20 mM 
PIPES, 200 mM NaCl, 25 mM EDTA, pH 6.8) and 10 equivalents of 
CysEDTA (from a stock dissolved in methanol and DMSO and stored 
at -80 °C) was added. The reaction mixture was incubated with 
rocking for 30 min at room temperature. Excess unbound CysEDTA 
was removed using a PD-10 buffer-exchange column pre-equilibrated 
with PRE buffer 2 (20 mM PIPES, 20 mM NaCl, pH 6.8). The sample 
was split into two and 50 mM (final concentration) MnCl2 or CaCl2 
added to the two samples. The samples were incubated with rocking at 
room temperature for 1 hr to facilitate metal chelation. Residual metal 
ions were removed from each sample using a PD-10 buffer-exchange 
column pre-equilibrated with PRE wash buffer (20 mM PIPES, 700 mM 
NaCl, pH 6.8). Each sample was then exchanged into PRE buffer 2 and 
concentrated to a volume suitable for NMR samples using centrifugal 
filters with a 3,000 MW cutoff. The advantage of the metal chelation 
approach is that the paramagnetic and diamagnetic samples are more 
similar, both containing alpha-synuclein covalently bonded to a metal-
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chelated EDTA moiety, while the chemical difference between the 
MTSL-conjugated and unconjugated samples is greater and even 
manifests as chemical shift perturbations around the conjugation site. 
In addition, Mn2+ exerts a greater PRE effect due to having 3 unpaired 
electrons. The drawback of the metal chelation approach lies in the 
fact that alpha-synuclein is known to bind divalent metal cations; thus, 
extensive washing is needed. 
Spin-labels were also incorporated into detergent micelles using 
5-doxyl-stearate, a fatty acid with a nitroxide spin-label installed near 
the headgroup, to measure PRE between the micelle and bound 
protein. The position of the nitroxide near the headgroup of the fatty 
acid results in a notable PRE effect to protein bound to the surface of 
the micelle; the reagent 16-doxyl-stearate can be used to probe for 
PRE effects deeper in the micelle core, but was not utilized in these 
studies. A similar approach using incorporation of 5- or 16-doxyl-
stearate into lipid vesicles can be used to examine protein-vesicle 
interactions, but was not used in this work [75]. 
PRE Experiments – Sample preparation for PRE experiments was 
described above. PRE experiments rely on the dipole-dipole 
interactions between introduced unpaired electrons, usually in the 
form of a spin-label radical, and NMR-active nuclei. Since the electron 
gyromagnetic ratio is about 1000 times greater than that of a proton, 
proton relaxation is greatly increased when compared to proton-proton 
dipole relaxation. The signal intensity is still lost as a function of r-6, 
where r is the distance between the unpaired electron and the proton 
or other NMR-active nucleus, but the PRE effect is typically seen out to 
 60 
 
distances as high as 25 Å away from the spin label. By controlling the 
location of the introduced paramagnetic moiety using site-directed 
spin-labeling, it becomes possible to identify nuclei on the same 
molecule (intramolecular PRE) or on contacting molecules 
(intermolecular PRE) that come within 25 Å of the labeling site, even 
transiently [192]. One advantage of PRE experiments is that even 
transient contacts leave a detectable signal; another is that rough 
distance restraints can be derived for structure calculation. 
Complete PRE experiments involve measuring the amide proton 
R2 relaxation rate in the presence and absence of paramagnetic moiety 
using a suitable pulse sequence (e.g. [193]) and the analysis discussed 
above, then subtracting the two rates to derive the PRE contribution to 
R2, termed Γ2. A plot of Γ2 versus protein primary sequence reveals the 
regions that come in proximity of the paramagnetically-labeled site. 
Since amide cross-peak signal intensities are proportional to R2, the 
ratio between signal intensities in matched paramagnetic and 
diamagnetic 1H,15N-HSQC experiments can approximate Γ2 [194]. The 
latter approach was used exclusively in this work. 1H,15N-HSQC 
experiments were collected on concentration-matched paramagnetic 
and diamagnetic samples and processed and described above. 
 
II.i. Amide Proton Exchange Experiments 
 
Amide protons not protected by participating in hydrogen bonds 
or buried in the protein core are subject to exchange with the solvent. 
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This exchange happens on a similar timescale to other chemical 
exchange events and often leads to broadening of signals beyond 
detection. This process occurs to an even greater degree at high 
temperature and pH. While amide proton exchange is often 
undesirable, measurement of the rate of exchange through amide 
proton exchange (HX) experiments can provide important information 
about the structure of the protein. 
HX experiments were performed on the SDS-bound state of 
alpha-synuclein at pH 8.4 to examine the extent of protection (by 
secondary structure or micelle-association) of different regions of the 
protein. The rate of proton exchange was measured using a modified 
Bruker HSQC sequence based on a previously published experiment 
by Ulmer et. al [74]. Ratios of peak intensity after application of a 
water inversion pulse to peak intensity without the pulse were 
calculated and plotted versus the protein primary sequence; peaks 
which were not observable at pH 8.4 without an inversion pulse were 
deemed to be exchanging very rapidly and assigned an intensity ratio 
of -1. Since the intensity ratio is proportional to the rate of exchange, 
it reports on the extent of protection from exchange for each residue. 
HSQC experiment parameters and processing were as described above. 
 
II.j. Diffusion NMR Experiments 
 
NMR spectroscopy has long been applied to measure diffusion 
rates in solution using pulsed field gradient (PFG) methods (e.g. [195–
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197]). The basic PFG LED (longitudinal-eddy-current delay) pulse 
sequence contains an “encoding” gradient pulse that imparts 
positional information to the nuclei in the sample, followed by a 
diffusion delay and a “decoding” gradient pulse that “reads” positional 
information from the nuclei. Since gradient pulses are by definition 
position dependent and the molecules are free to diffuse to different 
positions in between the encoding and decoding gradients, the full 
signal intensity will not be recovered after a diffusion delay. The rate of 
diffusion of each molecule/nucleus, as described by the diffusion 
constant, will determine how much signal intensity is recovered. In 
addition, the signal intensity depends on the diffusion delay length 
and gradient strength by the following relationship [195,196]: 
    DGII 23exp 20         (7) 
where I/I0 is the relative signal intensity, γ is the gyromagnetic ratio (of 
proton in this case), δ is the length of the gradient pulse, G is the 
strength of the gradient pulse, ∆ is the diffusion delay, τ is the gradient 
spacer delay, and D is the diffusion coefficient. As can be seen from 
equation 7, the signal intensity depends on the diffusion delay or the 
square of the gradient strength; thus, either can be varied and the 
diffusion coefficient determined by fitting to equation 7. 
The diffusion coefficient depends on solution viscosity and other 
variables, as per the Stokes-Einstein equation and can thus yield size 
information. Although molecular shapes differ from that of a perfect 
sphere, the Stokes-Einstein equation can be used to calculate the 
hydrodynamic radius (RH, or “radius of hydration”), the radius of the 
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molecule if it were a sphere, a useful size parameter. Since D and RH 
are inversely correlated, the other components of the Stokes-Einstein 
equation can be canceled out by including a standard of known RH in 
the same sample and calculating the RH of the unknown molecules 
from the inverse ratio of the diffusion coefficients. One commonly used 
standard is 1,4-dioxane, which has a hydrodynamic radius RH of 2.12 
Å [198]. 
Diffusion measurements were performed using a standard 
Bruker PFG LED pulse sequence [196] on proteins and 2H SDS (so as 
not to swamp the protein signal) dissolved in D2O with 0.03% v/v (~4 
mM) dioxane at 300 K using a Bruker AVANCE 500 MHz spectrometer 
with a room-temperature probe. Gradient strength was varied in a 32-
step linear gradient between 2 and 95% of the maximum strength. The 
diffusion delay was optimized to achieve ~10% signal intensity with 
95% gradient strength. The signal intensity for several protein and 
SDS aliphatic peaks, as well as the dioxane peak at ~3.6 ppm, was 
plotted as a function of gradient strength and fit to equation 7 using 
the Bruker TopSpin relaxation analysis module, which also provided 
the default value for maximum gradient strength. Maximum gradient 
strength can also be calculated by measuring the diffusion coefficient 
of residual HDO in D2O and setting it equal to the published value of 
1.902 +/- 0.002 x 10-9 m2-sec-1 [199]. 
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II.k. CD Spectroscopy 
 
CD Spectroscopy Experiments – Far-UV CD spectroscopy can 
rapidly provide low-resolution information about protein secondary 
structure, requiring moderate sample concentration, by measuring the 
ellipticity of circularly polarized light passed through the sample 
[200,201]. While ellipticity spectra can be quantitatively decomposed 
into fractional contributions of helix, sheet, and coil structure 
[202,203], robust results require very high quality data that extends to 
short wavelengths (at least down to 190 nm). Reasonable estimates of 
secondary structure can be made more easily using specific spectral 
features in the far-UV region. Random coil or unstructured proteins 
have a relatively flat spectrum with a minimum at 195 nm [204], while 
α-helical structure shows characteristic minima at 208 and 222 nm 
and a maximum at 193 nm [205]. The signature for β-sheets is a 
minimum at 218 nm and a maximum at 195 nm [206]. Folding or 
unfolding events can thus be tracked by a gain or loss of signal at one 
of these signature wavelengths; for example, CD spectroscopy 
(monitored at 220 or 222 nm) is often used to determine thermal 
denaturation curves for proteins (e.g. [207]). In the case of alpha-
synuclein, where the transition is from predominantly disordered to α-
helix, ellipticity at 222 nm serves as a useful measure of helical folding 
and thus binding to detergent micelles or lipid vesicles [208]. 
Far-UV CD spectra from 200 to 250 nm were collected on an 
AVIV Biomedical Model 410 CD spectrometer with bundled software. 
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Due to scattering/absorption between 190 and 200 nm by sample 
components such as Cl- ions or lipid vesicles, spectral quality below 
200 nm degraded rapidly. The wavelength step was 1 nm, with an 
averaging time of 1.5 sec per measurement. All spectra were collected 
at 25 °C on 50-100 μM alpha-synuclein dissolved in NMR buffer in a 
quartz cuvette (Starna) with a pathlength of 0.02 cm. Titrations were 
carried out with matched samples (70 μL) made from the same stocks 
of protein and lipid vesicles or detergent. Matched “blank” samples 
containing buffer and the same concentration of titrant without 
protein were collected for each titration point. 
Each spectrum was collected 3 or 4 times, then averaged and 
the matching blank average subtracted. The measured signal was 
converted into mean residue ellipticity using the following equation: 
  Cnl10          (8) 
where [Θ] is mean residue ellipticity in deg-M-1-m-1, θ is ellipticity in 
millidegrees, C is protein concentration in molar, n is the number of 
amino acids, and l is the pathlength in centimeters. The value of [Θ]222 
was then used for fitting binding equations (see below) or to calculate 
percent helicity: 
        coilhelixcoilhf  222        (9) 
where fh is the fraction of helical residues, [Θ]222 is mean residue 
ellipticity at 222 nm, and [Θ]coil and [Θ]helix estimate minimum and 
maximum ellipticity, calculated from the equations below: 
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  Tcoil 532220          (10) 
    rhelix NT 3125044000         (11) 
where T is temperature in degrees Celsius and Nr is the number of 
residues [209,210]. 
Fitting of Titrations – Binding titrations were monitored by CD 
and spectroscopy and binding was quantified as increase in helical 
structure as measured by the mean residue ellipticity at 222 nm. 
Fitting of CD binding data was complicated by the inability to reach 
saturation at maximum attainable detergent concentrations (~600 
mM), which were limited by low solubility and increased scattering at 
low wavelengths. To overcome this, bound fractions were not 
calculated before fitting; instead, the mean residue ellipticities at no 
binding and at full binding were estimated from inspection of the 
binding curves. These values were then used in the following equation: 
            minminmaxtappDtDtt +BK+P+BK+P+B= 


  4P2P/1
2
,222 (12) 
where [Θ]222 is mean residue ellipticity at 222 nm, Pt is protein 
concentration, B is the bulk BOG concentration, KD,app is the apparent 
dissociation constant, [Θ]max is mean residue ellipticity at full binding 
and [Θ]min is mean residue ellipticity at no binding. Fitting was done 
with the nonlinear curve fitting module in XMgrace and the curve_fit 
function in SciPy. 
To compare binding data derived from CD and NMR 
measurements, the signal reporting on binding, [Θ]222 in CD 
measurements and ∆δavg for well-resolved residues in the NMR 
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titrations, was normalized to between 0 and 1 at the minimum  and 
maximum values obtained, respectively. The normalized CD and NMR 
binding data could thus be compared on a unitless axis. Since the 
data reported on the fraction bound, they were fit to equation 2. 
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III. N-terminal acetylation increases alpha-synuclein helicity and 
binding to curved, low-negative-charge membranes 
 
III.a. Introduction 
 
N-terminal acetylation, first discovered in 1958 in the TMV coat 
protein [135], is one of the most common protein modifications in 
eukaryotic organisms. It has been known since the 1970s that as 
much as 80% of cytosolic mouse proteins (measured in Ehrich ascites 
cells) may be N-terminally acetylated [136]. More recent proteomics 
analyses have determined that 84% of human and 57% of yeast 
proteins are N-terminally acetylated [137]. N-terminal acetylation is 
thought to occur on the ribosome [139,140], often in concert with 
initiator methionine cleavage [141,142], and involves the transfer of an 
acetyl group from acetyl coenzyme A to the primary N-terminal amine 
by one of a group of N-acetyltransferase complexes (NatA-NatF) 
conserved in eukaryotes [137,138]. Each of the different N-
acetyltransferase complexes acetylates a subset of proteins depending 
on the sequence of the N-terminal two or three residues [143,144]. 
Prokaryotes, on the other hand, have a completely incompatible N-
terminal acetylation system [145]; thus, eukaryotic proteins produced 
recombinantly in bacterial systems are not N-terminally acetylated. 
Unlike phosphorylation and lysine acetylation, N-terminal 
acetylation is not a reversible modification and therefore unlikely to be 
involved in dynamic protein regulation [138]. Although the majority of 
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eukaryotic proteins are N-terminally acetylated, there is no consensus 
as to a general role or effect of this modification, although several 
suggestions have been put forth. One of the most well-established 
candidates for a global function of N-terminal acetylation is the Ac/N-
end rule pathway, a subset of the N-end rule degradation pathway in 
which N-terminally acetylated proteins are recognized by a specific E3 
ubiquitin ligase, polyubuquitylated, and subsequently degraded 
[211,212]. The Ac/N-end rule pathway is hypothesized to regulate, via 
degradation, the proper localization of N-terminally acetylated proteins 
via exposure or shielding of the acetylated N-terminus [212]. In this 
model, all N-terminally acetylated proteins are targeted for degradation 
unless the N-terminal degradation signal is shielded via intramolecular 
folding, oligomerization, or interaction with a binding partner. This 
system could be used to regulate protein levels to prevent the 
overabundance of nonfunctioning proteins. The process of shielding 
and exposure of a protein’s N-terminal acetyl group can thus 
counteract the irreversibility of the N-terminal acetylation reaction 
itself and function as a dynamic signal similar to phosphorylation. 
Accumulated evidence of acetylated N-termini playing important 
roles in protein-protein or protein-membrane interactions support this 
regulatory model. N-terminal acetylation has often been shown to 
increase avidity in specific protein-protein interactions, such as 
carboxypeptidase Y with its inhibitor Tfs1p [213]; tropomyosin with 
actin [214]; the Nedd8 E2 Ubc12 with the E3 Dcn1 [215]; and Sr3 with 
nucleosomes [216]. The crucial role that N-terminal acetylation plays 
in protein-protein recognition and binding in these biologically-varied 
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cases suggests that this modification can play a general role as an 
avidity enhancer. Additionally, the burial of the acetylated N-terminal 
in all of these cases supports the Varshavsky model of Ac/N-end rule 
degradation. 
N-terminal acetylation does not only affect protein interactions 
with other proteins; it has also been shown to play a role in membrane 
localization. For instance, N-terminal acetylation of chaperonin 10 was 
shown to increase the helicity of its N-terminal, uncleaved 
mitochondrial import sequence and posited to promote mitochondrial 
import by increasing membrane binding [217]. This finding agrees with 
early work on synthetic model peptides, which found that acetylation 
of the N-terminal amine stabilizes helicity by acting as a helix N-cap 
[218,219]. More specifically, N-terminal acetylation (and C-terminal 
amidation) increased the helicity of a model peptide derived from an 
amphipathic helix from a plasma apolipoprotein both in buffer and in 
the presence of lipids [218]. These early data provide evidence that N-
terminal acetylation can increase binding to membranes, and also 
propose a structural mechanism in the form of stabilized helicity in an 
amphipathic N-terminal region. 
Further evidence implicates N-terminal acetylation of proteins in 
their localization to specific membranes. For instance, the loss of the 
N-acetyltransferase NatC activity in yeast resulted in failure of the 
nuclear protein Trm1-II to localize to the inner nuclear membrane 
[220]. N-terminal acetylation by NatC was found to be necessary but 
not sufficient for inner nuclear membrane localization. Similar 
situations were described for Arl3p targeting to the Golgi [221,222], 
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Grh1 localization to the cis-Golgi [223], and Gag coat protein (N-
terminally acetylated by NatC) incorporation into viral particles [224]. 
While some of these systems have also been demonstrated to have an 
N-terminal amphipathic helix [221–223], the fact that other proteins 
are required to effect the correct localization means that either protein-
protein interactions or direct protein-membrane interactions (or both) 
are affected by N-terminal acetylation in these cases. 
Modification of the N-terminus of alpha-synuclein was noted as 
early as 1994 when alpha-synuclein purified from human brain was 
found to be N-terminally blocked and not amenable to Edman 
degradation [24]. Similar findings were made for 
“phosphoneuroprotein-14,” eventually named beta-synuclein [22,23]. 
However, the shift to recombinantly-produced proteins for biophysical 
and biochemical studies precluded further study of the nature of this 
N-terminal modification for over a decade.  
Then, a study comparing modifications of cytosolic and Lewy 
body alpha-synuclein in human brains by mass spectrometry 
confirmed that N-terminal acetylation is ubiquitous in both pathogenic 
and nonpathogenic species of alpha-synuclein [146]. Additionally, 
members of the yeast NatB complex appeared in a screen targeting 
mislocalization of alpha-synuclein heterologously expressed in yeast 
[147]. When either of two subunits of the NatB complex was knocked 
out, the usual plasma membrane localization of alpha-synuclein in 
yeast was lost, resulting in a diffuse, cytosolic localization. NatB is 
known to acetylate proteins with N-terminal Met-Asp and Met-Glu 
sequences [143], which includes alpha-synuclein; therefore, it was 
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posited that NatB directly acetylates the N-terminal amine of alpha-
synuclein, and this modification is important for its membrane 
localization. However, since N-terminal acetylation of alpha-synuclein 
was not measured directly in this study, it remained possible that the 
mislocalization was due to loss of N-terminal acetylation of any 
number of other proteins. 
Further evidence for a potential role of N-terminal acetylation in 
alpha-synuclein function surfaced in 2011-12, when several research 
groups reported the isolation of a form of alpha-synuclein with 
characteristics of a helical tetramer. In each of these reports, the 
isolated protein was N-terminally modified, either by N-terminal 
acetylation [114,118] or by a decapeptide left over from a cleaved 
purification tag [117]. One of the studies suggested that N-terminal 
acetylation, along with purification in a buffer containing the detergent 
β-octyl glucoside was necessary for isolation of the helical tetramer 
[118]. These findings sparked intense interest in the structural and 
functional effects of N-terminal acetylation of alpha-synuclein. 
 
III.b. Methods 
 
Production of Acetylated Protein – N-terminally acetylated alpha-
synuclein was produced recombinantly in E. coli using a previously 
developed co-transformation method [168,169]. The bacterial cells are 
transformed with the T7 alpha-synuclein plasmid and with a 
pACYCduet plasmid containing the subunits (Naa20 and Naa25) of the 
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yeast N-acetyltransferase complex NatB (pNatB), kindly provided by Dr. 
Daniel Mulvihill (University of Kent, UK) via Dr. Elizabeth Rhoades 
(Yale University). Upon induction, the NatB components are produced 
and acetylate the alpha-synuclein protein co-translationally in the 
bacterial cells. The pNatB plasmid contains a chloramphenicol 
resistance marker for co-selection with the T7 alpha-synuclein plasmid. 
For production of N-terminally acetylated alpha-synuclein, the T7 
alpha-synuclein plasmid and pNatB plasmid were simultaneously 
transformed into the bacterial cells, which were then plated on agar 
plates containing ampicillin (100 μg/mL) and chloramphenicol (34 
μg/mL). The protein was then expressed and purified as detailed in 
section II.a. 
In-Cell NMR – The effects on alpha-synuclein structure in the 
absence of potentially perturbing purification methods were 
determined using in-cell and cell lysate NMR. E. coli BL21 (DE3) cells 
were transformed with the T7 alpha-synuclein plasmid, the pNatB 
plasmid, or both. Cells expressing solely the NatB complex served as a 
control, since the complex is over 100 kDa in size and should not give 
rise to detectable signals on an HSQC spectrum in either intact cells or 
cell lysates. Transformed E. coli cells were grown according to the 
media swap method in a lower culture volume. Specifically, cells were 
grown in 1 L LB broth until an OD of 0.6-1.0 was reached, then 
centrifuged at 6,000 rpm (6,900 x g) for 15 minutes at 24 °C and the 
pellet resuspended in 0.25 L wash medium. The resuspended cells 
were then centrifuged again at 6,000 rpm (6,900 x g) for 15 minutes at 
24 °C and the pellet resuspended in M9 minimal medium, 
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supplemented with BME vitamins, the appropriate antibiotics, and 1 g 
uniformly labeled 15N ammonium chloride and 4 g natural abundance 
dextrose. After recovery at 37 °C in minimal medium for 0.5-1 hr, 
protein expression was induced using ~1 mM IPTG and continued for 
3 hr. A 1 mL sample was taken every 1 hr to check OD and saved to 
estimate protein expression using SDS-PAGE. Cells were harvested by 
centrifugation at 6,000 rpm (6,900 x g) for 15 minutes and the pellet 
used immediately for in-cell NMR. 
The cell pellet was resuspended by adding 500 μL NMR buffer to 
a total volume 2.5 mL, 500 μL of which was taken to serve as the in-
cell NMR sample after adding 55 μL D2O. The remainder of the slurry 
was diluted by addition of 2 mL NMR buffer and (final concentrations) 
1 mM EDTA and 1 mM PMSF. The suspension was subjected to 
sonication by a micro-tip sonifier (Branson) for 6 minutes at a power 
setting of 4 with a duty cycle of 50%, on ice. The lysed cell suspension 
was then centrifuged at 15,000 rpm (18,000 x g) for 20 min at 4 °C 
and 500 μL of the supernatant were supplemented with 55 μL D2O 
and used as the lysate NMR sample. The resuspended cell sample 
proved refractory to shimming, so shimming was performed on the 
volume- and length-matched lysate sample. Both samples were 
analyzed by Varian BioPack standard HSQC experiments at 10 °C, 
with parameters as described above. The high concentration of protein 
the resuspended cells and cell lysates allowed for high signal-to-noise 
with only a few transients.  
Protein concentrations in the resuspended cell and lysate 
samples for both alpha-synuclein and alpha-synuclein + NatB were 
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quantified by SDS-PAGE with BSA standards. Samples of the 
resuspended cells or cell lysates (usually 2, 3, 4, 5, and 6 μL in 16 μL 
total sample) were run on an SDS gel along with samples of BSA with 
a predetermined concentration (by absorbance at 280 nm using an 
extinction coefficient of 43824 M-1*cm-1). The gel was stained, 
destained overnight, imaged, and the band intensity quantified using 
ImageJ software [171]. The band intensity was then correlated with 
concentration for the BSA samples, and concentration of alpha-
synuclein was calculated from the band intensity, adjusted for number 
of amino acids, of resuspended cell and lysate samples. The relative 
concentrations of acetylated and unmodified alpha-synuclein observed 
by NMR were estimated using the intensities of several well-resolved 
amide cross-peaks arising from residues 31, 41, 54, 67, 86, 92, and 
140 and compared to that measured by SDS-PAGE. 
NMR Experiments on Purified Protein – Purified N-terminally 
acetylated protein was used to characterize the effects of the 
acetylation on the free and micelle- and vesicle-bound states of alpha-
synuclein. Backbone assignments were transferred from previously 
determined ones using high-resolution HNCA experiments, which also 
provided alpha-carbon chemical shifts for secondary structure 
analysis (see section II.f). Amide chemical shift deviations derived from 
1H,15N-HSQC experiments were used to monitor the effects of N-
terminal acetylation (see section II.c). The effect of N-terminal 
acetylation on the broken-helix state of alpha-synuclein was assessed 
at 40 mM SDS, a concentration at which the detergent is expected to 
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form spheroidal micelles [225,226]. Again, secondary structure 
information was derived from HNCA experiments. 
Most NMR experiments in the presence of BOG micelles were 
performed at 100 mM BOG to avoid the peak intensity loss seen at 
higher BOG concentrations. An HNCA experiments was performed at 
higher (300 mM) BOG concentration to determine the maximum 
helical structure in the BOG-bound state. Deuterated BOG was 
employed for this experiment to minimize magnetization loss from the 
protein nuclei via spin diffusion within the micelle. 
Amide Proton Exchange Experiments – Amide protons 
participating in hydrogen bonds as part of stable secondary structure 
are protected from exchange with the solvent, even at high pH and 
temperature, and display decreased exchange rates. HX experiments 
were performed on the SDS-bound state of alpha-synuclein at pH 8.4 
to examine the extent of protection (by secondary structure or micelle-
association) of different regions of the protein. The rate of proton 
exchange was measured using a modified Bruker HSQC sequence 
based on a previously published experiment by Ulmer et. al [74]. A 5 
msec Q3 inversion pulse [227] was applied to the water signal 10, 20, 
or 50 msec before the start of the HSQC experiment, resulting in 
greatly reduced or even inverted signal intensity for rapidly-exchanging 
amide protons, compared to the signal intensity in a spectrum 
collected without the inversion pulse. Intensity ratios were calculated 
and plotted versus the protein primary sequence; those peaks which 
were not observable at pH 8.4 even without an inversion pulse were 
deemed to be exchanging very rapidly and assigned an intensity ratio 
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of -1. Since the intensity ratio is proportional to the rate of exchange, 
it reports on the extent of protection from exchange for each residue 
(see section II.i). 
CD Spectroscopy – Binding to BOG micelles was monitored by 
increasing helicity as measured by far-UV CD spectroscopy. Percent 
helicity was calculated using equation 9 from ellipticity at 222 nm and 
converted to number of fully helical residues using the number of 
residues in alpha-synuclein (140). Fitting of CD binding data was 
complicated by the inability to reach saturation at the concentrations 
of detergent used. To overcome this, bound fractions were not 
calculated before fitting; instead, the mean residue ellipticities at no 
binding and at full binding were estimated from inspection of the 
binding curves. The value of the mean residue ellipticity at 222 nm at 
0 mM BOG for unmodified and acetylated alpha-synuclein was used 
as the value for no binding, while the value at 400 mM BOG for 
acetylated alpha-synuclein was used as the value for full binding for 
both proteins, assuming the fully-bound state has similar levels of 
helicity regardless of acetylation. Thus, BOG binding data from CD 
spectra was fit to equation 12, with [Θ]max (mean residue ellipticity at 
full binding) set to -5060 deg-M-1-m-1 and [Θ]min (mean residue 
ellipticity at no binding) set to -2343 and -2811 deg-M-1-m-1 for 
unmodified and acetylated alpha-synuclein respectively. 
A titration of unmodified and acetylated alpha-synuclein with 
similar concentrations of BOG (0 to ~300 mM) was performed and the 
interaction monitored by 1H,15N-HSQC spectra. In the NMR 
experiments, binding to detergent micelles was quantified as the amide 
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chemical shift difference from the free spectrum for several well-
resolved residues, with residues 11 and 16 shown here. To compare 
BOG binding data derived from CD and NMR measurements, the 
signal reporting on binding, [Θ]222 in CD measurements and ∆δavg for 
two residues in the NMR titrations, was normalized to between 0 and 1 
at the minimum (at 0 mM BOG) and maximum (at 400 mM BOG in CD 
experiments and 321 mM BOG in NMR) values obtained, respectively. 
The two sets of normalized NMR binding data from residues 11 and 16 
were averaged, although they were nearly identical. The normalized CD 
and NMR binding data could thus be compared on a unitless axis. 
Since the data reported on the fraction bound, they were fit to 
equation 2. 
Relaxation Experiments – Amide proton R2 measurements in the 
presence of BOG micelles were carried out by running Varian BioPack 
HSQC-based T2 experiments with spectral windows and number of 
points as described in section II.c, using delays of 10, 10, 10, 30, 30, 
50, 70, 90, and 110 msec. CPMG 15N refocusing pulses were at 625 
μsec intervals. The relaxation rates for each residue were calculated as 
detailed in section II.g. Spin-labels were also incorporated into 
detergent micelles using 5-doxyl-stearate, a fatty acid with a nitroxide 
spin-label installed near the headgroup, to measure PRE between the 
micelle and bound protein. The spin-label was dissolved in DMSO and 
mixed into stock solutions of BOG prior to mixing with alpha-
synuclein stock solutions. The final concentration of spin-label was 4 
mM in 100 mM BOG. 
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Amide proton R2 measurements in the presence of lipid vesicles 
were carried out by running Bruker HSQC-based T2 experiments with 
spectral windows and number of points as described above, using 
delays of 16.32, 16.32, 32.64, 130.56, 261.12, and 456.96 msec. 
CPMG 15N refocusing pulses were at 900 μsec intervals.  The 
relaxation rates for each residue were calculated as detailed in section 
II.g. The on-rate for each residue was calculated by taking the 
difference of R2 rates in the presence and absence of lipid vesicles, 
then dividing by the concentration of lipid vesicles (2.6 mM) and 
protein (80 μM for acetylated and 215 μM for unmodified alpha-
synuclein). The on-rates for residues 3-9 and 65-80 were averaged to 
obtain the on-rates for N-terminal binding and fully-helical binding, 
respectively. The off-rate for each binding mode was then calculated by 
multiplying the off-rate by the apparent dissociation constant 
determined from an independent titration (Table 3.3). 
Lipid Vesicle Binding – Binding to lipid vesicles was measured by 
decrease of amide cross-peak intensity in 1H,15N-HSQC spectra in the 
presence of lipid vesicles as detailed in section II.d. For the one-point 
measurements, protein concentration was ~140 μM, as determined by 
SDS-PAGE comparison with BSA stocks, and lipid concentration was 3 
mM. For the one-point measurements, and the titrations presented in 
Table 3.2, samples for acetylated and unmodified protein were made in 
parallel with the same lipid stock, resulting in well-matched samples. 
Those titrations were performed by adding increasing volumes of lipid 
stock into the same NMR tube, while the titrations presented in Table 
3.3 used independently made samples for each point. 
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III.c. Results Overview 
 
In-cell conformation of alpha-synuclein is not affected by 
acetylation – The conformation of alpha-synuclein with and without N-
terminal acetylation in intact E. coli cells was queried by two-
dimensional NMR, making use of isotopic labeling. The 1H,15N-HSQC 
spectrum of human alpha-synuclein overexpressed in E. coli (Figure 
3.1A, black) is very similar to previously published in-cell spectra of 
alpha-synuclein [54,120] and shows the same disordered 
characteristics as the HSQC spectrum of the purified, monomeric 
protein (Figure 3.1B, blue). Peak linewidths in intact cells are 
significantly broader than in lysates or dilute aqueous solution, likely 
due to the effects of molecular crowding and nonspecific interactions 
within the cells. The majority of cross-peaks observed in the cells arise 
from alpha-synuclein, aside from several peaks likely corresponding to 
flexible small peptides and bacterial metabolites. These same 
background peaks appear in the spectrum of cells expressing only the 
NatB complex (Figure 3.1A, green), confirming that they do not arise 
from alpha-synuclein protein; since the NatB complex is too large to 
give rise to observable signal (~100 kDa), there are no peaks arising 
from any protein amide groups. While the alpha-synuclein spectrum is 
overall quite overlapped, several well-resolved N-terminal peaks (such 
as leucine 8 and serine 9) were not observed in intact cells. This 
selective N-terminal broadening has been previously observed [120], 
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and suggests that the N-terminus of alpha-synuclein may interact with 
large cellular components or undergo slow conformational exchange 
within E. coli cells. 
 
Figure 3.1: HSQC spectra of alpha-synuclein in intact cells and 
cell lysates. (A) 1H,15N-HSQC spectra of intact E. coli cells expressing 
alpha-synuclein (black), alpha-synuclein + NatB (red), and NatB alone 
(green). (B) Supernatant of sonicated cells expressing alpha-synuclein 
(black), alpha-synuclein + NatB (red), and NatB alone (green), overlaid 
with the spectrum of purified alpha-synuclein (blue). 
The spectrum of alpha-synuclein co-expressed with the NatB 
complex in intact cells (Figure 3.1A, red) is nearly identical to that of 
alpha-synuclein alone. There are some peaks that display line 
broadening, such as that of serine 129, but the overall spectra are very 
similar, indicating that N-terminally acetylated and unmodified alpha-
synuclein adopt the same disordered state inside intact E. coli cells, in 
the absence of any potentially structure-disrupting purification steps, 
as the purified unmodified protein does in dilute aqueous solution. 
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Additionally, there are no large conformational changes as a result of 
acetylation. 
 
Figure 3.2: Relative alpha-synuclein concentration in intact cell 
samples and in-cell NMR spectra. (A) Alpha-synuclein concentration 
in intact cell samples run on SDS-PAGE with BSA standards of known 
concentration. (B) Relative intensity of acetylated to unmodified alpha-
synuclein for each of 7 well-resolved cross-peaks and the average. 
However, there remains a possibility that some fraction of 
acetylated alpha-synuclein protein in cells adopts a structured 
oligomeric assembly that would be invisible on an NMR-spectrum due 
to its size. In order to assess this possibility, the fraction of acetylation 
alpha-synuclein that was visible by NMR was estimated by comparing 
it with the signal observed for the unmodified protein, under the 
assumption that no alternate NMR-invisible state is formed by 
unmodified alpha-synuclein [120]. The total concentration of 
unmodified and acetylated alpha-synuclein in cells was quantified 
using SDS-PAGE with standards of BSA of known concentration 
(Figure 3.2A). In a representative experiment, the ratio of acetylated to 
unmodified alpha-synuclein concentration was 0.456. The relative 
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concentrations of acetylated and unmodified alpha-synuclein observed 
by NMR were then estimated using the integrated intensities of several 
well-resolved amide cross-peaks; the ratio of NMR-observable 
acetylated to unmodified alpha-synuclein concentration was 0.419 
(Figure 3.2B), within 10% of that measured by SDS-PAGE, indicating 
that N-terminal acetylation does not result in the formation of any 
substantial NMR-invisible population of alpha-synuclein in intact 
bacterial cells. 
A comparison of the HSQC spectra of unmodified alpha-
synuclein in fresh cell lysate and in purified form (Figure 3.1B) shows 
that essentially all amide cross-peaks occupy the same positions, 
aside from the extra peaks arising from peptide contaminants in the 
lysate spectra. The HSQC spectrum of acetylated alpha-synuclein in 
cell lysates is also very similar to that of the unmodified protein; 
however, several cross-peaks arising from N-terminal residues, such 
as leucine 8 and serine 9, are noticeably shifted upon acetylation. The 
lack of peaks, down to the level of noise, in the peak positions 
corresponding to the unmodified protein demonstrates that, in this 
case, N-terminal acetylation is quantitative. This finding was 
supported by mass spectrometry analysis on the purified protein (data 
not shown); only one batch of coexpressed alpha-synuclein and NatB 
did not result in 100% N-terminal acetylation. 
Acetylation increases N-terminal helicity in the free state of alpha-
synuclein – In order to more accurately describe the structural 
difference between unmodified and acetylated alpha-synuclein, 
isotopically-labeled proteins were purified and subjected to 
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multidimensional NMR analysis. A comparison of the HSQC spectra of 
purified unmodified and acetylated alpha-synuclein (Figure 3.3A) 
shows the same N-terminal spectral differences as the lysate spectra. 
Backbone amide assignments for acetylated alpha-synuclein were 
transferred from those previously determined for unmodified alpha-
synuclein [42]. With the assignments in hand, structural differences 
can be localized by plotting amide chemical shift changes (∆δavg, 
section II.b, equation 1) versus residue number. A plot of chemical 
shift changes between acetylated and unmodified alpha-synuclein 
shows that peak shifts for the majority of the protein sequence are 
very small; only residues 3-13 show significant perturbations (Figure 
3.3B). In addition, peaks for methionine 1 and aspartate 2 are visible  
 
Figure 3.3: HSQC spectra and amide chemical shift differences for 
acetylated and unmodified alpha-synuclein in aqueous buffer. (A) 
1H,15N-HSQC spectra of purified unmodified (black) and acetylated 
alpha-synuclein (red) in aqueous buffer. (B) Plot of amide chemical 
shift differences (equation 1) between unmodified and acetylated 
alpha-synuclein in aqueous buffer versus residue number. 
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in spectra of (purified and lysate) acetylated alpha-synuclein but not in 
the unmodified protein spectra, likely due to amide proton exchange 
with the solvent in the absence of acetylation. The extent of these 
effects is greater than would be expected from the addition of a small 
acetyl group to the very N-terminus of the protein, as a variety of point 
mutant have been shown to result in chemical shift perturbations in 
disordered alpha-synuclein that extend only +/- 3 residues around the 
site of modification (e.g. [228]). 
Loss of one positive charge at the N-terminal amine could 
contribute to the unexpectedly long range of effect of N-terminal 
acetylation. However, examination of the secondary structure 
propensity using alpha-carbon secondary shifts, which are very 
sensitive to secondary structure, reveals that the N-terminal ~10 
residues of acetylated alpha-synuclein display increased helicity vis a 
vis the unmodified protein (Figure 3.4A). While the unmodified protein 
residues have a secondary shift ranging from 0 to 0.2 in that region, 
the N-terminally acetylated protein secondary shifts reach 0.8. 
Although the amplitude of this deviation from random coil values does 
not indicate a stable, fully-formed helix in this region, it does suggest 
that the N-terminal 10 or so residues populate helical conformations a 
significant fraction of the time. Both proteins display the characteristic 
helical signature between residues 15 and 30, again indicative of 
significant populations of helical conformations, though acetylated 
alpha-synuclein does display slightly lower helicity in the region of 
residues 14-18. However, this is not reflected in significant changes in 
the amide chemical shifts. The rest of the protein sequence displays 
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highly similar alpha-carbon secondary shifts within the experimental 
error of the measurement. 
 
Figure 3.4: Alpha-carbon secondary shifts and intramolecular 
contacts for unmodified and acetylated alpha-synuclein in 
aqueous buffer.  (A) Plot of alpha-carbon secondary shifts versus 
residue number for unmodified (black) and acetylated alpha-synuclein 
(red) in aqueous buffer. (B) Plot of the ratio of peak intensity for 
samples paramagnetically labeled at E20C to peak intensity in 
unlabeled samples versus residue number for unmodified (black) and 
acetylated alpha-synuclein (red) in aqueous buffer. 
Despite being disordered, alpha-synuclein forms transient 
intramolecular contacts that can be measured by PRE experiments. 
The N- and C-terminal regions of alpha-synuclein contact each other, 
as evidenced by a PRE effect at the C-terminus when the N-terminus is 
spin-labeled and vice versa [28]. To examine the effects of N-terminal 
acetylation on these contacts, a spin-label was attached to a cysteine 
introduced at position 20 of the primary sequence in both unmodified 
and acetylated alpha-synuclein. The PRE effect plotted versus residue 
number shows a similar pattern in unmodified and acetylated alpha-
synuclein (Figure 3.4B). The “well” of signal intensity around the 
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labeling site is almost identical irrespective of acetylation, and the 
intensity minimum indicating an intramolecular contact at around 
position 125 is present in both samples. However, all contacts of the 
spin-label with the polypeptide chain C-terminal to position 45 are 
weaker in acetylated alpha-synuclein. This can be attributed to the 
loss of the positive charge of the amino-terminus, since the 
intramolecular contacts between the net positive N-terminal region 
and net negative C-terminal region are mostly electrostatic in nature. 
Acetylation stabilizes helicity in SDS-bound state of alpha-
synuclein – Since N-terminal acetylation increase N-terminal helicity, 
which is intimately involved in alpha-synuclein binding to membranes 
and membrane mimics, this increase might be expected to affect this 
binding process. First, the effect of N-terminal acetylation on alpha-
synuclein binding to SDS micelles was studied by NMR. In the 
presence of SDS micelles, alpha-synuclein adopts a broken-helix 
conformation that has been often used as an NMR-tractable model for 
the membrane-bound state of alpha-synuclein [71,72,74]. A 
comparison of the HSQC spectra of unmodified and acetylated alpha-
synuclein in the presence of spheroidal SDS micelles shows two highly 
similar spectra with several notable spectral differences (Figure 3.5A). 
The overall similarity of the spectra suggests that acetylated alpha-
synuclein adopts a very similar conformation to the unmodified 
protein on SDS micelles. Backbone amide assignments for acetylated 
alpha-synuclein were transferred from those previously determined for 
the unmodified protein [71] and the observed spectral differences were 
localized to the very N-terminus of the protein, with the N-terminal 13 
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residues showing significant peak shifts upon acetylation, much like in 
the free state (Figure 3.5B). 
 
Figure 3.5: HSQC spectra and amide chemical shift differences for 
acetylated and unmodified alpha-synuclein in the presence of SDS 
micelles. (A) 1H,15N-HSQC spectra of purified unmodified (black) and 
acetylated alpha-synuclein (green) in 40 mM SDS. (B) Plot of amide 
chemical shift differences (equation 1) between unmodified and 
acetylated alpha-synuclein in 40 mM SDS versus residue number. 
Since N-terminal acetylation was shown to increase N-terminal 
helicity of alpha-synuclein in aqueous solution and the SDS-bound 
protein already contains extensive stable helical structure throughout 
the N-terminal domain, N-terminal acetylation was not expected to 
greatly perturb the secondary structure of the SDS-bound state. 
However, the extent of the amide chemical shift changes upon 
acetylation (up to residue 13) suggested an effect on the local 
secondary structure, as in the free state. Thus, secondary structure 
propensity was determined by using alpha-carbon secondary shifts. 
Surprisingly, while the overall structure of two stable helical regions 
with a break around residue 40 is conserved, the N-terminal 10 
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residues of acetylated alpha-synuclein display increased helicity 
compared to the unmodified protein in the presence of SDS micelles 
(Figure 3.6A). These findings suggest that, in the absence of N-
terminal acetylation, helix-1 of alpha-synuclein is frayed at the N-
terminus, and acetylation reduces the extent of this fraying by 
stabilizing helical structure. In this way, studying the modified protein 
provided an insight into the structure of the unmodified protein. 
 
Figure 3.6: Alpha-carbon secondary shifts and extent of amide 
proton exchange for unmodified and acetylated alpha-synuclein in  
the presence of SDS micelles. (A) Plot of alpha-carbon secondary 
shifts versus residue number for unmodified (black) and acetylated 
alpha-synuclein(green) in 40 mM SDS. (B) Plot of the ratio of peak 
intensity with a water inversion pulse to peak intensity without water 
inversion versus residue number for unmodified (black) and acetylated 
alpha-synuclein (green) in 40 mM SDS at pH 8.4. The intensity ratio 
reports on level of protection of amide protons from solvent exchange. 
In order to confirm increased helix stability at the N-terminus of 
alpha-synuclein, the extent of amide proton protection from exchange 
with the solvent was quantified. The N-terminal 10 residues were 
found to be more protected from exchange in the acetylated protein 
(Figure 3.6B), confirming the conclusions drawn from the secondary 
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shift analysis. These data show that the N-terminal acetyl group 
stabilizes helicity at the very N-terminus in the SDS micelle-bound 
state and, by inference, may be expected to do so in other lipid- and 
detergent-bound states. 
Acetylated alpha-synuclein binds to BOG micelles in a novel 
partly-helical conformation – Several reports of a structured, helical 
form of alpha-synuclein purified from E. coli involved purification in a 
buffer containing low, sub-micellar concentrations of β-octyl-glucoside 
(BOG), a nonionic detergent commonly used to purify membrane 
proteins [117,118]. Since alpha-synuclein is known to bind to 
membranes and detergent micelles with a concomitant induction of 
helical structure, it is possible that N-terminally acetylated alpha-
synuclein binds to BOG during purification, promoting helical 
structure in the protein. While the effects of a number of detergents on 
alpha-synuclein structure have been studied, the detergents employed 
tend to be negatively-charged and do not include BOG in their number 
[74,78,84,229]. 
In order to determine whether BOG induces helical 
conformations in unmodified and acetylated alpha-synuclein, the 
proteins were titrated with increasing concentrations of BOG and the 
secondary structure monitored using far-UV CD spectroscopy. CD 
spectra of unmodified and acetylated alpha-synuclein with increasing 
concentrations of BOG, far above the critical micellar concentration 
(CMC) of BOG, (~25 mM) are consistent with mostly disordered 
conformations, but with an increase of helicity, especially for the N-
terminally acetylated protein (Figure 3.7A,B). In the absence of  
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Figure 3.7: Far-UV CD spectra of unmodified and acetylated alpha-
synuclein with increasing BOG concentration. Plot of mean residue 
ellipticity with increasing concentrations of BOG versus wavelength for 
(A) unmodified alpha-synuclein (black) and (B) acetylated alpha-
synuclein (blue). BOG concentrations are 0, 10, 50, 100, 200, 400, 
500, and 600 mM increasing with increasing lightness of line. Dashed 
lines indicate data from a second titration. The inset contains a zoom 
into the region containing the minimum associated with helical 
structure at 222 nm. (C) Plot of the mean residue ellipticity at 222 nm 
with increasing BOG concentration for unmodified (black) and 
acetylated alpha-synuclein (blue). The points are fit to equation 12 
with a KD,app of 613 and 51 mM for unmodified and acetylated alpha-
synuclein, respectively. 
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detergent, acetylated alpha-synuclein already displays a higher 
fraction of helical residues (10%, corresponding to 14 fully-helical 
residues) than the unmodified protein (9%, 12 residues). At the end 
point of the titration (600 mM BOG), the maximum concentration 
practically attainable given the solubility of BOG, acetylated alpha-
synuclein had a fractional helicity of 16%, corresponding to 22 fully-
helical residues, while the unmodified protein only reached 13%, 
corresponding to 18 helical residues. These data strongly suggest a 
direct interaction between alpha-synuclein and BOG that results in 
induction of helical structure, most likely as a result of alpha-
synuclein binding to the detergent micelles, similar to its interactions 
with SDS and other detergents [42,74]. This is a novel, heretofore 
uncharacterized interaction. 
The mean residue ellipticity at 222 nm, proportional to fractional 
helicity, is plotted as a function of BOG concentration in Figure 3.7C. 
From the plot, it appears that the binding of acetylated alpha-
synuclein to BOG reaches saturation in the concentration range 
studied, while the situation for unmodified alpha-synuclein is less 
clear. The binding could be reaching saturation around 600 mM BOG, 
but at an endpoint corresponding to lower fractional helicity than the 
acetylated protein, or it could be far from reaching saturation. Since 
higher concentrations of BOG were not reachable for this 
measurement, it was reasoned that the N-terminal modification should 
not have a large effect on the final conformation of the BOG-bound 
alpha-synuclein, which should therefore have similar levels of helical 
structure in unmodified and acetylated protein. As a result, when the 
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binding curves were fit to equation 12, final values of mean residue 
ellipticity at 222 nm were constrained to be the same for unmodified 
and acetylated alpha-synuclein. The fitting allowed apparent KD values 
to be extracted; acetylated alpha-synuclein bound with a KD,app of 51 
mM and unmodified alpha-synuclein with an order of magnitude 
higher KD,app of 613 mM. Thus, while unmodified alpha-synuclein 
binds BOG weakly, with an induction of some helical structure, N-
terminal acetylation greatly increases the affinity of the binding 
interaction. 
 
Figure 3.8: HSQC spectra and amide chemical shift differences for 
acetylated alpha-synuclein with increasing BOG concentration. (A) 
Zoomed regions of 1H,15N-HSQC spectra of unmodified (black, right) 
and acetylated alpha-synuclein (blue, left) with increasing 
concentrations of BOG. The red arrows illustrate linear paths of peak 
shifts for two peaks (A11 and A16). BOG concentrations are 0, 25, 50, 
75 (acetylated), 100, ~200, and ~300 mM increasing with increasing 
darkness of contour. (B) Plot of the amide chemical shift difference 
from 0 mM BOG (equation 1) with increasing BOG concentration for 
the peaks of A11 (circles) and A16 (squares) for unmodified (black) and 
acetylated alpha-synuclein (blue). 
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In order to describe this interaction at single-residue resolution, 
NMR spectroscopy was employed. Increasing concentrations of BOG 
resulted in dose-dependent position shifts in several N-terminal peaks; 
two well-resolved peaks (A11 and A16) are shown in Figure 3.8A. The 
observed peak shifts are linear and do not show any peak doubling, 
consistent with a two-state equilibrium with exchange occurring faster 
than the NMR timescale in the experiment. The original peak position 
corresponds to fully free alpha-synuclein, the theoretical “final” peak 
position (not reached at these concentrations) corresponds to fully 
bound alpha-synuclein, and each intermediate peak corresponds to an 
average of the initial and final positions weighted by the relative 
populations of free and bound protein at that concentration. With only 
two states (free and bound), each intermediate peak falls on a straight 
line between the initial and final positions. Since the peaks broaden 
and decrease in intensity with increasing BOG concentrations, the 
exchange rate between the two states may be close to the relevant 
experiment timescale (i.e. approaching the “intermediate exchange 
regime,” in which signals are highly broadened), or, alternatively, the 
bound state may give rise to broad peaks due to increased relaxation, 
reflecting its larger size or dynamics in the bound state. 
The change in chemical shift from the initial position can be 
plotted versus BOG concentration, giving titration curves similar to 
those obtained from CD data, which measure induction of helicity. The 
titration curves obtained from chemical shift perturbation for two N-
terminal residues (A11 and A16) are shown in Figure 3.8B. The 
interaction between acetylated alpha-synuclein and BOG approaches 
 95 
 
saturation by the end of the titration (~300 mM BOG), while 
unmodified alpha-synuclein shows small peak shifts even at the high 
end of the titration. Interestingly, amide cross-peaks of acetylated 
alpha-synuclein do not shift appreciably from the initial position at the 
lowest concentration of BOG added (~25 mM), which is very close to 
the CMC of BOG (20-25 mM), and only begin to shift above that 
concentration. The CD-monitored titration had only one measurement 
at a lower concentration (10 mM), and the ellipticity measured at that 
point was very similar to that for the free protein as well (Figure 3.7). 
 
Figure 3.9: Binding curves derived from CD and NMR data for 
acetylated alpha-synuclein with increasing BOG concentration. 
Plot of the binding curves derived from mean residue ellipticity (circles) 
and amide chemical shift difference from 0 mM BOG averaged for 
residues 11 and 16 (triangles) with increasing BOG concentration for 
acetylated alpha-synuclein (blue). The points are fit to equation 2 with 
a KD,app of 51 and 54 mM for CD and NMR data, respectively. 
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The NMR and CD titration data ostensibly report on the same 
binding event of acetylated alpha-synuclein to BOG; the titrations were 
thus compared to see if they match. In order to compare the extent of 
the binding reaction, the signal reporting on binding in each 
experiment was normalized (see Methods, section III.b). A plot of this 
normalized signal change from both experiments is shown in Figure 
3.9. The extents of binding at similar BOG concentrations from the two 
experiments are very similar. When fitted to equation 2, the CD data 
yield a KD,app of 51 mM (as seen in Figure 3.7C) while the NMR data 
result in a KD,app of 54 mM. The two methods are thus in very close 
agreement in measuring this novel binding interaction. 
Since the binding of any form of alpha-synuclein to BOG 
micelles has not been reported before, the structural basis of this 
interaction is unknown and warrants further description. While the 
binding of acetylated alpha-synuclein to BOG micelles appears to 
saturate at ~300 mM BOG, the NMR signals for the affected residues 
are extremely weak at this high concentration (Figure 3.8A). Thus, an 
intermediate BOG concentration (100 mM) was chosen for further 
NMR analysis. From the titration curves (Figure 3.8B), approximately 
70% of acetylated alpha-synuclein is bound at this concentration, and 
the peaks have sufficient intensity to be analyzed by NMR experiments. 
Comparison of the 1H,15N-HSQC spectra of acetylated alpha-synuclein 
in the presence and absence of 100 mM BOG shows several spectral 
changes that appear to be localized to a small region of the protein 
(Figure 3.10A). While backbone amide assignments had been 
provisionally transferred from the free state of acetylated alpha-
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synuclein during the titration, they were confirmed by means of an 
HNCA experiment. A plot of peak position shifts versus protein 
primary sequence localizes the affected region to the N-terminal ~25 
peaks (Figure 3.10B). This interacting region differs from the 
previously described SDS- and lipid vesicle-interacting region, which 
encompasses the entire N-terminal domain of ~100 amino acids 
[42,71]. However, it is similar to a region that forms a partially vesicle-
bound state proposed based on NMR experiments at low 
vesicle:protein ratios [91,92] and is also similar to the region of alpha-
synuclein that interacts with calmodulin [113]. 
 
Figure 3.10: HSQC spectra and amide chemical shift differences 
for acetylated alpha-synuclein in the presence and absence of 
BOG micelles. (A) 1H,15N-HSQC spectra of acetylated alpha-synunclein 
in aqueous buffer (black) and 100 mM BOG (blue). (B) Plot of amide 
chemical shift differences (equation 1) for acetylated alpha-synuclein 
between aqueous buffer and 100 mM BOG versus residue number. 
The chemical shift perturbations delineate the region interacting 
with BOG but, by themselves, do not provide any structural 
information about the nature of the interaction. Secondary shifts for 
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the alpha-carbons, derived from the abovementioned HNCA 
experiment, provide secondary structure information (Figure 3.11A, 
blue). The N-terminal 25-30 residues display increased positive 
deviations from random coil values, compared to the free protein, 
demonstrating that this region populates significant helical 
conformations. The values of the secondary shifts range from 0.5 to 2 
ppm, indicating some regions (residues 1-10) of stable α-helical 
structure and other regions of labile, frayed, or partially occupied 
helices. Since only ~70% of the protein is bound at this BOG 
concentration, it is possible that at full binding, the entire interacting 
region becomes stably helical. To examine this hypothesis, an HNCA 
experiment was performed on acetylated alpha-synuclein in the 
presence of 300 mM BOG. The secondary shifts at this concentration 
when almost all of the protein is micelle-bound show the same pattern 
in the N-terminal 25-30 residues as at 100 mM BOG, although the 
magnitude of the shift is 0.3-0.4 ppm higher (Figure 3.11A, orange). 
However, the pattern of secondary shifts suggests that even at full 
binding, only the N-terminal half of this region forms a stable helix, 
while the C-terminal half remains labile. 
To confirm whether this helical interacting region directly binds 
the BOG micelle, two approaches were employed: amide nitrogen R2 
relaxation rates, which report on flexibility or dynamics of the protein 
backbone on a picosecond-nanosecond timescale, and PRE NMR with 
spin-label-doped BOG micelles, which delineates the regions that come 
within ~25 Å of the micelle. Amide nitrogen R2 rates were similarly low 
between residues 30 and 140 (Figure 3.11B). The values of the R2  
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Figure 3.11: Alpha-carbon secondary shifts, R2 relaxation rates, 
and PRE effects from doped micelles for acetylated alpha-
synuclein in the presence of BOG micelles. (A) Plot of alpha-carbon 
secondary shifts versus residue number for acetylated alpha-synuclein 
in aqueous buffer (black), 100 mM BOG (blue), and 300 mM 2H BOG 
(orange, only the first 40 residues are plotted). (B) Plot of transverse 
relaxation rate R2 for acetylated alpha-synuclein in 100 mM BOG 
versus residue number. Error bars show the error of fitting provided 
by NMRViewJ. (C) Plot of the ratio of peak intensity in the presence of 
paramagnetically doped BOG micelles (100 mM) to peak intensity in 
the presence of undoped micelles (100 mM) for acetylated alpha-
synuclein versus residue number. The gray bars indicate which peaks 
were included in the analysis.
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rates in this region (4-5 sec-1) are very similar to those obtained 
throughout the polypeptide chain for free alpha-synuclein [43] and 
(accounting for temperature difference) for the disordered C-terminal 
tail of SDS micelle-bound alpha-synuclein [75], suggesting that this 
region remains free and disordered in solution in the presence of BOG. 
The R2 rates of the N-terminal ~30 residues, however, are much higher 
(10-20 sec-1), indicative of increased relaxation due to slower backbone 
motions or slow overall tumbling upon the formation of a protein-
micelle complex. The magnitude of the R2 rates in this N-terminal 
region is similar, accounting for temperature difference, to that seen in 
the SDS micelle-bound region of alpha-synuclein [75], suggesting that 
a similar protein-micelle complex is formed between the N-terminal 
~25 residues of acetylated alpha-synuclein and BOG micelles. 
The PRE results also implicate the same N-terminal region in 
binding to the micelle. In the presence of spin-label-containing BOG 
micelles, the cross-peaks for the N-terminal ~25 residues show greatly 
decreased signal intensity, indicating that that region is in close 
contact with the micelle (Figure 3.11C). The C-terminal portion of the 
protein does not show decreased signal intensity in the presence of 
spin-label, aside from a minimum near the aromatic tyrosine 39 
residue, which may bind the spin-label directly [75]. The secondary 
shift, PRE and R2 data are very consistent, strongly supporting a 
binding mode in which the N-terminal 25-30 residues bind to the 
detergent micelle in a mostly-helical conformation while the rest of the 
protein remains disordered. Intriguingly, there may be a slight 
decrease near residue 10 in both PRE effect and R2 rate. This dip 
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suggests that binding to the micelle is not uniform throughout the N-
terminal 25-30 residues and some detachment from the micelle may 
occur roughly in the middle of this region. This minimum may also 
signify a break in the helical structure of this region, as there is also a 
small dip in helicity around residue 10 in the alpha-carbon secondary 
shift data (Figure 3.11A). Clearly, while the binding region is more 
structured compared to the rest of the protein, it does not form a 
stable, well-formed helix. Additionally, the size and shape of the BOG 
micelle is not known, nor the extent of protein insertion into the 
micelle. 
Acetylation increases alpha-synuclein binding to curved lipid 
vesicles of lower charge – Unmodified alpha-synuclein has been shown 
conclusively to bind to synthetic lipid vesicles, specifically those with 
significant proportions of negatively-charged lipids, with a concomitant 
adoption of helical structure in the N-terminal region [42,55,61,62]. A 
modification that affects the level of helicity at the very N-terminus 
may thus be expected to have an effect on alpha-synuclein binding to 
lipid vesicles. Early studies obtained contrasting results, with 
acetylated alpha-synuclein showing no difference from the unmodified 
protein in binding to large (~120 nm diameter) vesicles of 100% 
negatively-charged POPG [230] but binding about two times more 
tightly to more curved (~40 nm diameter) vesicles containing 30% 
negatively-charged DOPS (and more kinked DO lipids) [231]. In order 
to harmonize these results, a systematic study of acetylated and 
unmodified alpha-synuclein binding to lipid vesicles of different 
curvature and charge was undertaken. Both unmodified and 
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acetylated alpha-synuclein were incubated with synthetic lipid vesicles 
of two sizes and two lipid compositions: SUVs made by sonication (~40 
nm diameter) and LUVs made by extrusion (~120 nm diameter) 
composed of either 50% DOPS, 35% DOPC, 15% DOPE (high negative 
charge) or 15% DOPS, 60% DOPC, 25% DOPE (low/medium negative 
charge). 
 
Figure 3.12: Binding profiles of unmodified and acetylated alpha-
synuclein to high and low negative charge SUVs and LUVs. Plot of 
the ratio of peak intensity in the presence of 3 mM 50% PS LUVs (A) 
and SUVs (B) and 15% PS LUVs (C) and SUVs (D) to peak intensity in 
the absence of vesicles versus residue number for unmodified (black) 
and acetylated alpha-synuclein (green). Bound fractions of total 
binding and fully-helical binding are shown in Table 3.1. 
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At first, the level of binding in the presence of 3 mM lipid 
vesicles, a concentration at which only partial binding is expected [91], 
was assessed. In a partial-binding regime, the level of free protein can 
be monitored by the remaining cross-peak signal intensity in an HSQC 
spectrum, thus providing residue- or region-specific extents of binding. 
In the presence of high negative charge (50% PS) LUVs and SUVs, 
unmodified alpha-synuclein bound very tightly (Figure 3.12A,B), with 
65% (LUVs) and 73% (SUVs) of the protein bound to some extent 
(Table 3.1). The N-terminally acetylated alpha-synuclein showed very 
similar extent of binding, with 49% and 73% binding to LUVs and 
SUVs, respectively (Figure 3.12A,B and Table 3.1). While the pattern of 
binding throughout the protein sequence was very similar for 
unmodified and acetylated alpha-synuclein, there was noticeably less 
binding of the acetylated protein in the N-terminal ~20 residues to 
50% PS LUVs (Figure 3.12A). This difference was not seen for SUVs. 
This loss of binding suggests that electrostatic attraction plays a large 
role in alpha-synuclein binding to high negative charge, less curved 
vesicles, since the loss of the primary amine positive charge has such 
a noticeable effect. 
In the presence of lower negative charge lipid vesicles (15% PS), 
much less unmodified alpha-synuclein was bound, approximately 14% 
for LUVs and 38% for SUVs (Table 3.1). Acetylated alpha-synuclein, 
however, displayed significantly more binding than the unmodified 
protein (Figure 3.12C,D), with 43% and 74% binding to LUVs and 
SUVs, respectively. The extent of acetylated alpha-synuclein binding to 
15% PS lipid vesicles is comparable to the extent of binding to 50% PS 
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vesicles, suggesting that N-terminal acetylation of the protein 
selectively enhances binding to lower negative charge vesicles. 
Table 3.1: Bound fractions of different populations of unmodified 
and acetylated alpha-synuclein in the presence of high and low 
negative charge SUVs and LUVs. Bound fractions were calculated as 
described in section III.b. 
Lipid and Protein Total Bound Fraction Fully-Helical Bound Fraction 
50% DOPS   
LUVs   
unmodified  0.645 0.241 
acetylated 0.494 0.281 
SUVs   
unmodified  0.733 0.437 
acetylated 0.727 0.464 
   
15% DOPS   
LUVs   
unmodified  0.135 0.077 
acetylated 0.428 0.143 
SUVs   
unmodified  0.383 0.234 
acetylated 0.742 0.428 
In order to assess the effects of acetylation on selectivity for 
membrane curvature or charge more quantitatively, unmodified and 
acetylated alpha-synuclein were titrated with increasing 
concentrations of the four previously studied synthetic lipid vesicles. 
Due to material limits, only 3 or 4 concentrations of each lipid vesicle 
stock were employed; the binding curves were fitted to equation 2, and 
apparent KD values extracted for different binding modes (see Methods,  
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Figure 3.13: Titrations of unmodified and acetylated alpha 
synuclein to high and low negative charge SUVs and LUVs. Plots of 
the bound fractions of total binding (squares) and fully-helical binding 
(circles) with increasing concentrations of 50% PS LUVs (A,E) and 
SUVs (B,F) and 15% PS LUVs (C,G) and SUVs (D,H) for unmodified 
(black) and acetylated alpha-synuclein (red). Panels A-D use total lipid 
concentration, while E-H use only accessible outer lipid concentrations. 
The points are fit to equation 2 and extracted KD,app values shown in 
Table 3.2. 
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section III.b) (Figure 3.13). The “total binding” apparent dissociation 
constants computed using total lipid concentrations agree with the 
single concentration results (Table 3.2). The affinity of unmodified 
alpha-synuclein for 50% PS lipid vesicles, both LUVs and SUVs, is very 
similar to that of the acetylated protein for the same curvature vesicles. 
In the case of 15% PS vesicles, the apparent KD values for acetylated 
alpha-synuclein are 2.9 and 3.4 times smaller than those of the 
unmodified protein for LUVs and SUVs, respectively, indicating 
significantly tighter binding of the modified protein. Both forms of 
alpha-synuclein have lower dissociation constants with SUVs than 
with LUVs, quantitatively demonstrating the previously observed 
selectivity of alpha-synuclein for more curved vesicles (Table 3.2). The 
acetylated protein displays slightly greater selectivity for SUVs, 
regardless of negative charge content. 
However, binding to SUVs and LUVs cannot be accurately 
compared using bulk lipid concentration, since vesicles of different 
curvature have different proportions of lipids available for binding on 
the outer leaflet. In order to facilitate these comparisons, the 
percentage of lipids on the outer leaflet was calculated for SUVs (64%) 
and LUVs (54%) (see Methods, section II.b) and the lipid 
concentrations normalized by those percentages for a second round of 
fitting (Figure 3.13E-H). The apparent dissociation constants thus 
obtained can be directly compared between SUVs and LUVs. When 
compared in this manner, acetylated alpha-synuclein shows 
significantly greater selectivity for SUVs than unmodified alpha-
synuclein (4.2 versus 2.4 for 50% PS, 4.4 versus 3.5 for 15% PS),  
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Table 3.2: Computed apparent KD values and other parameters for 
unmodified and acetylated alpha-synuclein binding to high and 
low negative charge SUVs and LUVs. Apparent KD values were 
calculated from fitting titrations to equation 2 (see Figure 3.13) using 
total lipid concentration and only accessible outer lipid concentration 
(see Chapter II). “Effect of N-ac” was calculated as the ratio of KD,app for 
acetylated alpha-synuclein over KD,app for unmodified alpha-synuclein. 
“SUV Selectivity” was calculated using equation 4 and “Full Helix 
Fraction” was calculated using equation 5 (see section II.d). 
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although both forms of the protein show a significant preference for 
binding the more highly curved SUVs (Table 3.2).  
The binding discussed so far and measured by the “total 
binding” KD potentially includes many different modes of alpha-
synuclein binding to vesicles, such as the “fully helical” mode in which 
the entire N-terminal ~100 residues become helical and bind the 
vesicle surface and an unknown number of partly-helical binding 
modes in which shorter N-terminal regions bind the vesicle surface 
(presumably as an α-helix). These partly-helical modes may include 
the proposed “SL1” binding mode comprising residues 1-25 [92] and a 
mode in which only helix-1 (residues 1-37) is bound. The “total 
binding” does not differentiate between these partly-helical modes, nor 
between them and fully-helical binding. Fully helical binding can be 
assessed on its own by measuring binding of a more C-terminal region 
of the lipid-binding ~100 residues. Apparent dissociation constants 
were also determined for this fully helical binding mode. In general, 
the relative affinities follow the same trend as those for total binding, 
with no effect of acetylation with 50% PS vesicles, and with increased 
binding to 15% PS vesicles, regardless of curvature (Table 3.2). 
When outer membrane lipid concentration was used to compare 
binding to vesicles of different curvature, unmodified and acetylated 
alpha-synuclein showed similar levels of preference for binding to 
SUVs in the fully-helical conformation (3.6 and 3.9 for 50% PS, 6.1 
and 5.6 for 15% PS) (Table 3.2). As for total binding, fully-helical 
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binding has greater selectivity for SUVs when binding to 15% PS 
vesicles. Contrary to the situation for total binding, however, 
acetylation does not increase selectivity for SUVs. This difference 
suggests that the curvature selectivity of the full helix is not greatly 
affected by N-terminal acetylation, and that most of the effect of N-
terminal acetylation on curvature selectivity is mediated through 
increased partly-helical binding. 
One other interesting finding is that higher curvature generally 
promotes “helix extension,” here estimated as the ratio of total binding 
KD to fully helical KD, which also corresponds to the fraction of fully-
helical bound protein (see Methods, section III.b) (Table 3.2). In 
addition, N-terminal acetylation generally disfavors helix extension, 
indicating that it stabilizes partly-helical states. The one exception to 
both is due to the low N-terminal binding of acetylated alpha-
synuclein to high negative charge LUVs, likely a result of the 
decreased electrostatic attraction at the very N-terminus due to loss of 
the positive charge at the amino-terminus. 
Treating alpha-synuclein binding to lipids as a one-binding-site 
system characterized only by affinity ignores one important factor: 
potentially different binding sites offered by lipid membranes of 
different curvature or lipid composition. In order to gain insight into 
the effect of vesicle type on alpha-synuclein binding sites, titrations 
were fit using equation 3, which allows a parameter Bmax, or maximum 
number of protein binding sites per lipid molecule, to be extracted. 
This parameter can yield how many lipid molecules are required to 
bind one protein molecule  and an estimate of the number of 
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productive binding sites offered by different membrane configurations 
(see Methods, section III.b). In order to perform fits with this equation, 
titrations with measurements at more concentrations were required. 
Unmodified alpha-synuclein was titrated with LUVs and SUVs of the 
low negative charge composition (15% DOPS, 60% DOPC, 25% DOPE) 
and the bound fractions plotted as a function of outer membrane lipid 
concentration and fit to equations 2 and 3. Interestingly, the curves 
derived from equation 3 fit the points much more closely, (Figure 3.14). 
On the other hand, equation 3 could not be fit to fully helical bound 
fractions while giving reasonable values for KD and Bmax. This suggests 
that fully-helical binding of alpha-synuclein to lipid vesicles cannot be 
described as a bimolecular binding equilibrium with independent 
binding sites. 
 
Figure 3.14: Titrations of unmodified alpha synuclein to low 
negative charge SUVs and LUVs. Plot of the bound fractions of total 
binding (squares) and fully-helical binding (circles) with increasing 
concentrations of 15% PS LUVs (black) and SUVs (red) for unmodified 
alpha-synuclein. Panel A uses total lipid concentration, while B uses 
only accessible outer lipid concentrations. The points are fit to 
equation 2 (solid, dashed lines) and equation 3 (dotted line, only total 
binding) and extracted KD,app and Bmax values shown in Table 3.3. 
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The apparent dissociation constants extracted from fitting to 
equation 2 showed increased affinity for curved SUVs, as before (Table 
3.3). The values were comparable to those derived from the 
independent titration in Table 3.2, despite the use of different protein 
and lipid stocks, showing the reproducibility of this method. The fit to 
the equation 3 was very good (Figure 3.14). However, the dissociation 
constant and number of binding sites extracted for LUV binding had 
very high error, precluding a comparison with SUV binding. 
Table 3.3: Computed apparent KD and Bmax values for unmodified 
and acetylated alpha synuclein with low negative charge SUVs and 
LUVs. Apparent KD and Bmax values were calculated from fitting 
titrations to equations 2 and 3 (see Figure 3.14 and 3.15) using total 
lipid concentration and only accessible outer lipid concentration (see 
section III.b). 
 Total Lipid Outer Lipid 
 Equation 2 Fit Equation 3 Fit Equation 2 Fit Equation 3 Fit 
Protein 
and 
Lipid 
KD,app 
(mM) 
– 
Total 
KD,app 
(mM) – 
Fully-
Helical 
KD,app Bmax KD,app 
(mM) 
– 
Total 
KD,app 
(mM) – 
Fully-
Helical 
KD,app Bmax 
Unmod-
ified 
        
LUVs 9.8 ± 
0.4 
61.7 ± 
0.9 
0.469 
± 
0.617 
0.057 
± 
0.063 
5.2 ± 
0.2 
33.2 ± 
0.5 
0.467 
± 
0.617 
0.106 
± 
0.116 
SUVs 4.1 ± 
0.7 
10.0 ± 
1.3 
0.031 
± 
0.003 
0.025 
± 
0.001 
2.6 ± 
0.4 
6.4 ± 
0.8 
0.031 
± 
0.003 
0.039 
± 
0.001 
         
Acetyl-
ated 
        
SUVs 1.0 ± 
0.1 
3.7 ± 
0.1 
0.015 
± 
0.002 
0.035 
± 
0.002 
0.6 ± 
0.1 
2.4 ± 
0.1 
0.015 
± 
0.002 
0.055 
± 
0.003 
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Figure 3.15: Titrations of acetylated alpha synuclein to low 
negative charge SUVs. Plot of the bound fractions of total binding 
(squares) and fully-helical binding (circles) with increasing 
concentrations of 15% PS SUVs for acetylated alpha-synuclein. Panel 
A uses total lipid concentration, while B uses only accessible outer 
lipid concentrations. The points are fit to equation 2 (solid, dashed 
lines) and equation 3 (dotted line, only total binding) and extracted 
KD,app and Bmax values shown in Table 3.3. 
An independent titration was carried out with acetylated alpha-
synuclein using different lipid stocks and protein concentration (Figure 
3.15). The apparent KD values extracted from fitting to equation 2 were 
again comparable to those shown in Table 3.2. Fitting to equation 3 
yielded the number of binding sites per lipid molecule Bmax, which was 
slightly larger than that obtained for unmodified protein (0.035 versus 
0.025, 29 versus 40 lipids per binding site, ~250 versus ~180 binding 
sites per SUV). Additionally, the dissociation constant for each binding 
site was smaller than that obtained for unmodified protein (0.015 
versus 0.031), suggesting that the increased binding of acetylated 
alpha-synuclein derives from both increased affinity and more 
“available” binding sites. Although the lipid configuration is the same, 
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acetylated alpha-synuclein can somehow “sense” more favorable 
binding sites than the unmodified protein. 
 
Figure 3.16: On-rate for unmodified and acetylated alpha-
synuclein binding to low negative charge SUVs. Plot of on-rate kon 
for unmodified (grey) and acetylated alpha-synuclein (orange) in the 
presence of 2.6 mM 15% PS SUVs versus residue number. The rate 
was calculated from R2 relaxation rates as described in sections II.g 
and III.b. 
The effect of N-terminal acetylation on alpha-synuclein binding 
to lipid vesicles can manifest itself as an effect on the on-rate and/or 
on the off-rate. In order to address this distinction, the on-rate for 
unmodified and acetylated alpha-synuclein binding to 15% PS SUVs 
was estimated by measuring R2 transverse relaxation rates in the 
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presence and absence of lipid vesicles (see sections II.g and III.b). The 
off-rate was then calculated using the equilibrium dissociation 
constant from the vesicle titrations (Table 3.3). The plot of kon versus 
residue number reveals three distinct regions of binding (Figure 3.16). 
The C-terminal tail, as seen before, shows no binding, while the N-
terminal ~10 residues display an increased on-rate of binding 
compared to the remainder of the N-terminal lipid-binding region, 
which has a relatively flat profile. The difference between the on-rates 
of these two regions is much more pronounced for acetylated alpha-
synuclein. Overall, acetylation increases the on-rate for the N-terminal 
region by a factor of ~6 (6.6 x 107 sec-1M-2 versus 1.0 x 107 sec-1M-2) 
and for the rest of the helical binding region by a factor of ~3 (1.3 x 107 
sec-1M-2 versus 4.8 x 106 sec-1M-2). The calculated off-rates are more 
comparable between acetylated and unmodified protein (Table 3.4), 
suggesting that N-terminal acetylation mostly increases the on-rate of 
alpha-synuclein binding to SUVs. 
Table 3.4: Computed on- and off-rates for unmodified and 
acetylated alpha-synuclein binding to low negative charge SUVs. 
On-rates were calculated from measured R2 relaxation rates in the 
presence and absence of SUVs (see sections II.g and III.b) and off-rates 
were calculated using the apparent KD values from Table 3.3. 
 N-terminal Binding Fully-Helical Binding 
Protein kon  
(sec-1M-2) 
koff  
(sec-1M-1) 
kon  
(sec-1M-2) 
koff  
(sec-1M-1) 
unmodified 1.0 x 107 4.1 x 104 4.8 x 106 4.8 x 104 
acetylated 6.6 x 107 6.6 x 104 1.3 x 107 4.8 x 104 
Overall, N-terminal acetylation stabilizes helical states at the 
very N-terminus of alpha-synuclein, both in the disordered state 
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prevalent in dilute aqueous solution and in lipid- and detergent-
stabilized fully-formed helical conformations. The N-terminally 
appended acetyl group has long been known, from previous research 
on peptides, to act as an N-terminal cap for α-helices [218,219]. 
Helical structure is stabilized by intraresidue i,i+4 hydrogen bonds 
between backbone amide protons and carbonyl oxygens; however, this 
pattern is broken at N- and C-terminal ends, leaving the first four  
amide protons and last four  carbonyl oxygen atoms without hydrogen 
bond partners [232]. Introduction of another amino acid into the 
helical structure would add one hydrogen bond partner, but would 
also add one partner-less hydrogen bond donor, leading to no net 
stabilization. 
 
Figure 3.17: Model of residues 1-7 as an ideal α-helix for 
unmodified and aceylated alpha-synuclein. (A) Unmodified alpha-
synuclein. (B) Acetylated alpha-synuclein. The acetyl group in (B) is 
shown as sticks. Hydrogen bonds between residues 1-4, 2-5, 3-6, and 
4-7, as well as acetyl-3, are shown as dashed yellow lines. 
Several amino acids, known as N-caps, can stabilize both N- and 
C-terminal ends of helices by forming side-chain-to-backbone 
hydrogen bonds without introducing another unsatisfied backbone 
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hydrogen bond donor [232,233]. Acetylation of the N-terminal amine 
can act in a parallel manner, allowing a hydrogen bond between its 
carbonyl oxygen atom and the amide proton of the fourth amino acid 
(phenylalanine 4 in alpha-synuclein) (Figure 3.17). This capping can 
lead to the observed stabilization of helicity in the N-terminal ~10 
residues of alpha-synuclein in the free and membrane-bound states. 
However, it is interesting that the addition of one hydrogen bond (~1 
kcal/mol stabilization) can stabilize up to 3 helical turns at the N-
terminus of alpha-synuclein; this likely points to very strong 
cooperativity in helix formation/propagation in the amphipathic helix 
region of alpha-synuclein. 
The straightforward stabilization of N-terminal helicity in the 
free and SDS-bound states of alpha-synuclein leads to more 
significant consequences in binding to lipid vesicles. N-terminal 
acetylation increases alpha-synuclein overall binding to lipid vesicles 
with lower proportions of negatively-charged lipids. This likely occurs 
through an increased on-rate in alpha-synuclein binding to the 
vesicles. The presence of negatively-charged phospholipids such as PS 
is often thought to be necessary for efficient alpha-synuclein binding 
to lipid membranes (e.g. [234]). This is at odds with the moderate 
negative charge content of synaptic vesicles, the putative binding 
partner for alpha-synuclein in vivo, which is thought to be ~10%, 
although the distribution between the outer and inner leaflet is not 
known [235]. However, the addition of an N-terminal acetyl group 
increases alpha-synuclein affinity for lipid vesicles with 15% PS by a 
factor of 3. In a similar manner, acetylated alpha-synuclein binds to 
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micelles of the nonionic detergent BOG, while the unmodified protein 
has practically no interaction with the detergent at similar 
concentrations. The conformation acetylated alpha-synuclein adopts 
upon binding to BOG micelles is a never-before-seen partly-helical 
state in which the N-terminal ~25 residues adopt helical structure 
while the rest of the protein remains disordered. 
 
III.d. Electrostatic and hydrophobic contributions to 
binding 
 
In two different systems (BOG and 15% PS vesicles), N-terminal 
acetylation increases alpha-synuclein interactions with relatively less 
charged binding surfaces. The N-terminal lipid binding region 
(residues 1-96) of unmodified alpha-synuclein has a net charge of +5 
at neutral pH, arising from 9 ionized negatively-charged side-chains, 
13 ionized positively-charged side-chains, 1 unprotonated histidine 
side-chain, and the protonated amino terminus. Thus, the binding 
interaction between this region of the protein and negatively-charged 
lipid membranes has a significant contribution from electrostatic 
attraction. In contrast, the C-terminal tail (residues 97-140) has a net 
charge of -14, explaining its strong reluctance to bind membranes. 
Another contributing driving force for alpha-synuclein binding to 
membranes is the favorable hydrophobic interaction between the 
apolar face of the amphipathic helix that forms on and partially inserts 
into membranes and the hydrophobic lipid acyl chains. Additionally, 
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there are contributions from the folding of the amphipathic helix and 
lipid defect healing in the membrane [59,63]. These contributions, 
summed together, result in the observed affinity of unmodified alpha-
synuclein for lipid membranes. 
One calorimetric study estimated the relative contributions to 
the enthalpy of alpha-synuclein binding to vesicles [59]. The helix 
folding was estimated to contribute ~75% of the binding enthalpy, 
leaving ~25% for the electrostatic attraction. When gel state vesicles 
(100% DPPC) were used, the binding enthalpy was found to be much 
greater, while final percent helicity remained comparable, suggesting 
that a large (~70%) contribution to binding to these SUVs comes from 
alpha-synuclein “healing” lipid membrane defects in the gel state 
membranes. In addition, there is some entropic contribution of helix 
folding and membrane defect healing. How does N-terminal acetylation 
change this balance of driving forces? 
The addition of an acetyl group at the N-terminus removes one 
positive charge, so it decreases the electrostatic attraction to 
negatively-charged membranes. However, the electrostatic contribution 
to binding is not very great, especially if the target membranes have a 
large number of defects and relatively low negative charge. The other 
effect of N-terminal acetylation is to stabilize helical states in both the 
free protein and, presumably, in the lipid-bound protein. In the case of 
high negative charge (50% PS) vesicles, both SUVs and LUVs, used in 
this study, the effect of the loss of one positive charge and increased 
helicity appear to be roughly equal and opposite, as seen in the similar 
levels of binding of N-terminally acetylated and unmodified alpha-
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synuclein. In the case of lower negative charge (15% PS) vesicles, the 
effect of losing one positive charge can be expected to be less than in 
the case of 50% PS due to the decrease in negative charge, while the 
effect of gaining helicity can be expected to remain the same as it was 
for highly charged vesicles. This differential effect is reflected in the 
increased (~3-times) binding affinity observed for acetylated alpha-
synuclein for lower negative charge vesicles. In the case of high 
negative charge, the electrostatic attraction dominates and N-terminal 
acetylation has very little effect. In the lower negative charge regime, 
the hydrophobic effects dominate and stabilization of the helix by N-
terminal acetylation increases binding. 
These findings can have interesting implications for alpha-
synuclein binding to membranes in the cell. While unmodified alpha-
synuclein exhibits a substantial preference for 50% PS vesicles over 
15% PS vesicles (4-6 times stronger binding), the difference is much 
smaller for the N-terminally acetylated protein (1.4 times stronger 
binding). All previous studies in reconstituted in vitro systems made 
use of the unmodified recombinant protein, and may have given a false 
impression of the necessity of high negative charge density for alpha-
synuclein binding. Many in vitro studies use lipid vesicles with 
unnaturally high PS (or PG) concentrations (50-100%) [62,230], while 
it is unlikely that the protein ever comes into contact with such 
membranes in its native environment. Even the plasma membrane or 
late secretory/synaptic vesicles probably do not contain more than 
15% PS in mammalian cells, although yeast cells may have 
significantly higher proportions of PS in the plasma membrane [236]. 
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Thus, it seems that in vivo, alpha-synuclein (which is N-terminally 
acetylated) interacts with membranes similar to the “low negative 
charge content” vesicles examined in this work, to which the 
acetylated protein binds nearly as tightly as to much more negatively 
charged membranes. 
 
III.e. Implications for curvature sensing in vivo 
 
N-terminal acetylation also affects alpha-synuclein selectivity for 
vesicle curvature. Unmodified alpha-synuclein has been shown to have 
a preference for more curved membrane surfaces, such as SUVs. This 
curvature preference is confirmed by the results obtained here, with 
unmodified alpha-synuclein displaying 2.5-3.5 times stronger binding 
to SUVs than LUVs (after accounting for different proportions of 
accessible outer leaflet lipids in SUVs and LUVs); however, the 
acetylated protein was found to have ~4 times greater affinity for the 
more curved SUVs than the LUVs. For both N-terminally acetylated 
and unmodified alpha-synuclein, preference for SUVs was more 
noticeable at lower negative charge compositions, suggesting that 
strong electrostatic attraction can mask curvature sensing. One can 
compare the effects of curvature (LUV to SUV) and of charge (15% to 
50% PS) for unmodified and acetylated alpha-synuclein. For 
unmodified protein, increasing negative charge and increasing 
curvature results in an increase in affinity by a factor of 6 and 3.5, 
respectively. For N-terminally acetylated alpha-synuclein, the same 
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increases are 1.4 and 4.4. Thus, unmodified alpha-synuclein binding 
affinity is increased more by the addition of negative charges to the 
membrane than by increasing the curvature, while for acetylated 
alpha-synuclein, the situation is reversed.  
How does one small modification change the effects of curvature 
and charge so much? The answer depends on the mechanism of 
alpha-synuclein curvature sensing, which is still unclear. One theory 
implicates the mismatch between the two faces of the amphipathic 
helix – the hydrophilic face is well-developed compared to other 
amphipathic helices, with many charged residues, while the 
hydrophobic face is quite small and composed of not very hydrophobic 
residues [62]. A balanced amphipathic helix would bind strongly to 
any hydrophobic surface, such as a flat membrane, while the 
mismatched alpha-synuclein amphipathic helix must derive more 
stabilization from membrane properties. In the case of highly curved 
membranes, this arises from the increased population of lipid packing 
defects, which allow the nonpolar face of alpha-synuclein to insert into 
the hydrophobic chain region of the bilayer. By increasing N–terminal 
helicity and removing the primary amino charge, N-terminal 
acetylation decreases non-curvature-specific electrostatic attraction 
that promotes alpha-synuclein binding to any negatively-charged 
surface, while increasing the contribution of forming the amphipathic 
helix, which relies on the membrane defects present in highly curved 
membranes for tight binding. 
One interesting observation in the binding profiles of unmodified 
and acetylated alpha-synuclein can be seen in the case of high 
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negative charge LUVs. While low negative charge LUVs lack both the 
high membrane curvature and high negative charge that drive alpha-
synuclein binding, and thus display the weakest binding, the higher 
negative charge LUVs at least have increased electrostatic attraction 
towards alpha-synuclein molecules. Here, the effect of the loss of the 
primary amino charge upon N-terminal acetylation is most evident, as 
the N-terminal 20 residues of the acetylated protein display less 
binding than those of the unmodified protein in the presence of the 
same concentration of lipid vesicles (Figure 3.12A). This observation 
suggests that the primary amino positive charge anchors the 
unmodified protein on very negatively charged vesicles, in the absence 
of other possible anchoring characteristics, such as high curvature. 
Therefore, in the absence of N-terminal acetylation, high negative 
charge in the binding partner can make up for non-ideal low curvature 
in terms of N-terminal binding initiation, but this effect is abrogated 
upon acetylation, and is not relevant in vivo. 
As mentioned above, one likely mechanism by which high 
membrane curvature promotes alpha-synuclein binding is by 
increasing the concentration of lipid packing defects to which the 
protein can preferentially bind. Membrane curvature is not the only 
property that affects the amount of membrane defects – the 
composition of fatty acid phospholipid chains also plays a role. Many 
cellular membranes contain phospholipids with unsaturated acyl 
chains, which are kinked and introduce disorder in the membrane. 
The presence of these kinked unsaturated acyl chains, as well as small 
lipid headgroups such as PE and PA, also increases the amount of 
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lipid packing defects, which expose the acyl chains and can promote 
binding of alpha-synuclein. In fact, alpha-synuclein has a strong 
preference for binding to lipid membranes containing unsaturated acyl 
chains, leading to increased recent use of DO (di-oleoyl) lipids in 
alpha-synuclein studies, which contain two monounsaturated acyl 
chains, (this work; [92,96,231]. Since it appears that alpha-synuclein 
has a strong preference for lipid packing defects [59,62], whether 
caused by high curvature or lipid composition, it can be posited that 
alpha-synuclein uses this preference to localize to a specific target 
membrane in cells. 
A simplified treatment of subcellular localization of different lipid 
membranes identifies three physicochemical properties of membranes: 
charge (mostly PS content), packing defects, and curvature (which also 
influences packing defects) [64]. These three properties define two 
broad regions of membranes in the cell – a region dominated by high 
curvature and high incidence of packing defects (ER and cis-Golgi) and 
a region dominated by electrostatics (secretory vesicles, endosomes, 
and plasma membrane). While this general treatment is useful, it is 
not very applicable to the situation of alpha-synuclein, which has 
preference for both lipid packing defects and negatively-charged lipids. 
However, synaptic vesicles offer a unique lipid environment which 
contains the relatively high negative charge of the plasma membrane 
while providing high curvature and a large proportion of lipids with 
unsaturated acyl chains, likely resulting in a significant amount of 
lipid packing defects [235]. This lipid composition thus seems ideally 
suited to promote alpha-synuclein binding, especially if the protein is 
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N-terminally acetylated. In addition, the large proportion of negatively-
charged lipids in the plasma membrane leaves open the possibility of 
significant alpha-synuclein binding there as well. 
 
III.f. Fully-helical and partly helical states 
 
Most of the discussion of binding to lipid vesicles has focused on 
total binding, which includes both fully- and partly-helical states. The 
effect of N-terminal acetylation on fully-helical binding generally 
mirrors that on total binding. Selectivity for highly curved vesicles, 
however, is not increased by N-terminal acetylation in the fully-helical 
bound state. This suggests that most of the increased binding to 
highly curved membrane surfaces engendered by N-terminal 
acetylation is in the form of partly-helical, N-terminally bound states.  
One interesting consequence of having measured separate 
affinities for total binding and fully-helical binding is the ability to 
calculate the full helix fraction (section II.d, Table 3.2). A pattern 
emerges in which the full helix fraction is higher for more curved SUVs 
than LUVs for each protein and lipid composition combination. The 
only exception is the higher full helix fraction for acetylated alpha-
synuclein on high negative charge LUVs, arising from decreased 
partly-helical binding due to the loss of the primary amino positive 
charge. In all other cases, increased curvature results in increased 
binding in the fully-helical mode. This finding can be interpreted as 
increased curvature promoting the folding of helix-2 and/or the 
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extended-helix state. This is possible since helix-2 displays a higher 
curvature than helix-1 on SDS micelles [74], while the extended helix 
is expected to have an overall curvature that matches an 
SUV/synaptic vesicle sized vesicle [77]. Alternatively, greater number 
of lipid packing defects, an indirect result of higher membrane 
curvature, can be responsible for increased helix-2 and/or extended-
helix binding due to the presence of more hydrophobic binding sites 
for a longer amphipathic helix. Whatever the mechanism, less curved 
membrane surfaces have a greater proportion of partly-bound states of 
alpha-synuclein, while more curved surfaces have more binding sites 
for the longer fully-bound state. 
What are these mysterious partly-bound states? The BOG-
bound conformation may offer some structural clues. There is 
significant evidence for a partly-helical state of alpha-synuclein that 
may be correlated with aggregation [92,95]. This partly-helical state is 
expected to have 20-25 helical residues, likely at the N-terminus. This 
description matches what is observed for N-terminally acetylated 
alpha-synuclein in the presence of BOG micelles. The unmodified 
protein does not appreciably bind to this nonionic detergent, but upon 
elimination of the primary amino positive charge and increase of 
helicity at the N-terminus, binding in a partly-helical state is favored. 
This binding interaction was measured by two complementary 
approaches, NMR chemical shifts, which report on extent of binding, 
and CD ellipticity, which reports on extent of helical structure. The two 
measurements of binding overlay very closely, showing that helix 
formation is concomitant with binding to the micelle, a situation that 
 129 
 
is different from that seen for other membrane-binding proteins, such 
as complexin [176]. There is evidence for the partly-helical state 
existing on lipid vesicles [92], and it may be an early intermediate in 
binding to the membrane, with binding nucleated at the N-terminus, 
then propagating through the formation of more helical structure. 
The end point of this helical intermediate, around residue 25-30, 
may be meaningful given the existence of the PD-linked mutant A30P, 
a helix-breaking mutation. This mutation greatly decreases lipid-
binding overall and increases the proportion of the partly-helical state 
[39,92]. Interestingly, other PD-linked mutations such as E46K and 
A53T, while not having such a stark effect on total lipid binding, 
increase the proportion of alpha-synuclein that is bound in a partly-
helical state, suggesting that this partly-helical state may be the 
common denominator among PD mutants of alpha-synuclein [92]. This 
potential link to pathology indicates that the partly-helical state is 
either itself pathogenic or interferes with alpha-synuclein carrying out 
its function in vivo. Previously, in order to glean information about the 
partly-helical state in the presence of lipid vesicles, very dilute 
concentrations of SUVs had to be used, as binding to SUVs causes the 
formation of a large immobile complex and the corresponding 
disappearance of amide cross-peaks. In the presence of BOG, the 
amide cross-peaks of bound residues remain visible (although 
decreased in intensity) even when fully bound, presumably due to the 
smaller size of BOG micelles. This allows for further high-resolution 
study of this state, and more specifically the effects of PD-linked 
mutations on its structure and folding pathways. 
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III.g. Implications for tetrameric assembly 
 
Increased N-terminal helicity in alpha-synuclein upon N-
terminal acetylation could be responsible for a helical, tetrameric 
assembly that was purified from various sources, all involving N-
terminally modified protein [114,117,118]. The NMR results (both in 
intact cells and on purified protein) presented here rule out the 
presence of significant amounts of such a conformation of acetylated 
alpha-synuclein both in E. coli cells and in the test tube. However, the 
glycerol and BOG used in the purification buffers in two of these 
studies [117,118] may interact with acetylated alpha-synuclein and 
contribute to detected helical structure and large molecule size. The 
conformation of acetylated alpha-synuclein in the presence of BOG 
micelles described here displays much less helical character than in 
those studies (~25 residues versus ~90 residues), so it is unlikely to be 
the culprit. However, the potential effect of glycerol or E. coli 
contaminants maintained through the purification scheme was not 
evaluated, and may be responsible. 
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IV. Phosphorylation at Y39 regulates the lipid-binding mode of 
alpha-synuclein 
 
IV.a. Introduction 
 
Although N-terminal acetylation is almost ubiquitous in 
eukaryotic proteins, protein phosphorylation is the most extensively 
studied post-translational modification since its discovery in the 1950s 
[148]. Unlike N-terminal acetylation, phosphorylation, which in 
eukaryotes consists of the transfer of a phosphate group, usually from 
ATP, to either a serine (86%), threonine (12%), or tyrosine (2%) residue 
by an enzyme called a kinase, is reversible [149,150]. Protein 
phosphorylation by a kinase and dephosphorylation by a phosphatase 
combine to form a dynamic signaling system that can regulate myriad 
cellular and organismal processes in space and time. Systems as 
varied as signal transduction through receptor tyrosine kinases [237], 
growth signal regulation through the mTOR pathway [238], and stress 
and inflammation response via MAPK pathways [239] all make use of 
networks of phosphorylation and dephosphorylation. When combined 
with other dynamic post-translational modifications, phosphorylation 
acts to increase the variety of protein surfaces for protein-protein 
interactions without increasing the gene number, as well as allowing 
the cell to respond to environmental changes faster than simple 
protein translation [151].  
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One advantage of a phospho-residue is the unique chemical 
surface formed by the addition of a highly negatively-charged 
phosphate group [150]. Thus, phosphorylated residues can be easily 
recognized by specific domains through hydrogen bonds or ionic 
interactions, either intra- or inter-molecularly. Addition of a phosphate 
group can lead to specific protein-protein recognition or to dissociation 
of protein complexes [240]. In a simple example, increasing 
phosphorylation of the N-terminal region of the circadian clock protein 
FRQ induces its dissociation from the C-terminus, allowing the protein 
to be degraded in a time-dependent manner [241]. In addition to 
modulating protein-protein recognition directly, phosphorylated 
residues can elicit conformational changes and thus indirectly affect 
protein-protein interactions [150,240]. Regulation of these interactions 
can also modulate protein localization as a result of phosphorylation 
or dephosphorylation. The creation and abolition of protein-recognition 
sites, dynamically and spatiotemporally regulated by kinases and 
phosphatases, is what allows protein phosphorylation to be such an 
effective signal integrator and regulator in the cell. 
While phosphorylation is known to affect protein conformations, 
there is no general model of the direct structural effects of the addition 
of a phosphate group to a serine, threonine, or tyrosine residue. 
Complicating matters is the fact that phosphorylation occurs 
disproportionately in areas of intrinsic disorder on proteins [242,243]. A 
review of 17 pairs of phosphorylated and unphosphorylated structures 
found that the changes effected by phosphorylation varied widely, but 
most were driven by the need to accommodate the large negative 
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charge introduced by the phosphate group [244]. The conformational 
changes included small and large effects, local and long-range changes, 
and order-to-disorder and disorder-to-order transitions. A later 
bioinformatics study of the structural effects of phosphorylation and 
other modifications found that, while local and global conformational 
changes due to phosphorylation are significant, most (>80%) are small 
[245]. In addition, phosphorylation was found to alter the global energy 
landscape of proteins, specifically by stabilizing the overall protein 
structure, likely through new hydrogen bonds and ionic interactions. 
These results suggest that phosphorylation acts to restrict 
conformational flexibility in a protein. Examples of phosphorylation 
suppressing intrinsic disorder have been seen in molecular dynamics 
simulation as well [246]. 
NMR studies on short, disordered model peptides showed that 
phosphorylation of serine and threonine residues directly affects the 
preferred dihedral angles of the polypeptides, while phosphorylation of 
tyrosine residues does not [247]. However, in the presence of charges in 
the vicinity of the phosphotyrosine, the addition of the phosphate 
group did affect the dihedral angles adopted by the peptide. These 
results suggest that phosphorylation of serine and threonine residues 
can directly affect peptide backbone conformations through hydrogen 
bonds between the amide proton and phosphate group of the 
phosphorylated residue. For tyrosine, on the other hand, the larger 
size and rotational range of the side-chain precludes a similar 
interaction between the phosphate and amide groups, and the effect of 
phosphorylation is mediated by interactions with nearby charges, 
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whether on the polypeptide chain or in an interacting partner. Another 
example of the specific structural effects of tyrosine phosphorylation 
occurs in the β3 integrin cytoplasmic tail [248]. Phosphorylation of one 
or two tyrosine residues in the tail region changes the conformation to 
one that does not interact with the α integrin tail, since the 
intramolecular interactions with the added phosphate group are 
stronger than intermolecular interactions between the two tails. 
Tyrosine phosphorylation also introduces repulsion from the 
membrane, which may free the tail for other interactions. 
Many kinases have been shown to phosphorylate alpha-
synuclein on several serine and tyrosine residues, mostly in the acidic 
C-terminal tail [152–156]. The most commonly detected 
phosphorylation of alpha-synuclein in vivo is at serine 129; this 
modification is seen in cytosolic alpha-synuclein [157] but to a greater 
extent in alpha-synuclein found aggregated in Lewy bodies [146,158,159]. 
While Ser-129 phosphorylation of alpha-synuclein has been 
extensively studied, its effect on alpha-synuclein fibril formation and 
PD progression is not clear and is most likely context-dependent. 
There is evidence that phosphorylation of alpha-synuclein at Ser-129 
(pS129) inhibits alpha-synuclein fibril formation in vitro [155] but also 
contradicting evidence that pS129 increases alpha-synuclein fibril 
formation in vitro and aggregation in cells [158,160]. Studies in several 
animal models of PD also produced conflicting results on the effect of 
Ser-129 phosphorylation on alpha-synuclein aggregation and toxicity 
(summarized in [156]). The major kinase families that have been shown 
to phosphorylate alpha-synuclein at Ser-129 are the Polo-like kinase 
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(PLK) family, specifically PLK2 and PLK3 [153] and the casein kinase 
(CK) family, specifically CK1 and CK2 [159]. Robust phosphorylation of 
alpha-synuclein at Ser-129 by PLK2 especially has been demonstrated 
in both mice and yeast models [156,249]. Complicating matters further, 
PLK2 has been shown to be upregulated in and to decrease alpha-
synuclein toxicity when introduced into animal models of PD [153,250]. 
Additionally, loss of pS129 (whether through dephosphorylation or 
truncation) may occur preferentially on synaptic membranes [251]. 
Phosphorylation of alpha-synuclein at a secondary site, serine 
87, was also detected in cell models and ascribed to CK1 [159]. In 
addition, phosphorylation of alpha-synuclein at Ser-87 was 
demonstrated in vitro by the tyrosine-regulated kinase Dyrk1A [161]. 
alpha-Synuclein phosphorylated at Ser-87 was found to be enriched in 
samples from PD patients or animal models of PD, especially in the 
membrane fraction [154]. Somewhat paradoxically, the pS87 alpha-
synuclein was shown to bind less tightly to acidic lipid vesicles 
composed of POPG. The same study also showed that phosphorylation 
at Ser-87 decreased alpha-synuclein fibril formation. While 
phosphorylation on the flexible C-terminal tail (such as pS129) may be 
more tolerated in the course of fibril formation, the addition of a highly 
negative chemical group in the fibril core region would be expected to 
inhibit the self-association required for fibril formation due to 
electrostatic repulsion. 
Phosphorylation of alpha-synuclein at these two serines has not 
been shown to result in major structural rearrangements in either the 
free, disordered or SDS-bound states of the protein [154,155]. The CD 
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spectrum of free alpha-synuclein reveals generally disordered 
structure regardless of phosphorylation at Ser-87 and Ser-129 and 
NMR chemical shifts are only perturbed for a few residues in the 
vicinity of the phosphorylation site, with no local induction of 
secondary structure. However, addition of the phosphate group at 
either site results in alpha-synuclein populating more expanded 
conformations in aqueous buffer, with a greater effect seen for pS129 
[154]. Interestingly, mutation to aspartate or glutamate at these sites, 
which is commonly used to mimic phosphorylation, does not result in 
the same expansion. This finding supports an important role for 
electrostatics in the expanded state of alpha-synuclein, since 
phosphoserine adds two negative charges while aspartate or glutamate 
only add one at physiological pH. 
Phosphorylation at Ser-129, as expected, has no effect on the 
membrane- and detergent-bound structure of alpha-synuclein [155]. 
Seeing as Ser-87 is within the membrane-binding region, addition of a 
phosphate group there decreases alpha-synuclein helicity upon 
binding to acidic lipid vesicles and local helicity at the C-terminal end 
of helix-2 in the SDS-bound state [154]. These results suggest that the 
very C-terminal end of the lipid-binding region dissociates from the 
membrane or micelle surface when Ser-87 is phosphorylated. Thus, 
phosphorylation at either of these serine residues only has a local, 
electrostatics-mediated effect on the membrane bound state, while 
adding the negatively-charged phosphate group, particularly at Ser-
129, biases the disordered ensemble toward more expanded 
conformations, possibly by disrupting the transient intramolecular 
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contacts within alpha-synuclein, although adding a negatively-charged 
phosphate group would be expected to strengthen these contacts. 
In addition to serine residues, eukaryotic proteins are often 
phosphorylated on threonine and tyrosine residues. Despite alpha-
synuclein containing 10 threonine residues due to the conserved 
KTKEGV repeat motif, there has been no evidence of any threonine 
phosphorylation. Tyrosine residues, however, have been shown to be 
phosphorylated (and nitrated). Early studies on alpha-synuclein 
transfected into cell lines showed that tyrosine 125 could be 
phosphorylated, and likely by members of the Src family of kinases, 
especially Fyn [162,163]. Phosphorylation at tyrosines 133 and 136 was 
also detected, but at lower levels [162,164]. alpha-Synuclein 
phosphorylated at Tyr-125 was shown in human samples and animal 
models, and its levels were found to decrease with age [165]. However, 
the difficulty of producing pY125 alpha-synuclein in vitro and lack of 
widely accepted mutations that mimic the physicochemical properties 
of a phosphotyrosine side-chain had previously prevented biophysical 
characterization of the phosphoprotein. In this work, such an analysis, 
using a chemically synthesized pY125 form of the protein is presented. 
Nitration of the C-terminal tyrosine residues of alpha-synuclein 
as a result of oxidative stress has also been observed in PD brain 
samples [252]. Damage from reactive oxygen species or oxidative stress 
has been implicated in PD for decades [253,254]. Peroxynitrite, 
generated by superoxide and nitric oxide, can react with tyrosine 
residues on proteins to generate 3-nitrotyrosine. Proteins containing 3-
nitrotyrosines were detected in Lewy bodies [255], and specifically 
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shown to be nitrated alpha-synuclein [252]. These alpha-synuclein 
species contained 3-nitrotyrosine residues at positions 39, 125, 133, 
and/or 136 [252,256]. 
Nitrated alpha-synuclein was shown to accelerate fibril 
formation of unmodified alpha-synuclein to which it had been added, 
while itself being resistant to fibrillization, and alpha-synuclein 
specifically nitrated at Tyr-39 exhibited decreased binding to acidic 
lipid vesicles [257]. A study that dissected the effects of Tyr-39 and C-
terminal tyrosine nitration in alpha-synuclein demonstrated that 
nitration of C-terminal tyrosine residues also decreased alpha-
synuclein binding to lipid vesicles [258]. This somewhat surprising 
result suggests that intramolecular interactions between the C-
terminal tail and N-terminal regions of alpha-synuclein [259] may 
affect membrane binding. Nitration of alpha-synuclein was also shown 
to result in high molecular weight aggregates covalently cross-linked 
via di-tyrosine linkages [260]. Within the framework of the toxic pre-
fibrillar oligomer hypothesis, such effects of nitration would suggest a 
pathogenic result of this modification. In fact, nitrated alpha-synuclein 
does exhibit cellular toxicity in various cell culture and animal models 
[261–263]. However, nitrated alpha-synuclein was not examined 
further here. Instead, attention was focused on examining the effects 
of phosphorylation at the only known site located well within the 
membrane-binding domain of alpha-synuclein, Y39. 
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IV.b. Methods 
 
Phosphorylated Protein Samples – The effects of phosphorylation 
of tyrosine residues 39 and 125 on alpha-synuclein structure and 
binding to membranes and membrane mimics were assessed using a 
number of different NMR experiments. Authentically phosphorylated 
alpha-synuclein was produced by a semisynthetic method for pY125 
alpha-synuclein and by incubating recombinant alpha-synuclein with 
the kinase c-Abl for pY39 alpha-synuclein. Partially isotopically labeled 
and unlabeled pY125 alpha-synuclein was produced by expressing 
A107C alpha-synuclein in E. coli and synthesizing the (unlabeled) 108-
140 peptide with a phosphotyrosine residue incorporated at position 
125, then ligating the peptides using intein chemistry [152]. While this 
method allows for the production of sufficient quantities of 
authentically phosphorylated protein for NMR studies, as a result the 
C-terminal region is not isotopically-labeled and thus invisible to 
heteronuclear NMR methods. Notably, this synthesis was carried out 
in the laboratory of Dr. Hilal Lashuel (EPFL, Switzerland) by his at the 
time student, Dr. Bruno Fauvet. 
Alpha-synuclein protein phosphorylated on tyrosine 39 was also 
produced by Dr. Fauvet in Dr. Lashuel’s lab. In order to avoid 
phosphorylation on sites other than Tyr-39, full-length Y125F Y133F 
alpha-synuclein or truncated alpha-synuclein 1-102 were used as the 
substrate. Isotopically-labeled protein was produced as described in 
section II.a. Lyophilized alpha-synuclein protein was dissolved in pH 
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7.5 buffer, filtered using a 100 kDa cutoff filter, and incubated with 
the SH2-CD fragment of c-Abl and ATP. After the reaction was 
completed, the phosphorylated alpha-synuclein was purified by 
reverse-phase HPLC and lyophilized. Phosphorylation was assessed by 
mass spectrometry. Due to the difficulty of producing large quantities 
of authentic pY39 alpha-synuclein, the phosphomimic mutant Y39E 
was also used. The Y39E alpha-synuclein protein was produced as 
described in section II.a. 
Basic NMR Experiments – Phosphorylation of alpha-synuclein by 
c-Abl was followed by NMR. Wild-type alpha-synuclein (~100 μM) 
dissolved in 20 mM tris, 10 mM MgCl2, 1 mM DTT, pH 6.8 buffer (400 
μL total volume) was incubated with 1 mM ATP and 10 μg of the 
catalytic truncation SH2-CD c-Abl and successive 1 hr 1H,15N-HSQC 
experiments were collected overnight at 15 °C. A spectrum was also 
collected on a matched alpha-synuclein sample with no c-Abl to serve 
as a zero timepoint. The relative intensity of each phosphorylated peak 
was calculated as the signal intensity of the peak arising from 
phosphorylated protein divided by the sum of intensities of the peaks 
arising from unphosphorylated and phosphorylated protein. This 
relative intensity was then plotted versus time, here taken as the mid-
point of each HSQC experiment (i.e. 0.5 hr, 1.5 hr, etc). 
Authentically phosphorylated and phosphomimic protein was 
used to characterize the effects of the phosphorylation on the free and 
micelle- and vesicle-bound states of alpha-synuclein. Backbone 
assignments were transferred from previously determined ones by 
transferring peaks to the closest unassigned peak in HSQC 
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experiments (pY125) or by using high-resolution HNCA experiments 
(pY39), which also provided alpha-carbon chemical shifts for 
secondary structure analysis (see section II.f). Amide chemical shift 
deviations derived from 1H,15N-HSQC experiments were used to 
monitor the effects of phosphorylation (see section II.c). 
The effect of pY125 and pY39 on the broken-helix state of alpha-
synuclein was assessed at 40 mM SDS, a concentration at which the 
detergent is expected to form spheroidal micelles [225,226]. Again, 
secondary structure information was derived from HNCA experiments. 
Deuterated SDS was employed for the triple resonance NMR 
experiments to minimize magnetization loss from the protein nuclei via 
spin diffusion within the micelle. The HNCA experiments provided 
alpha-carbon chemical shifts which were used to analyze the 
secondary structure of pY39 and Y39E alpha-synuclein in the 
presence of SDS micelles using secondary shifts. In addition, carbonyl 
carbon chemical shifts were obtained from HNCO experiments and 
used to assess secondary structure as well. A 1H,15N-HSQC-NOESY-
HSQC experiment was used to determine whether helical structure is 
continuous in the SDS-bound pY39 and Y39E alpha-synuclein [71] 
(see section II.f). 1H,15N-HSQC-NOESY-HSQC experiments were run 
using a pulse sequence adapted from a four-dimensional proton-
nitrogen-nitrogen-proton experiment [189] to yield proton-nitrogen-
nitrogen chemical shifts and collected with 96 complex pairs in the 
first nitrogen dimension and at least 128 complex pairs in the second 
nitrogen dimension to provide sufficient resolution to overcome peak 
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overlap. The NOE mixing time was 300 msec and deuterated SDS was 
used to prevent transfer of NOE through detergent protons. 
PRE Experiments – Intramolecular contacts in the free state of 
pY125 and Y39E alpha-synuclein were assessed using PRE 
experiments. Paramagnetic spin-labels were covalently linked to 
cysteine residues introduced by mutagenesis at position 9 for Y39E 
and 107 for pY125, which was left over from the semisynthesis scheme. 
PRE experiments were also used to determine whether pY39 and Y39E 
alpha-synuclein adopts and antiparallel helical conformation in the 
presence of SDS micelles. The paramagnetic labels were linked to 
cysteines introduced at the ends of helix-1 and helix-2, namely 
position 9 or 83. An observed PRE effect on the opposite helix suggests 
that the helices are in an antiparallel, broken-helix-like conformation. 
For more details on the preparation of samples and execution of PRE 
experiments, see section II.h. 
Lipid Vesicle Binding – Binding to lipid vesicles was measured by 
decrease of amide cross-peak intensity in 1H,15N-HSQC spectra in the 
presence of lipid vesicles as detailed in section II.d. Samples for 
unphosphorylated and pY39 or wild-type and Y39E proteins were 
made in parallel with the same lipid stock, resulting in well-matched 
samples. Those titrations were performed on independently made 
samples for each point. 
Diffusion Experiments – Diffusion measurements were performed 
using the Bruker “ledbpgp2s192d” PFG LED pulse sequence [196] on 
proteins and 2H SDS (so as not to swamp the protein signal) dissolved 
in D2O with 0.03% v/v (~4 mM) dioxane at 300 K using a Bruker 
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AVANCE 500 MHz spectrometer with a room-temperature probe. 
Gradient strength was varied in a 32-step linear gradient between 2 
and 95% of the maximum strength. The diffusion delay was optimized 
to achieve ~10% signal intensity with 95% gradient strength. The 
diffusion delay was 100 msec, the tau was 0.2 msec, the gyromagnetic 
ratio was 4,257.7 Hz/G for proton, the shape factor was 0.630 for a 
sine-shaped gradient, the gradient duration was 7 msec, and the 
maximum gradient strength was 85 G/cm. The signal intensity for 
several protein and SDS aliphatic peaks, as well as the dioxane peak 
at ~3.6 ppm, was plotted as a function of gradient strength and fit to 
equation 7 (see section II.j) using the Bruker TopSpin relaxation 
analysis module, which also provided the default value for maximum 
gradient strength. Maximum gradient strength can also be calculated 
by measuring the diffusion coefficient of residual HDO in D2O and 
setting it equal to the published value of 1.902 +/- 0.002 x 10-9 m2-
sec-1 [199]. 
 
IV.c. Results Overview 
 
Structure of alpha-synuclein is not greatly perturbed by pY125 –  
The 1H,15N-HSQC spectra of full-length unphosphorylated alpha-
synuclein A107C was compared to that of pY125 alpha-synuclein 
A107C thus produced, in aqueous buffer (Figure 4.1A). Since the 
region containing the phosphorylation site was NMR-invisible, no 
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spectral changes were seen, suggesting that phosphorylation may have 
only local effects on the structure of the free state of alpha-synuclein 
(Figure 4.1B). 
 
Figure 4.1: HSQC spectra and amide chemical shift differences for 
unphosphorylated and pY125 alpha-synuclein A107C in aqueous 
buffer. (A) 1H,15N-HSQC spectra of unphosphorylated (black) and 
pY125 (purple) alpha-synuclein A107C in aqueous buffer. (B) Plot of 
amide chemical shift differences (equation 1) between 
unphosphorylated and pY125 alpha-synuclein A107C versus residue 
number. 
In addition, the effect of phosphorylation of tyrosine 125 on the 
intramolecular contacts of alpha-synuclein was assessed by PRE 
experiments with MTSL spin-labels attached at position A107C and by 
PFG diffusion measurements. The PRE effect, when plotted against 
protein primary sequence, was not significantly different for the 
phosphorylated and unphosphorylated protein (Figure 4.2). 
Interestingly, spin-labeling at position 107 does not seem to report on 
the known C- to N-terminal contacts in alpha-synuclein, so this 
technique was not able to determine whether those contacts are 
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preserved upon phosphorylation. However, the well near the label site 
appears to be narrower in the pY125 sample, with the intensity ratio 
reaching 1 by residue 85, while it remains below that value until 
residue ~70 in the unphosphorylated sample. This discrepancy 
suggests that the C-terminal region occupies more extended 
conformations when tyrosine 125 is phosphorylated, thus experiencing 
less PRE due to the spin-label at 107. Intramolecular contacts were 
also assessed by measuring the diffusion coefficient, and thus the 
hydrodynamic radius, of the phosphorylated protein molecule.  
 
Figure 4.2: Intramolecular contacts for unphosphorylated and 
pY125 alpha-synuclein A107C in aqueous buffer. Plot of the ratio of 
peak intensity for samples paramagnetically labeled at A107C to peak 
intensity in unlabeled samples versus residue number for 
unphosphorylated (A) and pY125 alpha-synuclein (B) in aqueous 
buffer. The gray bars indicate which peaks were included in the 
analysis. 
Previous studies on phosphorylated alpha-synuclein (pS129) [155] had 
shown that phosphorylation results in drastic expansion of the protein 
molecules, reflected in ~25% increase in hydrodynamic radius. The  
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pY125 alpha-synuclein displayed a hydrodynamic radius virtually 
identical (102%) to that of the unphosphorylated protein, thus 
precluding any expanded protein conformations such as those seen for 
pS129. 
 
Figure 4.3: HSQC spectra and amide chemical shift differences for 
unphosphorylated and pY125 alpha-synuclein A107C in the 
presence of SDS micelles. (A) 1H,15N-HSQC spectra of 
unphosphorylated wild-type (black) and pY125 alpha-synuclein A107C 
(purple) in 40 mM SDS. (B) Plot of amide chemical shift differences 
(equation 1) between unphosphorylated wild-type and pY125 alpha-
synuclein A107C in 40 mM SDS versus residue number. 
The effect of phosphorylation at tyrosine 125 on the micelle-
bound form of alpha-synuclein was also assessed. Comparison of 
1H,15N-HSQC spectra of unphosphorylated and pY125 alpha-synuclein 
in the presence of 40 mM SDS reveals overall similarity between the 
spectra, reflecting a lack of large-scale structural changes due to 
phosphorylation (Figure 4.3A). Assignments from the wild-type protein 
were transferred to the closest unassigned peak in the pY125 
spectrum and the transferred assignments were then used to analyze 
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the locations of the spectral changes along the peptide chain (Figure 
4.3B). The magnitude of most of the peak shifts was very low, except 
for that of histidine 50, which is very sensitive to even small changes 
in pH. These shifts suggest that the phosphorylation does not affect 
the overall fold of the protein. 
 
Figure 4.4: HSQC spectra and increasing intensity of 
phosphorylated peaks during phosphorylation reaction. (A) Zooms 
of consecutive 1-hour 1H,15N-HSQC spectra of alpha-synuclein 
incubated with SH2-CD c-Abl. The regions focus on the peak for G41 
and show the disappearance of the unphosphorylated peak and 
appearance of the phosphorylated peak. (B) Plot of relative intensity of 
the phosphorylated peak for G41 with increasing time. Red lines show 
the approximate level of noise. 
Free state structure of alpha-synuclein is not greatly perturbed by 
pY39 – alpha-Synuclein can also be phosphorylated on tyrosine 39, 
which is located within the membrane-binding domain, albeit in a 
region that forms the somewhat flexible linker region in the broken 
helix state. The tyrosine kinase c-Abl specifically phosphorylates this 
site [264]. The phosphorylation reaction can be followed in real time by 
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multidimensional NMR; wild-type alpha-synuclein was incubated with 
SH2-CD c-Abl and consecutive 1 hr 1H,15N-HSQC spectra were 
collected. The spectral changes were characterized by disappearance of 
cross-peaks arising from residues near position 39 (such as glycine 41) 
in the unphosphorylated protein and appearance of new peaks nearby, 
ostensibly arising from the phosphorylated protein (Figure 4.4A). 
The fact that peaks arising from phosphorylated and 
unphosphorylated alpha-synuclein are both visible demonstrates that 
the phosphorylation reaction is slower than the NMR timescale in the 
experiment. The intensities of the phosphorylated and 
unphosphorylated peaks are anti-correlated with increasing time, 
suggesting that the progress of the reaction can be monitored by the 
increasing intensity of the phosphorylated peaks. When plotted against 
time (the midpoint of each hour-long HSQC experiment), the intensity 
of the phosphorylated peak relative to the total intensity for both peaks 
increases and reaches a maximum by ~3 hr (Figure 4.4B). 
Interestingly, the unphosphorylated peaks remain at ~20% of the total 
intensity after this time, consistent with the noise threshold of this 
experiment, as estimated by the NMRViewJ peak picking module 
(Figure 4.4B, red). While secondary phosphorylation at tyrosine 125 
was detected by mass spectrometry [264], the peak for that residue is 
in a very crowded region and no spectral changes could be resolved. 
To determine the effects of phosphorylation at tyrosine 39 on the 
conformation of alpha-synuclein in aqueous buffer, isotopically-labeled 
pY39 alpha-synuclein was produced by incubating alpha-synuclein 
Y125F Y133F (to increase the efficiency of phosphorylation) with c-Abl. 
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A comparison of 1H,15N-HSQC spectra of unphosphorylated and pY39 
alpha-synuclein Y125F Y133F reveals small spectral changes, 
although the overall spectrum is very similar (Figure 4.5A).  
Figure 4.5: HSQC spectra, amide chemical shift differences, and 
alpha-carbon secondary shifts for unphosphorylated and pY39 
alpha-synuclein Y125F Y133F in aqueous buffer. (A) 1H,15N-HSQC 
spectra of unphosphorylated (black) and pY39 (blue) alpha-synuclein 
Y125F Y133F in aqueous buffer. (B) Plot of amide chemical shift 
differences (equation 1) between unphosphorylated and pY39 alpha-
synuclein Y125F Y133F versus residue number. (C) Plot of alpha-
carbon secondary shifts versus residue number for unphosphorylated 
(black) and pY39 alpha-synuclein Y125F Y133F (blue) in aqueous 
buffer. (D) Plot of the ratio of peak intensity for samples 
paramagnetically labeled at S7C to peak intensity in unlabeled 
samples versus residue number for wild-type (black) and Y39E alpha-
synuclein (cyan) in aqueous buffer. 
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Assignments for backbone amide resonances were transferred from 
those for wild-type alpha-synuclein using an HNCA experiment. When 
the amide cross-peak chemical shift deviations upon phosphorylation 
were plotted as a function of primary sequence, the major changes 
localized to the region immediately surrounding the phosphorylation 
site (±5 residues) (Figure 4.5B). The extent of these perturbations was 
similar to that seen for phosphorylation of alpha-synuclein at other 
disordered sites [154,155]. In addition, alpha-carbon secondary shifts 
were very similar for phosphorylated and unphosphorylated protein 
(Figure 4.5C), and the N-terminal to C-terminal transient 
intramolecular contacts were not affected by a phosphomimic Y39E 
mutation (Figure 4.5D), suggesting that pY39 does not induce any 
secondary structural changes in the protein in aqueous buffer. 
 
Figure 4.6: HSQC spectra and amide chemical shift differences for 
unphosphorylated and pY39 alpha-synuclein Y125F Y133F in the 
presence of SDS micelles. (A) 1H,15N-HSQC spectra of 
unphosphorylated wild-type alpha-synuclein (black) and pY39 alpha-
synuclein Y125F Y133F (green) in 40 mM SDS. (B) Plot of amide 
chemical shift differences (equation 1) between unphosphorylated 
wild-type alpha-synuclein and pY39 alpha-synuclein Y125F Y133F in 
40 mM SDS versus residue number. 
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Linker region structure in micelle-bound state is altered by pY39 
but broken-helix state remains – While the phosphorylation of Tyr-39 
does not have a large effect on the structure of alpha-synuclein in 
aqueous solution, the position of the phosphorylation site in the linker 
region between the two helices in the SDS-bound state suggests that 
phosphorylation may have some structural effects on the broken-helix 
conformation. Figure 4.6A shows a comparison of 1H,15N-HSQC 
spectra of unphosphorylated and pY39 alpha-synuclein Y125F Y133F 
in the presence of SDS. Significantly more spectral changes can be 
seen than in the absence of SDS. The backbone resonance 
assignments were transferred from those of wild-type 
unphosphorylated protein in SDS [71]. The major chemical shift 
changes localize to approximately residues 30-50, or ~10 residues in 
each direction from the phosphorylation site (Figure 4.6B). The greater 
extent of significant chemical shift perturbations along the peptide 
chain in the presence of SDS suggests that phosphorylation has some 
structural effects. Alternatively, the change in the electrochemical 
environment upon addition of a phosphate group may be sensed by 
residues farther away in primary sequence due to the compact, helical 
structure in the presence of SDS micelles. 
In order to elucidate the potential changes in secondary 
structure due to phosphorylation at Y39, alpha- and carbonyl carbon 
secondary shifts were calculated from chemical shifts measured via 
HNCO and HNCA experiments and plotted versus residue number 
(Figure 4.7). The secondary shifts were quite similar to that of the 
unphosphorylated protein throughout the peptide chain, except for the 
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linker region (res. 37-45), which showed increased average alpha-
carbon (from 1.43 to 2.42 ppm) and carbonyl (from 0.92 to 1.34 ppm) 
secondary shifts. This increase is suggestive of increased helicity in the 
linker region, although the level of secondary shift (and thus helicity) 
does not reach the maximum seen for helix-1 and helix-2. The 
increase in secondary shifts in two different carbon nuclei strongly 
suggests that phosphorylation at Y39 increases helicity in the linker 
region and potentially eliminates the break between helix-1 and helix-
2, thus promoting the extended-helix state, in which the two 
antiparallel helices fuse into one long helix. 
 
Figure 4.7: Alpha-carbon and carbonyl secondary shifts for 
unphosphorylated and pY39 alpha-synuclein in the presence of 
SDS micelles. Plot of alpha-carbon (A) and carbonyl (B) secondary 
shifts versus residue number for unphosphorylated wild-type (black) 
and pY39 alpha-synuclein Y125F Y133F (green) in 40 mM SDS. 
The broken-helix state is characterized by a break in the i,i+1 
amide-amide NOE peaks between residue 41, 42, and 43 [71]. These 
NOE peaks are usually indicative of helical structure, so a break in 
them argues against an extended helix. Additionally, in the broken-
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helix state, there are PRE effects on one helix from a spin-label on the 
opposing helix [75]; these effects would not be seen in the extended-
helix state. These two methods were used to ascertain whether the 
broken-helix conformation is lost upon Y39 phosphorylation. For PRE 
experiments, truncated alpha-synuclein (1-102) was used. This 
fragment of alpha-synuclein contains the entire lipid-interacting 
domain and lacks the other tyrosine residues that can be 
phosphorylated by c-Abl. 
Since cross-peaks arising from residues distant from pY39 in 
both phosphorylated and unphosphorylated protein have the same 
chemical shift, it is impossible to separate the PRE effect measured on 
a mixture of phosphorylated and unphosphorylated material. Such a 
mixture is to some extent unavoidable due to the incompleteness of 
the phosphorylation reaction and inability to fully separate the 
modified and unmodified protein by HPLC, thus complicating analysis 
of PRE data. Unphosphorylated protein, labeled at position E83C, 
shows an unmistakable PRE effect at the N-terminal end of helix-1, 
around residues 3-8, confirming the presence of the broken-helix state 
(Figure 4.8A). However, the phosphorylated sample, which contains 
~25% unphosphorylated material (as estimated by peak intensities), 
shows a PRE effect on the N-terminal residues comparable to that seen 
in the wholly unphosphorylated sample (Figure 4.8B). The extent of 
the PRE effect seen across helices is too great to arise from only 25% of 
the alpha-synuclein molecules, arguing strongly for the presence of the 
broken-helix state even in pY39 alpha-synuclein. 
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Figure 4.8: Intramolecular PRE and partial sequential amide-
amide NOE cross-peaks for pY39 alpha-synuclein in the presence 
of SDS micelles. Plot of the ratio of peak intensity for samples 
paramagnetically labeled at E83C to peak intensity in unlabeled 
samples versus residue number for unphosphorylated (A) and pY39 (B) 
alpha-synuclein 1-102 in 40 mM SDS. The gray bars indicate which 
peaks were included in the analysis. (C) Plot of average intensity of the 
sequential amide NOE cross-peaks between each pair of residues 
between 24 and 53 for pY39 alpha-synuclein Y125F Y133F in 40 mM 
SDS versus residue number. 
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Figure 4.9: HSQC spectra and amide chemical shift differences for 
wild-type and Y39E alpha-synuclein in the presence of SDS 
micelles. (A) 1H,15N-HSQC spectra of wild-type (black) and Y39E 
(purple) alpha-synuclein in 40 mM SDS. (B) Plot of amide chemical 
shift differences (equation 1) between wild-type and Y39E alpha-
synuclein in 40 mM SDS versus residue number. 
Sequential (i,i+1) NOE cross-peak intensities from an H-N-N 
HSQC-NOESY-HSQC experiment were analyzed to determine the 
extent of continuous helical structure. Since only the linker region 
chemical shifts are perturbed upon phosphorylation, NOE cross-peaks 
for only 30 residues centered on Y39 were included in the analysis. 
The rest of the micelle-binding region is expected to show the same 
pattern of sequential NOEs as the unphosphorylated protein [71]. 
Sequential NOE cross-peaks were detected for all residues in the 
region analyzed, although the intensity of NOE peaks between residue 
pairs 41/42 and 42/43, was quite weak (Figure 4.8C). While this 
suggests that the helix is continuous throughout the linker region, 
these NOE peaks can also arise from the compact and rigid turn 
structure that the linker adopts in the broken-helix state. In fact, weak 
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NOE cross-peaks have been detected for unphosphorylated wild-type 
alpha-synuclein under similar conditions as well (see below, Figure 
4.11C). 
 
Figure 4.10: Alpha-carbon and carbonyl secondary shifts for wild-
type and Y39E alpha-synuclein in the presence of SDS micelles. 
Plot of alpha-carbon (A) and carbonyl (B) secondary shifts versus 
residue number for wild-type (black) and Y39E (purple) alpha-
synuclein in 40 mM SDS. 
Due to the difficulty of obtaining sufficient quantities of pure 
phosphorylated protein, a parallel set of experiments were carried out 
with the Y39E mutant of alpha-synuclein, which served as a 
phosphorylation mimic, although a glutamic acid side-chain differs 
from a phosphorylated tyrosine side-chain in length, chemical 
composition, flexibility, and number of charges at neutral pH. The 
1H,15N-HSQC spectrum of alpha-synuclein Y39E in the presence of 40 
mM SDS showed significant differences from that of the wild-type 
protein in the same region as, though to a lesser extent than, the 
phosphorylated protein (Figure 4.9). Alpha-carbon and carbonyl 
secondary shifts, averaged over the entire linker region, were more 
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positive for alpha-synuclein Y39E than wild-type protein (0.27 ppm 
greater for alpha-carbon, 0.02 ppm greater for carbonyl) (Figure 4.10); 
however, the extent of secondary shift increase was much lower than 
for the authentically phosphorylated protein (compare Figure 4.7). 
These data suggest that the linker region of the mutant protein also 
exhibits increased helicity, although less so than in the 
phosphorylated protein. 
The extended or broken nature of the helices in the SDS-bound 
state of alpha-synuclein Y39E was also queried by intramolecular PRE 
and HSQC-NOESY-HSQC experiments in 40 mM SDS. The PRE effect 
from a spin-label covalently attached at position 9 was seen on the C-
terminal end of helix-2 (residues 90-105), much as in wild-type protein 
(Figure 4.11A,B). In addition, i,i+1 amide proton NOE cross-peaks were  
present between residue pairs 41/42 and 42/43, although at a low 
intensity; in fact, NOE cross-peaks were present for all pairs of 
residues in the linker region that could be resolved from the dominant 
diagonal peaks (Figure 4.11C). Notably, a parallel matched experiment 
on wild-type protein revealed a similar pattern of i, i+1 NOE cross-
peaks in the linker region at this SDS concentration (Figure 4.11C). 
Thus, the mutant protein does not differ significantly from the wild-
type in secondary structure at the linker region. 
As the wild-type protein has definitively been shown to adopt a 
non-helical conformation in the linker region [74], the continuous i,i+1 
NOE peaks may result from the relatively structured turn that the 
linker adopts, bringing residues close together. In fact, helix-1 was 
determined to end at residue 37, while strong i,i+1 NOEs continue at  
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Figure 4.11: Intramolecular PRE and partial sequential amide-
amide NOE cross-peaks for wild-type and Y39E alpha-synuclein in 
the presence of SDS micelles. Plot of the ratio of peak intensity for 
samples paramagnetically labeled at S9C to peak intensity in 
unlabeled samples versus residue number for wild-type (A) and Y39E 
(B) alpha-synuclein in 40 mM SDS. The gray bars indicate which 
peaks were included in the analysis. (C) Plot of average intensity of the 
sequential amide NOE cross-peaks between each pair of residues 
between 24 and 53 in 40 mM SDS versus residue number for wild-type 
(black) and Y39E (purple) alpha-synuclein. (D) Plane of HSQC-NOESY-
HSQC spectrum showing strong i,i-1 NOE peak for residues 40/41 and 
weak i,i+3 NOE peak for residues 41/44. 
least until position 40, suggesting that these NOEs do arise from the 
compact conformation of the linker, and not from helical structure. 
One interesting spectral difference between the wild-type and Y39E 
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alpha-synuclein is the presence of a weak i,i+3 NOE cross-peak 
between residue 41 and 44 in the mutant protein in the presence of 
SDS micelles (Figure 4.11D). This cross-peak may be indicative of 
more compact structure in the linker region, although it was not 
detected for pY39 alpha-synuclein. 
 
Figure 4.12: Binding profiles of unphosphorylated and pY39 alpha-
synuclein to low negative charge SUVs. Plot of the ratio of peak 
intensity in the presence of 3 (black), 6 (red), and 12 (green) mM 15% 
PS SUVs to peak intensity in the absence of vesicles versus residue 
number for unphosphorylated wild-type alpha-synuclein (A) and pY39 
alpha-synuclein Y125F Y133F (B). 
Binding of helix-2 to lipid vesicles is lost in pY39 and Y39E alpha-
synuclein – The addition of a negatively-charged phosphate group in 
the middle of the membrane-binding domain of alpha-synuclein might 
be expected to perturb alpha-synuclein binding to negatively-charged 
lipid vesicles. Parallel titrations using matched samples made from the 
same lipid vesicle stock of 15% DOPS, 60% DOPC, 25% DOPE SUVs 
with unphosphorylated wild-type and pY39 Y125F Y133F alpha-
synuclein showed an interesting binding profile for the phosphorylated 
protein (Figure 4.12). The extent of binding at the N-terminus (until 
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residue ~40) is very similar for both wild-type and mutant protein; 
however, C-terminal to position 30, the mutant displays greatly 
reduced binding at all lipid concentrations. 
 
Figure 4.13: Binding profiles of wild-type and Y39E alpha-
synuclein to low and high negative charge SUVs. Plot of the ratio of 
peak intensity in the presence of 1.5 (black), 3 (red), 6 (green), 9 
(purple), and 12 (blue) mM 15% (A,B) and 50% (C,D) PS SUVs to peak 
intensity in the absence of vesicles versus residue number for wild-
type (A,C) and Y39E (B,D) alpha-synuclein. Bound fractions of total 
binding and fully-helical binding were calculated and fit to equation 2, 
with the KD,app values shown in Table 4.1. 
Due to phosphorylated sample limitations, the Y39E mutant of 
alpha-synuclein was also used as a phosphomimic for lipid vesicle 
titration experiments, allowing for a more thorough and quantitative 
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comparison. Parallel titrations using matched samples of 15% DOPS, 
60% DOPC, 25% DOPE SUVs with wild-type and Y39E alpha-
synuclein showed that the mutant protein binds in a similar manner 
to the authentically phosphorylated protein (Figure 4.13A,B). Bound 
fractions for total binding and fully-helical binding were calculated and 
fit to equation 2 to extract apparent dissociation constants for both 
binding modes. The calculated KD,app values are shown in Table 4.1 
and are very similar for total binding of wild-type and mutant alpha-
synuclein (3.8 +/- 0.5 versus 3.4 +/- 0.4 mM), but differ by nearly a 
factor of 3 for the fully-helical binding mode (9.9 +/- 1.0 versus 26.0 
+/- 1.1 mM). The wild-type binding affinities are also similar to that 
measured for the “unmodified alpha-synuclein” in section III.c. 
Table 4.1: Computed apparent KD values and other parameters for 
wild-type and Y39E alpha-synuclein with low and high negative 
charge SUVs. Apparent KD values were calculated from fitting 
titrations to equation 2 (see Figure 4.13) using total lipid concentration. 
“Full Helix Fraction” was calculated using equation 5 (see section II.). 
Protein and 
Lipid 
Total Binding 
KD,app (mM) 
Fully-Helical Binding 
KD,app (mM) 
Full Helix 
Fraction 
15% DOPS    
WT 3.8 ± 0.5 9.9 ± 1.0 0.38 
Y39E 3.4 ± 0.4 26.0 ± 1.1 0.13 
    
50% DOPS    
WT 0.6 ± 0.1 2.1 ± 0.3 0.29 
Y39E 0.4 ± 0.1 3.4 ± 0.4 0.13 
The “helix extension” parameter (see section II.d), which also 
estimates the percent of fully-helical binding, was computed from the 
apparent dissociation constants (Table 4.1). This parameter illustrates 
the striking difference in binding between the wild-type and mutant 
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protein, with 38% of the bound wild-type alpha-synuclein in the fully-
helical state, compared to only 13% for alpha-synuclein Y39E. These 
data show that binding in the fully-helical state is strongly disfavored 
by the tyrosine-to-glutamate mutation and that helix-2 binding is lost 
while helix-1 remains bound. Based on the similar shape of the 
binding profiles for pY39 and Y39E alpha-synuclein, a similar effect 
likely occurs in the authentically phosphorylated protein. 
 
Figure 4.14: PFG LED diffusion fits for alpha-synuclein in low and 
high SDS. Representative plots of the intensity for SDS (A,C) and 
alpha-synuclein (B,D) signal with increasing gradient strength in 40 
(A,B) and 450 (C,D) mM 2H SDS. The points are fit to equation 7 and 
the diffusion coefficients shown in Table 4.2. 
A binding titration was also carried out with SUVs composed of 
50% DOPS, 15% DOPE, 35% DOPC to determine if higher negative 
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charge content ameliorates the loss of helix-2 binding due to the Y39E 
mutation. The binding profiles in the presence of higher negative 
charge vesicles are qualitatively similar to those in the presence of 
lower negative charge vesicles (Figure 4.13C,D). Apparent dissociation 
constants were computed for different binding modes, and although 
binding affinity was greater across the board, alpha-synuclein Y39E 
still showed decreased fully-helical binding (Table 4.1). The “helix 
extension” parameter illustrates that, while the percent of bound 
alpha-synuclein in the fully-helical state is slightly lower than in the 
presence of lower negative charge SUVs for the wild-type protein (29% 
versus 38%), the percentage is very similar for the mutant protein 
(12% versus 13%) (Table 4.1). Thus, increased negative charge does 
not overcome the inhibitory effect of the Y39E mutant on helix-2 
binding. 
Table 4.2: Hydrodynamic radii and diffusion coefficients for alpha-
synuclein-micelle complex at low and high SDS. Diffusion 
coefficients were extracted by fitting PFG experiments to equation 7, 
and hydrodynamic radii calculated relative to the known radius of 
dioxane. 
 40 mM SDS 450 mM SDS  
Signal D (cm2/sec) RH (Å) D (cm2/sec) RH (Å) RH,450 / RH,40 
Dioxane 8.97 x 10-10 2.12 6.67 x 10-10 2.12  
SDS 8.66 x 10-11 22.0 5.17 x 10-11 27.4 1.25 
alpha-
synuclein 
7.40 x 10-11 25.7 3.58 x 10-11 39.5 1.54 
High SDS concentrations slightly favor extended state of alpha-
synuclein – At higher concentrations of SDS (> 400 mM), detergent 
micelles are expected to take on an elongated shape [84]. This 
geometry could favor the formation of the extended-helix conformation 
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of alpha-synuclein [84]. The size of the protein-micelle complex at 
different concentrations of SDS was measured by determining the 
diffusion coefficient using SDS and protein signals in a PFG diffusion 
experiment, then converting to the hydrodynamic radius using a 
known standard (dioxane, 2.12 Å). Representative PFG diffusion plots 
derived from the protein and detergent signals are shown in Figure 
4.14 and hydrodynamic radii summarized in Table 4.2. The increased 
hydrodynamic radius of the detergent micelle at 450 mM SDS (1.25 
times greater than at 40 mM SDS) confirms the presence of elongated 
micelles. In addition, the protein signals, which ostensibly report on 
the subset of micelles which also have protein bound, show an even 
greater hydrodynamic radius increase (1.54 times greater than at 40 
mM SDS), suggesting the presence of the extended-helix state of 
alpha-synuclein on these elongated micelles. However, intramolecular 
PRE experiments show that contact between helix-1 and helix-2 is not 
fully lost at the high detergent concentration (Figure 4.15). 
 
Figure 4.15: Intramolecular PRE for alpha-synuclein at low and 
high SDS. Plot of the ratio of peak intensity for samples 
paramagnetically labeled at S9C to peak intensity in unlabeled 
samples versus residue number for alpha-synuclein in 40 (A) and 450 
(B) mM SDS. The gray bars indicate which peaks were included in the 
analysis. 
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Results summary – The effect of tyrosine phosphorylation on the 
structure of alpha-synuclein and its interactions with membranes and 
detergents strongly depends on the location of the modified residue in 
the polypeptide chain of alpha-synuclein. Phosphorylation of Y125, 
located in the extended C-terminal tail that does not interact with 
membrane surfaces, does not have a major effect on the conformations 
of alpha-synuclein both in dilute aqueous buffer and in the presence 
of membrane-mimetic detergent micelles. The addition of a phosphate 
group does result in locally more expanded conformations in the C-
terminal tail; while the effect on transient C- to N-terminal contacts 
was not able to be determined directly via PRE measurements, the 
overall hydrodynamic radius of the protein is not significantly altered. 
Phosphorylation of Y39 by c-Abl tyrosine kinase was followed in 
real-time by collecting successive HSQC spectra. Peaks arising from 
the unphosphorylated protein decreased in intensity while those 
arising from the phosphorylated species increased in intensity. The 
affected peaks seemed to localize to the vicinity of the modification site. 
Backbone assignments confirmed that only the ~10 residues around 
Y39 were affected in amide chemical shift. However, in the presence of 
spheroidal SDS micelles, the area of effect was expanded to ~20 
residues and secondary shifts of both alpha- and carbonyl carbon 
nuclei increased, suggesting higher helicity in the non-helical linker 
region. These effects on the chemical shifts were recapitulated by the 
phosphomimic Y39E mutation, although to a lesser extent. In both 
cases (pY39 and Y39E), the secondary shifts of the linker region did 
not reach the high levels of the stable helix-1 and helix-2. 
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The effects on chemical shifts suggested that phosphorylation of 
Y39 may be promoting the existence of the extended-helix state, in 
which the linker region becomes helical, fusing the two antiparallel 
helices into one long helix. Inter-helix PRE effects are characteristic of 
the broken-helix state and thus were used to test this hypothesis. For 
both pY39 and Y39E in the presence of spheroidal SDS micelles, the 
PRE effect remained, indicating that there was still a population 
containing an antiparallel helix arrangement. Additionally, the 
intensity of sequential NOE cross-peaks throughout the linker region 
was not very different from that of unphosphorylated wild-type alpha-
synuclein for both mutant and phosphorylated alpha-synuclein, and 
none of the experiments recapitulated the clear break around residue 
42 observed for the wild-type protein previously [71]. This could be due 
to slightly different micelle geometry/concentration or the fact that 
partially deuterated protein was used in previous work, minimizing 
spin diffusion effects. In addition, i,i+1 NOE cross-peaks past position 
37 may not result from helical structure, as the linker has been shown 
to adopt a non-helical conformation on the micelle surface [74]. These 
follow-up experiments argue strongly against the phosphorylated or 
phosphomimic protein adopting an extended-helix conformation. 
The phosphorylation of Y39 also has a clear effect on alpha-
synuclein binding to lipid vesicles. Upon the addition of the phosphate 
group or mutation to glutamate, alpha-synuclein binding to 15% PS 
SUVs is severely decreased C-terminal to the modification site. While 
the N-terminal ~40 residues of both modified and unmodified alpha-
synuclein bind to a similar extent, the C-terminal half of the lipid 
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binding domain, corresponding roughly to helix-2, binds much less, 
suggesting that phosphorylation at Y39 can uncouple helix-1 and 
helix-2 binding to membranes. The same binding profile is seen for 
Y39E alpha-synuclein in the presence of 50% PS SUVs, arguing that 
increased attraction to the vesicle surface due to increased negative 
charge does not suffice for helix-2 binding. 
 
IV.d. General structural effects of phosphotyrosine 
 
There have been relatively few studies of the direct effects of 
phosphorylation on the inherent structural properties of polypeptide 
chains. The addition of two negative charges via the phosphate group 
can be expected to repel other negative charges or form salt bridges 
with positively-charged side-chains. Thus, phosphorylation can 
destroy existing or form new secondary structure elements through 
tertiary contacts, or promote or inhibit intermolecular interactions 
with binding partners. However, in the case of a disordered protein like 
alpha-synuclein, the effects of phosphorylation are harder to predict. 
In addition, among phosphorylated amino acids, tyrosine is the least 
studied structurally. One important difference between 
phosphotyrosine and phosphoserine/threonine is the length of the 
side-chain. The tyrosine side-chain is significantly longer, allowing the 
phosphate group to interact with somewhat distant atoms. For this 
reason, the common phosphomimics glutamate and aspartate are not 
ideal for emulating the effects of phosphotyrosine (Figure 4.16). 
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Figure 4.16: Model of phosphorylated and phosphomimic amino 
acids. Phospho-threonine (A), phospho-serine (B), phospho-tyrosine (C) 
and glutamate (D) were modeled in PyMol. 
One effect of the addition of the phosphate group is the 
formation of hydrogen bonds between the phosphate and backbone 
amide protons nearby. This sort of hydrogen bonding occurs for 
glutamate side-chains with amide protons belonging to the glutamate 
or a nearby residue [265]. Possibly acting through a similar hydrogen 
bonding mechanism, phosphoserine and phosphothreonine were 
found to change the preferred backbone structures of short disordered 
peptides, as measured by coupling constants [247]. However, the same 
study found no such effects for phosphotyrosine, except in the 
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presence of flanking charges (arising from the unblocked N- and C-
termini of the short peptides). This difference suggests that the length 
and rotational range of the tyrosine side-chain precludes interactions 
with nearby backbone atoms, but allows for longer-range interactions. 
Chemical shift values reflect the entire electrochemical 
environment of a nucleus; as such, this one parameter combines 
myriad inputs, from nearby chemical groups, transient contacts, 
hydrogen bonds, secondary structure, backbone angle preferences, etc. 
It is often difficult to extract the structural cause of a chemical shift 
change. While carbonyl and alpha-carbon shifts are more sensitive to 
secondary structure, and thus used to delineate secondary structure 
elements, they still reflect many contributions from different sources. 
Thus, the effects of phosphorylation of alpha-synuclein on chemical 
shifts (proton, nitrogen, and carbon) in the disordered state is likely a 
combination of the effects of introduction of a highly-negatively-
charged moiety, altered transient contacts with other charged regions 
of the polypeptide chain, and newly preferred backbone conformations. 
In the presence of detergent micelles, all of these contributing factors 
remain, and thus it is difficult to use chemical shift changes alone to 
determine the effect of phosphorylation on interaction with the micelle. 
 
IV.e. Functional implications for pY125 alpha-synuclein 
 
The evidence of implicating pY125 in alpha-synuclein function 
and dysfunction is scant: the levels of pY125 alpha-synuclein were 
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found to decrease with age (especially in PD brains) and to correlate 
with decreased alpha-synuclein oligomers in fly models [165]. These few 
findings suggest that pY125 alpha-synuclein may play a 
neuroprotective role; however, the structural findings here do no 
suggest any obvious mechanism for the modification to affect alpha-
synuclein function. It is likely that phosphorylation at Y125 affects 
transient contacts between the N- and C-terminal regions of alpha-
synuclein, as these are mediated by electrostatics. In addition, pY125 
has been shown to modulate the preferred binding sites for various 
metal ions in alpha-synuclein [266]. Furthermore, the C-terminal tail of 
alpha-synuclein is known to be a protein-protein interaction motif [90], 
and phosphorylation of residues in this region may regulate protein-
protein interactions of alpha-synuclein. It is likely that if 
phosphorylation of Y125 plays some role in alpha-synuclein biology, it 
is through these mechanisms. 
 
IV.f. Does pY39 alpha-synuclein form an extended-helix? 
 
While most of the phosphorylation sites in alpha-synuclein are 
in the C-terminal tail that remains disordered even in the presence of 
membranes, the location of Y39 suggests that pY39 would have a 
significant effect on the membrane-bound form. In fact, the amide 
proton and nitrogen, as well as alpha- and carbonyl carbon, chemical 
shifts in the entire linker region are strongly affected by 
phosphorylation at Y39. The region showing chemical shift 
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perturbations is almost exactly coincident with the non-helical region 
that links the two helices in the broken-helix state. That coincidence, 
along with the increased carbon secondary shifts indicative of greater 
helicity upon phosphorylation, suggested that the linker region may be 
becoming helical, leading to alpha-synuclein adopting an extended-
helix conformation. 
Would phosphorylation of tyrosine be expected to increase 
intrinsic helicity of peptide? In early studies of context-independent 
amino acid helical propensity, tyrosine was found to be a helix-
breaking residue in both model peptides and model protein helices 
[267,268]. This helix-destabilizing effect is usually attributed to the 
conformational restriction of tyrosine side-chains (along with other β-
substituted and β-branched amino acids) in the helical state compared 
to the conformational freedom these side-chains experience in the 
random coil state.  
Addition of a charged phosphate group to the tyrosine side-chain 
can be expected to complicate matters. Charged amino acids in model 
peptides can form hydrogen bonds with the peptide backbone in 
unfolded states, but these potential hydrogen bonds are lost in the 
rigid helical conformation; thus, charged amino acids are not likely to 
promote helix formation [267]. However, this helix-destabilization seems 
to decrease with side-chain length due to the lower likelihood of 
forming hydrogen bonds in the random coil state [268]. In addition, 
charged side-chains such as glutamate have been shown to form 
electrostatic interactions with nearby oppositely charged residues, 
specifically in i,i+3 and i,i+4 patterns [268–270]. As alpha-synuclein 
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contains many lysine residues (present in the KTKEGV repeat core 
sequence), and specifically one at position 43, the potential 
electrostatic interaction with the very long negatively-charged side-
chain of phosphotyrosine can be expected to promote helical structure. 
The presence of the membrane-mimicking detergent micelle factors in 
as well, since a conformation in which the negatively-charged 
phosphotyrosine side-chain is facing away from the negatively-charged 
micelle surface will be favored as well. These theoretical considerations 
support the conclusion that pY39 increase helicity in the linker region, 
drawn from increased carbon secondary shifts. 
However, as mentioned above, chemical shifts report on many 
disparate structural and electrochemical properties, and the 
perturbations could simply be a result of inserting a highly negative 
moiety into a region of the protein that is closely associated with the 
(negative) SDS micelle. Therefore, further examination is required to 
determine whether pY39 alpha-synuclein adopts the extended-helix 
conformation. The existence of an inter-helical PRE effect in the pY39 
and phosphomimic Y39E proteins argues quite strongly against an 
extended-helix conformation. The PRE effect scales with the distance 
between the nuclei to the power of -6, so it can be observed between 
two nuclei that that not more than ~25 Å apart. The distance between 
the two alpha-synuclein helices in the broken-helix state on spheroidal 
SDS micelles is ~23 Å [74]; thus, the PRE effect is expected to be lost if 
the helices splay apart even slightly more. The NOE data is more 
difficult to interpret, with weak sequential NOEs observed throughout 
the linker region for pY39 and Y39E alpha-synuclein. While this would 
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argue for continuous helical structure throughout that region of the 
polypeptide chain, similar weak NOEs are also observed for wild-type 
alpha-synuclein with similar SDS concentrations. Thus, the NOEs 
could arise from the compact turn-like structure of the linker region, 
without requiring helical structure, or by spin diffusion through 
aliphatic protein protons, given the long NOE mixing time employed 
(300 msec). The chemical shift changes would then be attributed to 
the presence of the phosphate group and potential dissociation of the 
linker region from the negatively-charged micelle. It is possible that in 
pY39 alpha-synuclein, the helical structure of helix-2 is stabilized in 
the N-terminal direction, but without complete fusion with helix-1. 
Alternatively, pY39 and Y39E alpha-synuclein could be adopting 
a flexible-yet-fully-helical conformation, such as that proposed for a 
shuffled alpha-synuclein variant on larger SLAS micelles [229]. Such 
flexibility or possibly an interconversion that allows the molecules to 
transiently sample the broken-helix state could be enough to explain 
the PRE effect, which is very sensitive to even short-lived contacts [192]. 
In fact, even at concentrations of SDS that result in larger micelles 
(Table 4.2) and longer interhelical distances as measured by ESR [79], 
an interhelical PRE effect is still visible (Figure 4.15). 
 
IV.g. Functional implications for pY39 alpha-synuclein 
 
It seems likely that the in vivo functional effect of 
phosphorylation of alpha-synuclein at Y39 involves the binding of the 
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protein to lipid vesicles rather than the conformation it adopts in the 
presence of detergent micelles. In the presence of negatively-charged 
lipid vesicles, pY39 and Y39E alpha-synuclein show significantly 
decreased binding of the entire helix-2 region, which is C-terminal to 
the site of the modification. The interaction is likely perturbed due to 
electrostatic repulsion between the phosphate group and the 
membrane surface, and the affinity of helix-2 for the membrane is not 
sufficient to overcome the loss of helix folding propagation from the N-
terminal helix-1. One can envision the phosphorylation at Y39 as a 
spatial and temporal cue for helix-2 to detach from the membrane 
alpha-synuclein is bound to (possibly synaptic vesicle membrane), 
allowing it to interact with protein binding partners or other cellular 
membranes (such as the synaptic plasma membrane) (Figure 4.17). In 
addition, this detachment of the helix-2 region may play a role in 
facilitating alpha-synuclein aggregation, as it contains the highly 
hydrophobic region that forms the core of the alpha-synuclein amyloid 
fibrils [271,272]. 
In the published structure of the SDS-micelle-associated alpha-
synuclein, the side-chain of Y39 is pointing toward the micelle surface, 
possibly inserted into the hydrophobic core [74]. This is expected due 
to the hydrophobic nature of the ring in the tyrosine side-chain 
(although tyrosine also contains a polar hydroxide). However, addition 
of a highly charged phosphate to the end of the side-chain most likely 
abrogates any insertion into and interaction with the micelle. The 
strong repulsion could potentially be mitigated by adoption of the 
extended-helix state, in which the tyrosine side-chain is expected to be 
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on the hydrophilic face of the helix [71], as well as detachment of the 
linker region from the micelle surface. If the linker region is detached, 
the more C-terminal helix-2 region remains helical and likely bound to 
the micelle surface.  
 
Figure 4.17: Model of pY39 alpha-synuclein modulating the 
interconversion between lipid-bound states. Phosphorylation 
(orange) of alpha-synuclein at tyrosine 39 by c-Abl (green) is 
envisioned to detach the helix-2 region from the synaptic vesicle 
surface and potentially allow it to bind to other membrane surfaces, 
such as the plasma membrane. Compare Figure 1.3. 
In the presence of negatively-charged SUVs, however, the linker 
region and helix-2 both seem to detach from the vesicle surface. This 
difference suggests that the affinity of helix-2 for spherical SDS 
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micelles and SUVs is very different. It remains to be determined what 
property is responsible for this difference in affinity. SDS micelles are 
both more negative and more highly curved than the SUVs studied 
here. The increased negative charge is unlikely to be responsible, since 
the fractional binding of helix-2 was not increased on SUVs with 
higher negative charge (Table 4.1). Increased curvature may be 
responsible for increased helix-2 affinity (see section III.f). Regardless, 
it is likely that some membrane composition exists that helix-2 has a 
high affinity for, and binding to such a membrane may be facilitated 
by phosphorylation of alpha-synuclein at Y39 by c-Abl. 
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V. PD-linked H50Q and G51D mutations have disparate effects on 
alpha-synuclein structure and interactions 
 
V.a. Introduction 
 
Throughout the study of alpha-synuclein, PD-linked point 
mutations have been discovered and used to propose and test 
potential mechanisms of alpha-synuclein pathology. However, unifying 
mechanisms among all PD-linked point mutations have been hard to 
come by, leading some to conclude that the mutants cause PD via 
diverse pathways (Table 5.1). The first two mutations discovered were 
A53T [11] and A30P [10]. From the beginning, the effects of these two 
mutations on alpha-synuclein were found to be different: the A30P 
mutation decreased the rate of mature amyloid fibril formation while 
A53T increased this rate. More relevant to the work described here, 
A30P decreased alpha-synuclein binding to crudely purified synaptic 
vesicles in a co-flotation assay while A53T did not [39]. This finding 
ruled out impairment of membrane binding as a common mechanism 
of alpha-synuclein pathology in PD, although altered membrane 
interactions remain as a hypothesis for alpha-synuclein dysfunction. 
Table 5.1: Summary of biophysical effects of alpha-synuclein 
mutations A30P, E46K, and A53T. 
Mutation Lipid 
Binding 
Helicity Transient 
Contacts 
Fibril 
Formation 
Partly-Bound 
State Proportion 
A53T No effect Decrease No effect Increase Increase 
A30P Decrease Decrease No effect Decrease Increase 
E46K Increase Increase Increase Increase No effect 
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After the disordered state of alpha-synuclein was shown to have 
helical propensity, the effect of PD point mutations on this latent 
secondary structure was posited to mediate alpha-synuclein 
pathogenicity, since the A30P and (to a lesser degree) A53T mutations 
were shown to decrease this helical propensity [43]. The discovery of 
the E46K mutation [13] afforded an opportunity to test the early 
hypotheses. Unlike A30P, the E46K mutation was shown to increase 
alpha-synuclein binding to lipid membranes [50], and unlike both 
A30P and A53T, E46K alpha-synuclein displays slightly increased 
local helical propensity [228]. Thus, the effects of the three PD-inked 
mutations on both alpha-synuclein lipid binding and helical 
propensity are variable. 
Another hypothesized common property of alpha-synuclein 
mutants was impaired transient long-range intramolecular contacts. 
Originally, these contacts were thought to be lost in A30P and A53T 
alpha-synuclein [48,49] and were thus proposed to be protective 
against aggregation. However, the E46K mutation was shown to 
enhance these contacts [44]. Additionally, the effect of A30P and A53T 
on the intramolecular contacts was not able to be replicated. As a 
result, another potential commonality of the PD-linked mutants was 
discarded. As mentioned above, the PD-linked mutations do not even 
affect alpha-synuclein fibrillization rate in the same way. The A53T 
and E46K mutations were shown to increase the rate of fibril 
formation while A30P decreases it [50,51]. 
A more recently proposed common mechanism involves the 
relative populations of different conformations of alpha-synuclein on 
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lipid vesicles. The population of N-terminal partially-bound states was 
found to be higher for the A30P and A53T mutants, relative to fully-
bound states, while the absolute population of the partially-bound 
states was increased by the E46K mutation [92]. These findings 
suggest that a more subtle perturbation of alpha-synuclein binding to 
lipids may be the common thread among the PD-linked mutations. The 
effects of these three mutations on different structural properties of 
alpha-synuclein are summarized in Table 5.1. 
Recently, two newly-discovered mutations in alpha-synuclein 
have come to the forefront: H50Q, identified in patients with late-onset 
PD [12,166], and G51D, identified in patients with early-onset PD and 
multiple system atrophy [9,167]. Interestingly, both of these mutations 
localize near to two of the previously characterized PD-associated 
mutations, E46K and A53T, potentially implicating this region in the 
pathogenic role of alpha-synuclein [273]. The discovery of these two 
mutations allows previously proposed hypotheses regarding the roles 
of disease-linked mutations in alpha-synuclein dysfunction to be 
tested. 
 
V.b. Methods 
 
Protein Samples – The mutant alpha-synuclein proteins were 
produced as described in section II.a. 
Basic NMR Experiments – Backbone assignments were 
transferred from those previously determined for the wild-type [42,71] 
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by using high-resolution HNCA experiments, which also provided 
alpha-carbon chemical shifts for secondary structure analysis (see 
section II.f). Amide chemical shift deviations derived from 1H,15N-HSQC 
experiments were used to monitor the effects of mutations (see section 
II.c). The effect of H50Q and G51D on the broken-helix state of alpha-
synuclein was assessed at 40 mM SDS, a concentration at which the 
detergent is expected to form spheroidal micelles [225,226]. Again, 
secondary structure information was derived from HNCA experiments. 
Intramolecular contacts in the free state of H50Q alpha-synuclein were 
assessed using PRE experiments. Paramagnetic spin-labels were 
covalently linked to cysteine residues introduced by mutagenesis at 
position 20. For more details on the preparation of samples and 
execution of PRE experiments, see section II.h. Binding to lipid vesicles 
was measured by decrease of amide cross-peak intensity in 1H,15N-
HSQC spectra in the presence of lipid vesicles as detailed in section 
II.d. Protein concentration was ~140 μM, as determined by SDS-PAGE 
comparison with BSA stocks, and lipid concentration was 3 mM. 
Metal Binding Experiments – Binding of Cu2+ and of Fe3+ and 
Zn2+ were assessed in two different ways. Since paramagnetic copper(II) 
ions lead to loss of NMR signal from nuclei in their vicinity, binding to 
Cu2+ was measured by decrease of amide cross-peak intensity in 
1H,15N-HSQC spectra of ~140 μM H50Q alpha-synuclein in the 
presence of 280 μM CuCl2 and compared to wild-type data previously 
collected in the lab [274]. Binding to the diamagnetic iron(III) and zinc(II) 
was assessed by amide chemical shift deviations derived from 1H,15N-
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HSQC experiments on ~140 μM wild-type and H50Q alpha-synuclein 
in the absence and presence of 1 mM FeCl3 and 1 mM ZnSO4. 
 
V.c. Results Overview 
 
H50Q mutation does not perturb free or lipid-bound state of 
alpha-synuclein – The effect of the H50Q mutation on the disordered 
state of alpha-synuclein in aqueous buffer is quite small, with amide 
chemical shift perturbations limited to the immediate vicinity (±5 
residues) of the mutation site (Figure 5.1A). The mutation also does 
not significantly affect either the secondary structure or the transient 
intramolecular contacts within alpha-synuclein in aqueous buffer 
(Figure 5.1B,C). Due to the location of the mutation site in the middle 
of the lipid-binding domain, the mutation might be expected to affect 
binding to membranes and membrane mimics. Substitution of a 
glutamine for the histidine at position 50 results in significant amide 
chemical shift differences extending up to 10 residues N- and C-
terminal to the site of mutation in the micelle-bound state, suggesting 
potential effects on secondary structure (Figure 5.2A). However, the 
secondary structure, as measured by alpha-carbon secondary shifts, is 
nearly unperturbed by the mutation (Figure 5.2B), suggesting that the 
extent of amide chemical shift changes is mostly due to the compact 
nature of the micelle-bound state. Additionally, the wild-type and 
mutant protein bind to the same extent to SUVs composed of 15%  
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Figure 5.1: Amide chemical shift difference, alpha-carbon 
secondary shifts, and intramolecular contacts for wild-type and 
H50Q alpha-synuclein in aqueous buffer. (A) Plot of amide chemical 
shift differences (equation 1) between wild-type and H50Q alpha-
synuclein in aqueous buffer versus residue number. (B) Plot of alpha-
carbon secondary shifts versus residue number for wild-type (black) 
and H50Q alpha-synuclein (blue) in aqueous buffer. (C) Plot of the 
ratio of peak intensity for samples paramagnetically labeled at E20C to 
peak intensity in unlabeled samples versus residue number for wild-
type (black) and H50Q alpha-synuclein (blue) in aqueous buffer. 
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Figure 5.2: Amide chemical shift difference and alpha-carbon 
secondary shifts in the presence of SDS micelles, and binding to 
low negative charge SUVs, for wild-type and H50Q alpha-synuclein. 
(A) Plot of amide chemical shift differences (equation 1) between wild-
type and H50Q alpha-synuclein in 40 mM SDS versus residue number. 
(B) Plot of alpha-carbon secondary shifts versus residue number for 
wild-type (black) and H50Q alpha-synuclein (blue) in 40 mM SDS. (C) 
Plot of the ratio of peak intensity in the presence of 3 mM 15% PS 
SUVs to peak intensity in the absence of vesicles versus residue 
number for wild-type (black) and H50Q alpha-synuclein (blue). Bound 
fractions of total binding, fully-helical binding, and partly-helical 
binding are shown in Table 5.2. 
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DOPS, 60% DOPC, 25% DOPE (Figure 5.2C; Table 5.2), although the 
H50Q alpha-synuclein displays slightly less fully-bound protein and 
slightly more partly-bound protein. These data strongly suggest that 
the H50Q mutation does not significantly perturb membrane- and 
micelle-binding of alpha-synuclein. 
Table 5.2: Bound fractions of different populations of wild-type 
and PD-mutant alpha-synuclein in the presence of low negative 
charge SUVs. Bound populations were calculated according to Bodner, 
et. al., which also provided starred data for wild-type, A30P, E46K, 
and A53T [92]. 
Protein Total Bound 
Population 
Partly-Bound 
Population 
Fully-Bound 
Population 
Partly- to 
Fully-Bound 
Ratio 
WT 0.378 ± 0.065 0.122 ± 0.115 0.256 ± 0.050 0.48 
H50Q 0.313 ± 0.050 0.142 ± 0.104 0.171 ± 0.054 0.83 
G51D 0.383 ± 0.068 0.279 ± 0.126 0.103 ± 0.058 2.70 
     
WT* 0.63 0.21 0.43 0.49 
A30P* 0.54 0.30 0.25 1.20 
E46K* 0.81 0.26 0.53 0.49 
A53T* 0.58 0.24 0.33 0.73 
H50Q mutation alters metal binding only at position 50 – The 
histidine at position 50 is a coordination site for various metal ions, 
such as copper (II) [274]. Thus, loss of the histidine side-chain would 
be expected to locally abrogate alpha-synuclein binding to metal ions. 
Binding of alpha-synuclein to copper (II) was assayed by incubating 
alpha-synuclein with varying concentrations of CuCl2 and measuring 
amide-cross peak intensity loss due to the presence of the 
paramagnetic copper ions. Wild-type and mutant alpha-synuclein 
bound copper to the same extent and at the same binding sites, except 
for the expected loss of the binding site at position 50 (Figure 5.3A).  
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Figure 5.3: Binding of wild-type and H50Q alpha-synuclein to 
copper(II), zinc(II), and iron(III). (A) Plot of the ratio of peak intensity 
in the presence of 2:1 CuCl2 to peak intensity in the absence of 
vesicles versus residue number for wild-type (black, [274]) and H50Q 
(blue) alpha-synuclein. (B,C) Plot of amide chemical shift differences 
(equation 1) in the presence of 1 mM ZnSO4 (B) and FeCl3 (C) versus 
residue number for wild-type (black) and H50Q (blue) alpha-synuclein. 
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While there was also loss of the partial binding at two sites near 
residues 40 and 80, other major binding sites in the C- and N-terminal 
regions were unaffected, confirming a general lack of cooperativity in 
copper (II) binding by alpha-synuclein. Binding to zinc (II) and iron (III) 
was assayed by the amide chemical shift changes in the presence of 
metal ions due to their diamagnetic nature. Again, the binding site at 
position 50 was lost in the mutant but binding sites in the C-terminus 
were unaffected (Figure 5.3B,C). Thus, the H50Q mutation mostly 
affects alpha-synuclein coordination of metal ions at the mutation site. 
 
Figure 5.4: Amide chemical shift difference and alpha-carbon 
secondary shifts for wild-type and G51D alpha-synuclein in 
aqueous buffer. (A) Plot of amide chemical shift differences (equation 1) 
between wild-type and G51D alpha-synuclein in aqueous buffer versus 
residue number. (B) Plot of alpha-carbon secondary shifts versus 
residue number for wild-type (black) and G51D alpha-synuclein 
(orange) in aqueous buffer. 
G51D mutation does not alter free state but disrupts lipid binding 
– Like the H50Q mutation, the effect of this mutation on the 
disordered state of alpha-synuclein in aqueous buffer is limited to the 
immediate vicinity (±5 residues) of the mutation site (Figure 5.4A). 
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While the mutation does perturb the alpha-carbon chemical shifts in 
the same small region, there is no concerted loss or gain of secondary 
structure, and the conformation remains disordered (Figure 5.4B). 
Unlike the H50Q mutation, which is somewhat conservative, the 
introduction of a negatively-charged aspartate side-chain into the N-
terminal domain is likely to disrupt its interaction with negatively-
charged phospholipids and detergent micelles, similar to introduction 
of a phosphate group at Y39 (see section IV.c). A comparison of the 
1H,15N-HSQC spectra of wild-type and G51D alpha-synuclein in the 
presence of spheroidal SDS micelles does reveal a large effect of the 
amino acid substitution, resulting in amide chemical shift changes 
that extend from approximately residue 40 to residue 60 (Figure 5.5A). 
While the extent of the effects throughout the peptide chain is 
comparable to that seen for H50Q, the magnitude of the peak shifts is 
about 2 times greater, even when disregarding the necessarily large 
peak shift upon mutation from glycine to aspartate. Unlike the 
situation for H50Q, the amide chemical shift changes for alpha-
synuclein G51D in the presence of micelles are accompanied by 
significant alpha-carbon secondary shift changes indicating a decrease 
in helicity from residue 45 to 55, as well as slightly increased helicity 
at residues 30-40 and 60-65 (Figure 5.5B). While the loss of helical 
structure near the mutation site is expected due to the likely 
electrostatic repulsion between the aspartate and micelle surface, the 
other, long-range effects on secondary structure are not expected. 
Although the magnitude of the differences is small, the continuous 
stretches of increased helicity in the mutant strongly suggest a real  
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Figure 5.5: Amide chemical shift difference and alpha-carbon 
secondary shifts in the presence of SDS micelles, and binding to 
low negative charge SUVs, for wild-type and G51D alpha-synuclein. 
(A) Plot of amide chemical shift differences (equation 1) between wild-
type and G51D alpha-synuclein in 40 mM SDS versus residue number. 
(B) Plot of alpha-carbon secondary shifts versus residue number for 
wild-type (black) and G51D alpha-synuclein (orange) in 40 mM SDS. 
(C) Plot of the ratio of peak intensity in the presence of 3 mM 15% PS 
SUVs to peak intensity in the absence of vesicles versus residue 
number for wild-type (black) and G51D alpha-synuclein (orange). 
Bound fractions of total binding, fully-helical binding, and partly-
helical binding are shown in Table 5.2. 
 190 
 
 
 191 
 
effect. Possibly, the structure of alpha-synuclein on the micelle is 
rearranged slightly to compensate for the loss of binding at the 
mutation site. 
The G51D mutation also greatly perturbs alpha-synuclein 
binding to negatively-charged lipid vesicles. In the presence of SUVs 
composed of 15% DOPS, 60% DOPC, 25% DOPE, binding at the 
mutation site is abrogated in the mutant, as well as in the lipid-
binding domain C-terminal to the mutation site (Figure 5.5C). This 
binding profile is qualitatively similar to that seen for pY39 and Y39E 
alpha-synuclein (Figures 4.12 and 4.13), suggesting that insertion of a 
negative charge stops helix binding and propagation at the insertion 
site and illustrating that different regions of the lipid-binding domain 
can bind as separate modules. In fact, while the total amount of 
vesicle-bound alpha-synuclein is quite similar to the wild-type protein, 
the relative partly-bound population is greatly increased and fully-
bound population greatly decreased, resulting in a very high ratio of 
partly- to fully-bound populations of alpha-synuclein (2.70 versus 0.49 
for wild-type) (Table 5.2). 
PD-linked mutations do not affect compactness of alpha-synuclein 
– The effect of four of the five currently identified PD-linked mutations 
(A30P, E46K, H50Q, A53T) on alpha-synuclein compactness in 
aqueous buffer  was determined by measuring the diffusion coefficient 
of the protein in D2O and calculating the radius of hydration (see 
section II.j). The calculated radius of hydration did not vary 
significantly between the mutant and wild-type proteins (~24-25 Å) 
(Table 5.3). 
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Table 5.3: Hydrodynamic radii and diffusion coefficients for wild-
type alpha-synuclein and PD-linked mutants in D2O. Diffusion 
coefficients were extracted by fitting PFG experiments to equation 7, 
and hydrodynamic radii calculated relative to the known radius of 
dioxane. 
Protein Ddioxane (cm2/sec) Dprot (cm2/sec) RH,prot (Å) 
WT 7.97 x 10-10 6.69 x 10-11 25.3 
A30P 7.76 x 10-10 6.78 x 10-11 24.3 
E46K 8.02 x 10-10 6.92 x 10-11 24.6 
H50Q 7.98 x 10-10 6.65 x 10-11 25.4 
A53T 7.83 x 10-10 6.65 x 10-11 25.0 
 
V.d. Potential role of H50Q mutation 
 
The H50Q mutation, which was identified in late-onset PD 
patients [12,166], does not have a major impact on the structural 
properties of alpha-synuclein. The disordered conformation alpha-
synuclein adopts in dilute aqueous buffer is not significantly 
perturbed by the presence of the H50Q mutation, nor is the helical 
conformation of alpha-synuclein when bound to SDS micelles. As 
histidine 50 is a major metal ion-chelating site, the mutation of 
histidine to glutamine results in loss of metal binding [Cu(II), Zn(II) 
and Fe(III)] at that site, and potentially perturbs Cu(II) binding at 
nearby sites. However, major metal ion chelation sites near the N- and 
C-termini are unaffected by the H50Q mutation. Additionally, alpha-
synuclein binding to 15% PS SUVs is largely the same in the presence 
and absence of the H50Q mutation; however, there is a small effect on 
the ratio of partly- to fully-bound alpha-synuclein states that could 
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play a role in PD pathology. Overall, the H50Q mutation seems fairly 
conservative in terms of its structural consequences, which may be 
related to the later onset of the disease it is associated with. 
 
V.e. Effect of G51D mutation on lipid vesicle binding 
 
In contrast, the G51D mutation has a larger effect on alpha-
synuclein interactions with membrane surfaces. While the mutation 
does not significantly perturb the disordered conformation of alpha-
synuclein in dilute aqueous buffer, the SDS-bound conformation is 
altered. The substitution of a negatively-charged aspartate for a 
glycine residue results in loss of helical structure around the site of 
the mutation, likely due to repulsion of the N-terminal ~5 residues of 
helix-2 from the negatively-charged micelle surface. In addition, 
regions N- and C-terminal to the area of decreased helicity show 
slightly increased alpha-carbon secondary shifts, suggesting that the 
secondary structure is affected as the protein (and potentially micelle) 
rearranges to accommodate the disruption in the structure of helix-2. 
In the presence of 15% PS SUVs, the effect of the G51D mutation is 
even more pronounced, with disruption of binding occurring at the site 
of mutation but persisting throughout the helix-2 region. The binding 
profile (Figure 5.5C) clearly demonstrates that helix-2 can bind or 
release as a module, with a relatively constant intensity decrease or 
increase, corresponding to fraction of protein molecules that are 
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bound, throughout. Meanwhile, binding N-terminal to the mutation 
site is not affected. 
While the N-terminus of alpha-synuclein G51D binds normally 
to the vesicle surface and helix propagation continues through the 
linker region, the presence of the negatively-charged aspartate residue 
at the beginning of helix-2 brings the extension of the helix to a 
premature end. Interestingly, the more C-terminal parts of helix-2 do 
not bind to membrane surface, suggesting that the entire helix-2 binds 
or does not bind in a concerted fashion. The binding profile is very 
similar to that seen for phosphorylation at Y39 and the Y39E mutation 
(section IV.c), although the point of perturbation (position 51) is at the 
beginning of helix-2 rather than at the beginning of the linker region 
(position 39). Nevertheless, these two binding perturbations (both 
caused by insertion of negative charge) both decouple helix-1 and 
helix-2 binding to lipid vesicles. 
 
V.f. Comparison of G51D effects to other mutations and 
modifications 
 
In its effect on alpha-synuclein-membrane interactions, the 
G51D mutation is qualitatively similar to the A30P mutation. The 
A30P alpha-synuclein shows a similar binding profile to SUVs, 
although the break in binding occurs at a different position (due to the 
different mutation site). In both cases, the mutations severely abrogate 
membrane binding and increase the proportion of partly-helical 
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conformations of alpha-synuclein on the vesicle surface (Table 5.2). In 
the study by Bodner, et. al., the A30P and A53T mutations were found 
to increase this proportion despite having different effects on overall 
vesicle binding, leading to the hypothesis that promoting the existence 
of the partly-helical states is a common thread among PD-linked 
mutants ([92] and Table 5.2). While the E46K mutation did not change 
the ratio of partly-helical to fully-helical states, the overall increased 
binding results in a higher absolute population of partly-helical states. 
The two mutants examined here, H50Q and G51D, both increase the 
ratio of partly- to fully-helical states on lipid vesicles, though the effect 
of G51D is much more pronounced. In this way, G51D acts very 
similarly to A30P, while H50Q is more similar to A53T in having a 
moderate effect on the relative population of partly-helical states. In 
cells, G51D alpha-synuclein shows decreased membrane association, 
suggesting that the in vitro findings of impaired vesicle binding also 
apply in cells [275]). Due to the mild effects on alpha-synuclein 
structure, the pathogenic effects of H50Q are thus more likely to be 
mediated by its altered metal-binding, enhanced secretion, or 
extracellular toxicity [276]. 
One interesting structural observation is the flatness of the 
binding profile C-terminal to perturbations by G51D, pY39/Y39E, and 
A30P (Figure 5.5C, Figure 4.12B, Figure 4.13B,[92]). Despite the 
different nature of the binding perturbations, in all cases the helix 
propagation/binding is stopped before the entire helical domain (~100 
residues) is bound. In the case of wild-type alpha-synuclein, the 
binding profile for this domain shows either monotonic or stepped 
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increase in signal intensity (decrease in binding) in the C-terminal 
direction. This can be interpreted as a superposition of signals from 
alpha-synuclein molecules with successively longer helices bound, 
with a greater number of shorter helices and fewer longer helices. This 
reflects a distribution of alpha-synuclein molecules with different 
lengths of folded/bound helix; for example, there are many molecules 
in which residues 1-9 form a helix, fewer in which residues 1-12 form 
a helix, etc. This suggests that folding of the alpha-synuclein helices 
and the concomitant binding to the membrane surface proceeds by 
propagation towards the C-terminus from a nucleation or anchor site 
at the N-terminus, with increasingly longer helical conformations more 
scarce. However, after loss of binding at any point in the middle of this 
region (residue 30, 39, or 51), the profile is quite flat, likely resulting 
from a superposition of two populations: one in which the entire C-
terminal part is free and one in which it is bound. Since the peptide 
chain does not resume folding/binding C-terminal to the perturbation 
site, it appears that propagation from the anchoring N-terminus is 
necessary for the binding of the rest of the helical region. 
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VI. Conclusions and future directions 
 
While many post-translational modifications and point 
mutations result in small changes of chemical groups and local 
physicochemical properties on a protein molecule, their effects on 
protein function can be great. This is the case for alpha-synuclein, 
specifically for two of the modifications studied here, N-terminal 
acetylation and phosphorylation on residue tyrosine 39. Both 
modifications have their most pronounced effects on the binding of 
alpha-synuclein to lipid membranes, which is considered to be an 
essential part of its as of yet poorly-defined native function. As a result, 
these modifications are likely to play an important role in the normal 
function as well as possibly in the dysfunction of alpha-synuclein in 
the brain. 
 
VI.a. Effects of N-terminal acetylation and tyrosine 
phosphorylation 
 
The major effect of N-terminal acetylation is to promote or 
stabilize helical states at the N-terminus of alpha-synuclein, likely via 
N-terminal helix capping. This stabilization results in tighter binding 
to more curved, less negatively-charged vesicles in in vitro assays when 
compared with the unmodified recombinant protein. This result 
constitutes an important contribution to a more complete 
understanding of alpha-synuclein function since physiological alpha-
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synuclein protein is N-terminally acetylated, and its putative binding 
target, synaptic vesicles, are small, highly-curved vesicles with a 
comparable proportion of negatively-charged phospholipids. 
Furthermore, for N-terminally acetylated alpha-synuclein, it appears 
that electrostatic attraction may not play as large a role in lipid 
membrane binding in the cell as previously thought on the basis of 
work with the unmodified protein. Additionally, the increased affinity 
of acetylated alpha-synuclein for less charged surfaces allowed for the 
identification and direct observation of a never-before-seen partly-
helical state of alpha-synuclein in the presence of BOG micelles, which 
may mimic partly-helical states that are thought to exist on vesicles in 
vivo and be involved in aggregation. 
The effects of phosphorylation at Y39 are more complex, with 
apparently divergent results in the presence of SDS micelles, a 
common NMR-friendly model for membranes, compared with those 
obtained in the presence of more physiologically-relevant synthetic 
lipid vesicles. On SDS micelles, Y39 phosphorylation potentially 
increases local helical character in the linker between the two helices 
of the broken-helix state, yet wihout driving the protein into a fully 
stable extended-helix state. On lipid vesicles, the addition of a 
phosphate group leads to decreased binding of the entire helix-2 
domain to the vesicle surface, which may allow alpha-synuclein to 
bind two different membrane surfaces and bridge two apposed 
membranes. The PD-linked G51D mutation has a similar phenotype in 
the presence of negatively-charged lipid vesicles, suggesting that these 
two modifications may also promote the existence of potentially 
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pathogenic partly-helical states. In addition, these two modifications 
demonstrate that membrane binding by helix-1 and helix-2 can be 
decoupled. 
 
VI.b. Insights into the normal function of alpha-synuclein 
 
What is the native function of alpha-synuclein (and other 
synucleins)? Why have vertebrates evolved this small, soluble protein 
that binds lipid membranes reversibly in their nervous systems? Many 
organisms, including C. elegans and D. melanogaster, have perfectly 
well-functioning nervous systems without any synucleins at all. It is 
thus difficult to implicate synuclein as a core member of the synaptic 
transmission machinery. However, it is reasonable to assume that 
some unique aspect of the vertebrate nervous system needs synucleins 
for optimal function. Alternatively, alpha-synuclein may be an 
accessory protein that makes some aspect of synaptic transmission 
more efficient, making it useful in a system with much greater burden 
on the synapses.  
What sort of function could this be? From the current literature 
on alpha-synuclein, it appears likely that its main function involves 
vesicle transport, and its localization at the synapse implicates 
synaptic vesicles as the target. Removal or overexpression of alpha-
synuclein perturbs pools of vesicles that are docked or about to be 
released. These data, coupled with the unique antiparallel 
arrangement adopted by the amphipathic helices of alpha-synuclein 
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(at least when binding to detergent micelles), tantalizingly suggest that 
alpha-synuclein can serve to stabilize or sense the unique geometry of 
docked vesicles at the synapse [107]. This binding could also serve to 
localize alpha-synuclein to the vicinity of docked vesicles, where it can 
interact with another protein via its free C-terminal tail. There is no 
shortage of potential protein partners for alpha-synuclein in the 
literature. One proposed binding partner for alpha-synuclein is the v-
SNARE synaptobrevin (see Appendix 2). Recent data from Südhof and 
coworkers suggest that alpha-synuclein binds to this protein through 
its C-terminal tail and somehow acts as a chaperone for the SNARE 
complex, preventing activity-dependent degradation [133,234]. 
Alternatively, alpha-synuclein could be altering the properties of the 
membranes it binds to and influencing exocytosis in that way. 
While alpha-synuclein is heavily implicated in a neuronal 
function, not least because of its role in a neurodegenerative disorder, 
the protein is highly expressed in other cell types. For example, red 
blood cells have been shown to express significant amounts of alpha-
synuclein [115,116]. This is a perplexing finding, as red blood cells are 
not likely to need a regulator or effector of membrane trafficking or 
fusion. One potentially interesting recent finding is that alpha-
synuclein N-terminal methionine residues are readily oxidized by lipid 
hydroperoxides found in the membranes alpha-synuclein is bound to 
and just as readily reduced by methionine sulfoxide reductase [277]. 
This suggests a mechanism for alpha-synuclein to act as a “membrane 
reductase” that relieves potentially dangerous oxidative damage to 
membrane lipids as it cycles on and off the membrane. The dopamine 
 201 
 
biosynthesis pathway active in the dopaminergic neurons of the 
substantia nigra results in a high burden of oxidative species [278] and 
elevated levels of lipid hydroperoxides have been found in PD brains 
[279]. Interestingly, red blood cells also contain an abundance of 
oxidative species that can oxidize the membrane lipids, as well as lack 
de novo lipid synthesis to replace damaged lipid molecules [280,281]. 
Thus, these cells could also benefit from a “membrane reductase” 
activity. 
 
VI.c. Future directions 
 
These are but two of the possible functions of alpha-synuclein. 
Determining what alpha-synuclein does in vivo and which aspect of 
that function is disrupted in PD will take time and more research. 
Some of the findings presented here open up new avenues of research. 
For example, the detachment of helix-2 from the synaptic-vesicle-like 
SUVs examined here by pY39 and G51D leaves open the question of 
whether helix-2 can then bind to another lipid membrane with 
different properties. Thus, it would be beneficial to determine what 
type of membrane helix-2 can bind to with tight affinity, as well as to 
test more realistic synaptic-vesicle-like and plasma-membrane-like 
lipid compositions for alpha-synuclein binding preferences. For 
example, the effect of cholesterol and acyl chain length and saturation 
has been largely ignored in this work and has high relevance to 
synaptic lipid compositions. Additionally, the identification of Y39E as 
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a potential mimic of pY39 alpha-synuclein function allows for it to be 
studied in cells using standard molecular biology techniques. If the 
glutamate side-chain does not fully mimic the double negative charge 
of pY39, an L38D Y39E double-mutant may be employed. These 
alpha-synuclein mutants could be used to examine the effects of 
phosphorylation on alpha-synuclein localization in cells, as well as 
whether increasing the population of partly-helical states contributes 
to aggregation and toxicity in cells. 
In addition, the effect of the PD-linked mutations on the 
structure and folding of the partly-helical state can now be examined 
at high resolution due to the discovery of the BOG-bound state. While 
many of the questions addressed herein are targeted toward 
understanding more about the murky native function of alpha-
synuclein, the insights gained can be applied to studies of both 
function and dysfunction in disease. The study of alpha-synuclein can 
never truly focus on only one side of this equation. Discoveries in PD 
patients are constantly informing basic science research about 
synaptic vesicle exocytosis, and findings about the native function of 
alpha-synuclein can lead to ideas for novel therapeutic strategies for 
Parkinson’s disease. 
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APPENDICES 
A1. Appendix 1: StARD4 
 
1a. Introduction 
 
Different membrane compartments within the cell contain 
different and tightly controlled levels of sterols. For instance, the 
plasma membrane and endocytic recycling compartments contain 
~30% cholesterol [282,283]. By contrast, the ER contains 5% 
cholesterol, although it is the site of cholesterol synthesis [284,285]. 
The cholesterol level in the ER is strictly maintained since the cell 
relies on sensing this level to regulate cholesterol synthesis through 
the SREBP pathway [284]. Thus, cholesterol transport between the ER 
and other organelles is crucial for myriad cell processes. This 
transport can take place through vesicular or non-vesicular means. 
There are many sterol-binding proteins, such as the OSBPs (oxysterol-
binding proteins) [286] and START (StAR-related lipid transfer) domain 
proteins [287,288], which contribute to non-vesicular cholesterol 
transport. 
The founding member of the START domain family is the 
steroidogenic acute regulatory protein (StAR), which was discovered in 
mouse Leydig cells and delivers cholesterol to the P450 side-chain 
cleavage enzyme localized to the inner membrane of mitochondria 
[289–291]. This delivery of cholesterol facilitates its conversion to 
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pregnenolone as a step in hormone biosynthesis. The StAR protein 
(also designated StARD1) contains a mitochondrial localization 
sequence prepended to a ~210 residue START domain, which is 
responsible for the cholesterol binding and transfer [291]. There are 15 
START domain-containing proteins in mammalian genomes, grouped 
into nine families, depending on ligand-specificity (sterol, phospholipid, 
sphingolipid) and the identity of other fused domains [287]. As there 
are many START domain proteins, there is also an abundance of 
crystal structures of START domains available, although the majority 
of them are in an apo, ligand-free form [292–294]. The ligand-bound 
structures that do exist are all of proteins that bind phospho- or 
sphingolipids [295–297]; thus, no sterol-bound START domains 
structure exists. The structures that have been solved all show a 
compact α/β helix/grip fold with a large (900-2000 Å3) hydrophobic 
cavity in which the various ligands bind. The size of the cavity is 
thought to correspond to the size of the native ligand of the protein 
[292]. 
StARD4, together with StARD5 and StARD6, is part of a 
subfamily of proteins that consist solely of a START domain. StARD4 
was originally identified as a protein downregulated in the livers of 
mice fed a high-cholesterol diet, and later to be directly activated by 
SREBP-2 in response to lack of cholesterol [298,299]. StARD4 was 
shown, indirectly, to transport cholesterol within mammalian cells in a 
steroidogenesis assay [299]. Sterol transport between different lipid 
membranes by StARD4 was more directly observed in cells and in vitro 
using the fluorescent sterol DHE, suggesting that StARD4 functions as 
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a general cholesterol transfer protein whose activity is required for 
proper processing of cholesterol, specifically acetylation in the ER 
[300]. It seems likely that the cholesterol transport function of StARD4 
can be compensated for, at least to some extent, by other cholesterol 
transport proteins, as StARD4 knockout in mice has only a mild 
phenotype, including slight weight decrease [301]. 
 
Figure A1.1: Crystal structure of mouse StARD4. Structure is 
visualized in PyMol from PDB entry 1JSS [293], with helices in red, 
sheets in yellow, and loops in green. The right view is looking down the 
putative ligand cavity from the C-terminal helix face. 
These data suggest that StARD4 may play an important, though 
not essential, role in cholesterol homeostasis in cells and in whole 
organisms and may be a target in disease therapies. However, 
mechanistic data on the process of sterol uptake, binding, and transfer 
by StARD4 (or other START domain proteins) is limited. Early NMR 
studies on StAR showed some promise [302], but have not yielded any 
insights into sterol binding, although StARD5, which is highly related 
to StARD4, has been suggested to bind bile acids rather than sterols 
[303]. Additionally, a computational study of cholesterol-docking into 
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structures of apo-START-domain proteins delineated a potential 
mechanism of cholesterol entry/exit into the binding cavity, involving 
motion of the C-terminal α-helix and ω1 loop [304] (Figure A1.1). With 
the thought that StARD4 may serve as a positive control for 
cholesterol-binding studies of alpha-synuclein, the mechanism of 
cholesterol binding and transfer by StARD4 was investigated by NMR 
spectroscopy. 
 
1b. Methods 
 
Protein Expression and Purification – The cDNA for mouse 
StARD4 (Dr. Jan Breslow, Rockefeller University) was cloned into the 
pET-SUMO vector (Invitrogen/Life Technologies), and the L124D 
mutant was generated using a QuikChange Site-Directed Mutagenesis 
Kit (Agilent). The L124D mutation greatly improved the stability of the 
protein and the quality of three-dimensional NMR spectra, presumably 
by reducing intermolecular interactions or aggregation of the wild-type 
protein. The pET-SUMO vector contains an N-terminally-fused 6xHis-
tagged yeast Smt3 SUMO protein that facilitates solubility, expression, 
and purification [305]. After purification using nickel affinity 
chromatography, the SUMO tag is efficiently cleaved using Ulp1 SUMO 
protease, which recognizes the SUMO fold rather than a specific cut 
site, eliminating unnecessary left-over linking residues. The SUMO tag 
and SUMO protease can then be removed by another round of nickel 
affinity chromatography. 
 207 
 
To produce isotopically-labeled protein, transformed E. coli cells 
were grown in LB broth (4 L) until an OD of 0.6-1.0 was reached, then 
centrifuged at 6,000 rpm (6,900 x g) for 15 minutes at 24 °C and the 
pellet resuspended in 1 L “wash medium,” consisting of M9 minimal 
medium without carbon or nitrogen sources and containing 
appropriate antibiotics. The cell culture was then centrifuged again at 
6,000 rpm (6,900 x g) for 15 minutes at 24 °C and the pellet 
resuspended in M9 minimal medium, supplemented with BME 
vitamins, the appropriate antibiotics, and either 1 g uniformly labeled 
15N ammonium chloride and 4 g natural abundance dextrose or 1 g 
15N ammonium chloride and 2 g 13C glucose for 15N-labeled protein or 
15N,13C-labeled protein, respectively. After recovery at 37 °C in minimal 
medium for 0.5-1 hr, protein expression was induced using ~1 mM 
IPTG and continued for 3-3.5 hr. A 1 mL sample was taken every 1 hr 
to check OD and saved to estimate protein expression using SDS-
PAGE. Cells were harvested by centrifugation at 6,000 rpm (6,900 x g) 
for 15 minutes and the pellet stored at -20 °C. 
Protein-containing cell pellets were resuspended in lysis buffer 
(350 mM NaCl, 20 mM tris pH 8, 20 mM imidazole, 1 mM PMSF, 0.2 
mM EDTA, 2 mM DTT, 1.5 mM BME) and was subjected to sonication 
by a tip sonifier (Branson) for 2 x 6 minutes at a power setting of 6 
with a duty cycle of 50%. The sample was stirred between the two 
applications of the sonifier. The lysed cell suspension was then 
subjected to ultracentrifugation at 40,000 rpm (145,000 x g) for 1 hr at 
4 °C. A Ni–NTA column was equilibrated with 100 mL equilibration 
buffer (350 mM NaCl, 20 mM tris pH 8, 20 mM imidazole, 2 mM DTT, 
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1.5 mM BME), and the ultracentrifugation supernatant loaded onto 
the column. Equilibration buffer (50 mL) was applied to the column as 
a wash step, with 5 fractions collected, followed by elution with ~100 
mL elution buffer (350 mM NaCl, 20 mM tris pH 8, 250 mM imidazole, 
2 mM DTT, 1.5 mM BME). Approximately 75 mL of the eluate were 
collected, then dialyzed overnight against ~1 L cleavage buffer (150 
mM NaCl, 20 mM tris pH 8, 1 mM DTT). The fusion protein was then 
incubated with 6xHis-tagged SUMO protease (~1:50 protease:protein) 
for 2 hr at 4 °C. The cleavage reaction mixture was passed over a Ni–
NTA column pre-equilibrated with 100 mL equilibration buffer, with 
the StARD4-containing flowthrough being collected. The column was 
washed with 50 mL equilibration buffer and the 6xHis-tagged SUMO 
tage and SUMO protease eluted with ~100 mL elution buffer. The 
StARD4 protein was run on a Superose6 gel filtration column (GE 
Healthcare) as a final cleanup and buffer exchange step, using 20 mM 
NaCl, 20 mM tris, 5 mM DTT, pH 6.4 buffer (“StARD4 NMR buffer”). 
The low salt and low pH of the StARD4 NMR buffer increased the 
number of observable peaks in triple-resonance spectra. NMR 
experiments were usually carried out immediately after purification, 
else the protein was stored at 4 °C for no more than 1 week. 
Sample Preparation – Large unilamellar lipid vesicles composed 
of 31% POPC, 23% POPE, 23% POPS, and 23% cholesterol were 
prepared for measuring membrane binding of StARD4 and to produce 
StARD4-sterol complexes. Cholesterol was sometimes replaced with 
DHE or a paramagnetic cholesterol analogue (3β-doxyl-5α-cholestane) 
at the same molar ratio. All phospholipids and cholesterol were 
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purchased from Avanti Polar Lipids as chloroform solutions, while 
DHE was purchased from Sigma-Aldrich and spin-labeled cholestane 
was kindly provided by Dr. Boris Dzikovski (ACERT), as powder which 
was dissolved in 2:1 methanol:chloroform prior to use. LUVs were 
prepared by mixing the lipid solutions in the appropriate ratios, drying 
under nitrogen at 50 °C, followed by drying under vacuum for 2 hr. 
The dried lipid film was resuspended by pipetting up and down and 
vortexing in StARD4 NMR buffer. The suspension was frozen (in liquid 
nitrogen) and thawed (in room temperature water) 10 times, then 
passed 21 times through a 400 nm membrane and 21 times though a 
100 nm membrane using an Avanti mini-extruder. 
Final StARD4 samples for triple-resonance NMR experiments 
consisted of protein concentrated to between 0.5 to 1 mM protein, 
estimated by the absorbance at 280 nm (using an extinction coefficient 
of 51910 M-1*cm-1). Lipid binding or sterol loading experiments were 
usually performed on samples containing ~50-100 μM StARD4 and 
the requisite lipid vesicles or cholesterol solubilized using 20 mM 
methyl-β-cyclodextrin or 5% v/v ethanol. Sterol or sterol analogue 
loading from liposomes was measured in the presence of non-excess 
amounts of liposomes or after removing liposomes by either 
ultracentrifugation or passage through a Superose6 gel filtration 
column, as indicated. All NMR samples were supplemented with 10% 
D2O. All NMR experiments were performed at 23 °C. 
Backbone assignments for mouse StARD4 L124D were 
determined using the following experiments, all collected at 600 MHz 
with spectral widths of 20 and 30 ppm in the proton and nitrogen 
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dimensions: HNCO, with 68 points and 10 ppm in the carbon 
dimension; HNCA and HN(CO)CA, with 136 points and 25 ppm in the 
carbon dimension; and HBHA(CO)NH, with 128 points and 10.8 ppm 
in the indirect proton dimension. Additionally, two experiments were 
collected at 800 MHz with spectral widths of 12 and 30 ppm in the 
proton and nitrogen dimensions: HNCACB, with 76 points and 65 ppm 
in the carbon dimension, and HN(CO)CACB, with 64 points and 65 
ppm in the carbon dimension. The amide proton and nitrogen, as well 
as alpha-carbon, assignments were transferred to wild-type StARD4 
using an HNCA experiment with spectral widths of 16 and 30 ppm in 
the proton and nitrogen dimensions and 68 points and 25 ppm in the 
carbon dimension. Transverse relaxation (R2) rates were measured 
using a standard HSQC-based T2 pulse sequence with time delays of 
0.01, 0.03, 0.05 (x3), 0.07, 0.09, and 0.11 sec for L124D and 0.01, 
0.03 (x2), and 0.07 sec for wild-type StARD4. 
 
1c. Results 
 
Of the 224 (213 non-proline) residues in mouse StARD4 L124D, 
backbone assignments were determined for 200 amide proton and 
nitrogen resonances, 217 alpha- and beta-carbon resonances, 200 
carbonyl carbon resonances, and 194 alpha-proton resonances. This 
results in 90-95% coverage of the backbone, with many (10) of the 
unassigned residues, due to no or fragmentary observed resonance 
peaks, residing in the N-terminal 23 residues of the protein, which are 
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not resolved in the X-ray crystal structure [293], likely due to a highly 
labile conformation, and most of which are absent in the human 
homologue of the protein. Secondary structure elements were 
predicted by submitting the chemical shifts of all assigned resonances 
to TALOS+ [306] and agreed fairly well with those in the published 
crystal structure [293]. 
 
Figure A1.2: HSQC spectra and amide chemical shift differences 
for wild-type and L124D StARD4. (A) 1H,15N-HSQC spectra of wild-
type (black) and L124D (red) StARD4 in aqueous buffer. (B) Plot of 
amide chemical shift differences (equation 1) between wild-type and 
L124D StARD4 versus residue number. 
Amide proton and nitrogen, and alpha-carbon assignments were 
transferred to the wild-type protein using an HNCA experiment. The 
chemical shift differences between wild-type and L124D StARD4 
localized regions around residues 80, 105, 120-130 (site of mutation), 
and 190-210 (Figure A1.2). These residues are all roughly found near 
the end of the ligand cavity capped by the C-terminal helix and ω1 loop, 
except for leucine 105, which is located on a different surface of the 
molecule. It is possible that Leu-105 is participating in the 
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intermolecular interactions mediated by Leu-124 and lost in the 
L124D mutant, since Leu-105 is a surface-accessible residue and 
flanked by aspartate and glutamate residues, which would be repulsed 
by the aspartate at position 124 in the mutant. Peak intensity for ω1 
loop residues and residues 205-210 were greatly decreased. 
In addition to backbone chemical shift assignments, the relative 
motions of wild-type and mutant StARD4 on the picosecond-
nanosecond time-scale were analyzed by measuring the R2 transverse 
relaxation rates of each protein on a per-residue basis, in the absence 
of ligand or liposomes. Consistent with the crystal structure of StARD4, 
which suggests a rigid molecule with no specific regions of high 
flexibility, the transverse relaxation rate was relatively constant 
throughout the protein, both wild-type and L124D. Somewhat 
surprisingly, the regions predicted to move to allow ligand uptake and 
transfer did not display increased mobility on this time-scale (Figure 
A1.3A). Instead, part of the ω1 loop displayed increased rigidity in the 
wild-type protein, but not the L124D mutant (residues 110-125). In 
addition, residues 185-195 and 205-215 displayed increased rigidity in 
both protein variants. These regions (colored red in Figure A1.3B,C) 
form part of the ligand-binding cavity, and thus may contribute to its 
stability in the presence or absence of ligand. The region that did 
display slightly increased mobility in both proteins was around 
residues 100-110, which forms a β-strand that is on the surface of the 
protein. Additionally, the L124D protein shows increased flexibility 
around residues 90-100, which share the same surface of the protein 
molecule with the mutated ω1 loop (Figure A1.3C, blue). 
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Figure A1.3: Amide nitrogen R2 relaxation rates for apo wild-type 
and L124D StARD4. (A) Plot of transverse relaxation rate R2 for wild-
type (black) and L124D (red) StARD4 versus residue number. Crystal 
structure of StARD4 (1JSS) with approximate regions of rigidity (red) 
and flexibility (blue) for wild-type (B) and L124D (C) StARD4. 
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Figure A1.4: HSQC spectra for wild-type and L124D StARD4 in the 
absence and presence of lipid vesicles. 1H,15N-HSQC spectra of wild-
type (A) and L124D (B) StARD4 in the absence (black) and presence 
(green) of 15 mM lipid vesicles composed of 31% POPC, 23% POPE, 
23% POPS, and 23% cholesterol. 
As a putative cholesterol transporter, StARD4 is expected to 
interact with lipid membranes within the cell at least transiently 
during ligand uptake and deposit. Both wild-type and L124D StARD4 
were incubated with an excess of synthetic LUVs meant to mimic a 
cholesterol-rich donor membrane (31% POPC, 23% POPE, 23% POPS, 
and 23% cholesterol) [300]. The wild-type protein displayed drastically 
reduced amide cross-peak intensity in the presence of liposomes, likely 
due to the formation of slow-tumbling protein-liposome complexes 
(Figure A1.4A). Unlike the binding regime of alpha-synuclein, in which 
different regions of the protein display different intensity decreases 
due to nonuniform binding, the loss of peak intensity is relatively 
uniform throughout the StARD4 spectrum. This uniformity illustrates 
that StARD4 molecules bind to lipid vesicles as a whole, unlike alpha-
synuclein, in which regions of the molecule that are not directly bound 
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Figure A1.5: PRE effect for wild-type StARD4 in the presence of 
increasing concentrations of doped lipid vesicles. (A) Plot of the 
ratio of peak intensity in the presence of 0.5:1 (black), 1:1 (red), and 
2:1 (blue) lipid vesicles doped with 5% 5-doxyl-stearate to peak 
intensity in the absence of vesicles for wild-type StARD4 versus 
residue number. (B) The 0.5:1 (black) and 2:1 (blue, with 3-residue 
average line) intensity ratios from panel A. (C) Crystal structure of 
StARD4 (1JSS) with approximate regions of PRE effect (blue). 
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retain their disordered character. Thus, no specific membrane-binding 
regions could be delineated by this approach. By contrast, the 
presence of lipid vesicles had no effect on the cross-peak intensity of 
L124D StARD4 spectra, showing that the mutant protein does no 
appreciably bind these liposomes (Figure A1.4B). 
 
Figure A1.6: HSQC spectra for wild-type StARD4 in the absence 
and presence of sterols presented by different means. 1H,15N-HSQC 
spectra of wild-type StARD4 in the absence (black) and presence (blue) 
of cholesterol presented in lipid vesicles (A), lipid vesicles removed by 
gel filtration (B), 5% v/v ethanol (C), and 20 mM methyl-β-cyclodextrin 
(D). 
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In order to delineate regions that specifically bind to or insert 
into the membrane, HSQC spectra were collected on StARD4 protein 
with increasing concentrations, at close to stoichiometric ratios, of 
liposomes doped with 5% 5-doxyl-stearic acid, a fatty acid with a 
paramagnetic moiety. In addition to the intensity loss due to formation 
of protein-liposome complexes, regions that come in proximity to the 
paramagnetic label can be expected to experience greater intensity loss 
due to PRE. Regions that display increased intensity loss are around 
residues 35-45, 140-150, 165-185, and 210-225 (Figure A1.5). Several 
of these regions are near a basic patch proposed to interact with 
negatively-charged lipid membranes [300] (Figure A1.5C). The other 
regions are found on the opposite side of the ligand-binding cavity, 
suggesting the possibility that some StARD4 molecules may take up 
the hydrophobic paramagnetic fatty acid, leading to PRE effects in that 
region. 
Since StARD4 is proposed to bind and transport cholesterol 
[293,300], binding of cholesterol should result in observable chemical 
shift changes of the residues near the binding site. Unfortunately, 
cholesterol is highly hydrophobic and not very soluble in aqueous 
buffer; thus, delivery of the ligand to the protein is quite difficult. 
Cholesterol can be presented to the protein in cholesterol-rich vesicles, 
mimicking the situation inside the cell, or solubilized with small 
molecules such as MBCD or cosolvents such as ethanol. All of these 
methods were attempted in order to obtain stable StARD4-cholesterol 
complexes that could be analyzed via heteronuclear NMR and yield 
information about the cholesterol binding site. While small chemical 
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shift changes were occasionally observed, no reproducible and 
significant spectral changes were seen by any of these methods (Figure 
A1.6). It is unclear whether the cholesterol-bound state does not result 
in significant chemical shift changes to the amide nuclei, or whether 
binding was simply never achieved. 
 
Figure A1.7: PRE effect for wild-type StARD4 in the presence of 
lipid vesicles containing spin-labeled cholestane. (A) Plot of the 
ratio of peak intensity in the presence of lipid vesicles (31% POPC, 
23% POPE, 23% POPS, and 23% spin-labeled cholestane) to peak 
intensity in the absence of vesicles for wild-type StARD4 versus 
residue number. (C) Crystal structure of StARD4 (1JSS) with 
approximate regions of PRE effect (red). 
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Figure A1.8: Carbon HSQC spectra for wild-type StARD4 in the 
absence and presence of lipid vesicles containing spin-labeled 
cholestane. 1H,13C-HSQC spectra of wild-type StARD4 in the absence 
(black) and presence (blue) of lipid vesicles (31% POPC, 23% POPE, 
23% POPS, and 23% spin-labeled cholestane). 
Binding of sterol analogues was also queried by using spin-
labeled cholestane in place of cholesterol, delivered in liposomes. Both 
1H,15N- and 1H,13C-HSQC spectra were collected on the apo and 
ostensibly loaded protein. If the interactions with ligand do not involve 
backbone amide groups, the 1H,13C-HSQC spectra can report on PRE 
effects on the side-chain nuclei, which may be more sensitive. The 
amide data showed several regions that may interact preferentially 
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with the spin-labeled moiety, such as residues 45-60, 90-100, 180-
190, and 195-210 (Figure A1.7A). These regions are near in primary 
sequence to but distinct from those modulated by the (presumably 
membrane-retained) 5-doxyl-stearate (Figure A1.5) and mostly localize 
to the C-terminal end of the ligand-binding cavity (Figure A1.7B). The 
1H,13C-HSQC spectra showed potentially localized signal ablation by 
the spin-labeled ligand, but the lack of resonance assignments 
precludes any real conclusions from being drawn (Figure A1.8). 
 
Figure A1.9: HSQC spectra for wild-type StARD4 in the absence 
and presence of IP2(4,5). 1H,15N-HSQC spectra of wild-type StARD4 in 
the absence (black) and presence (purple) of 2:1 IP2(4,5). 
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Early evidence suggests that StARD4 cholesterol transfer activity 
is stimulated by PI(4,5)P2 lipids (Iaea and Maxfield, unpublished). 
Therefore, StARD4 was incubated with two times excess concentration 
of the soluble headgroup IP2(4,5). No large spectral changes were seen 
in the backbone amide cross-peaks, although this could be a low 
affinity interaction that requires a large excess of IP2(4,5) to see (Figure 
A1.9). 
 
1d. Conclusions 
 
In conclusion, more work is required to obtain reproducible 
sterol-loaded StARD4 complexes. In this case, the fluorescent 
cholesterol analogue DHE may be beneficial as its presence can be 
confirmed via fluorescence. Once these are in hand, the assignment 
data provides a good base for further structural studies using the 
backbone amide or side-chain nuclei as probes. In addition, the lipid 
membrane interactions can be studied further using techniques such 
as hydrogen-deuterium exchange NMR. 
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A2. Appendix 2: Alpha-synuclein and synaptobrevin 
 
2a. Introduction 
 
One recently proposed function for alpha-synuclein in the 
synaptic vesicle cycle is a chaperone-like promotion of SNARE complex 
formation [133,234,307,308]. The SNARE complex consists of proteins 
attached to the vesicle membrane (v-SNAREs) and the target 
membrane (t-SNAREs), which recognize each other and zipper up to 
mediate membrane fusion [131]. At the synapse, these functions are 
fulfilled by the v-SNARE synaptobrevin-2 (Syb, VAMP) and the t-
SNAREs syntaxin-1 and SNAP-25 [309]. The interaction between 
alpha-synuclein and the SNARE complex is thought to be mediated by 
the C-terminal tail of alpha-synuclein and the N-terminal 28 residues 
of Syb [133]. However, the existence and functional relevance of this 
protein-protein interaction remains controversial [130,310]. Thus, the 
interaction of full-length synaptobrevin-2 and alpha-synuclein was 
investigated using NMR spectroscopy in membrane and detergent 
systems. 
 
2b. Methods 
 
Protein Expression and Purification – The cDNA for a cysteine-free 
version of rat synaptobrevin-2 (C103A) was obtained as a GST-fusion 
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vector, kindly donated by Dr. Yeon-kyun Shin (Iowa State University). 
The cDNA was cloned into the pET-SUMO vector (Invitrogen/Life 
Technologies). The pET-SUMO vector contains an N-terminally-fused 
6xHis-tagged yeast Smt3 SUMO protein that facilitates solubility, 
expression, and purification [305]. After purification using nickel 
affinity chromatography, the SUMO tag is efficiently cleaved using 
Ulp1 SUMO protease, which recognizes the SUMO fold rather than a 
specific cut site, eliminating unnecessary left-over linking residues. 
The SUMO tag and SUMO protease can then be removed by another 
round of nickel affinity chromatography. 
To produce isotopically-labeled protein, transformed E. coli cells 
were grown in LB broth (4 L) until an OD of 0.6-1.0 was reached, then 
centrifuged at 6,000 rpm (6,900 x g) for 15 minutes at 24 °C and the 
pellet resuspended in 1 L “wash medium,” consisting of M9 minimal 
medium without carbon or nitrogen sources and containing 
appropriate antibiotics. The cell culture was then centrifuged again at 
6,000 rpm (6,900 x g) for 15 minutes at 24 °C and the pellet 
resuspended in M9 minimal medium, supplemented with BME 
vitamins, the appropriate antibiotics, and either 1 g uniformly labeled 
15N ammonium chloride and 4 g natural abundance dextrose for 15N-
labeled protein. After recovery at 37 °C in minimal medium for 0.5-1 
hr, protein expression was induced using ~1 mM IPTG and continued 
for 3-3.5 hr. A 1 mL sample was taken every 1 hr to check OD and 
saved to estimate protein expression using SDS-PAGE. Cells were 
harvested by centrifugation at 6,000 rpm (6,900 x g) for 15 minutes 
and the pellet stored at -20 °C. 
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Since the Syb construct contains the transmembrane helix 
portion of the protein, all purification buffers contained 2% w/v 
sodium cholate (Amresco) to help solubilize the protein. Protein-
containing cell pellets were resuspended in lysis buffer (350 mM NaCl, 
20 mM tris pH 8, 20 mM imidazole, 1 mM PMSF, 0.2 mM EDTA, 2 mM 
DTT, 1.5 mM BME, 2% sodium cholate) and was subjected to 
sonication by a tip sonifier (Branson) for 2 x 6 minutes at a power 
setting of 6 with a duty cycle of 50%. The sample was stirred between 
the two applications of the sonifier. The lysed cell suspension was then 
subjected to ultracentrifugation at 40,000 rpm (145,000 x g) for 1 hr at 
4 °C. A Ni–NTA column was equilibrated with 100 mL equilibration 
buffer (350 mM NaCl, 20 mM tris pH 8, 20 mM imidazole, 2 mM DTT, 
1.5 mM BME, 2% sodium cholate), and the ultracentrifugation 
supernatant loaded onto the column. Equilibration buffer (50 mL) was 
applied to the column as a wash step, with 5 fractions collected, 
followed by elution with ~100 mL elution buffer (350 mM NaCl, 20 mM 
tris pH 8, 250 mM imidazole, 2 mM DTT, 1.5 mM BME, 2% sodium 
cholate). 
Approximately 75 mL of the eluate were collected, then dialyzed 
overnight against ~1 L cleavage buffer (150 mM NaCl, 20 mM tris pH 8, 
1 mM DTT, 2% sodium cholate). Sodium cholate, SDS, and Triton X-
100 were tested for their effect on the cleavage reaction and sodium 
cholate had the least deleterious effect. The fusion protein was then 
incubated with 6xHis-tagged SUMO protease (~1:50 protease:protein) 
for 2 hr at 4 °C. The cleavage reaction mixture was passed over a Ni–
NTA column pre-equilibrated with 100 mL equilibration buffer, with 
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the StARD4-containing flowthrough being collected. The column was 
washed with 50 mL equilibration buffer and the 6xHis-tagged SUMO 
tag and SUMO protease eluted with ~100 mL elution buffer. The Syb 
protein was run on a Superose6 gel filtration column (GE Healthcare) 
as a final cleanup and buffer exchange step, using 100 mM NaCl, 10 
mM NaH2PO4, 25 mM sodium cholate, pH 6.8 buffer. NMR 
experiments were usually carried out immediately after purification, 
else the protein was stored at 4 °C for no more than 1 week. 
Sample Preparation – NMR samples consisted of natural 
abundance or isotopically-labeled Syb protein reconstituted in SDS 
micelles or 15% DOPS, 60% DOPC, 25% DOPE SUVs with or without 
isotopically-labeled or natural abundance alpha-synuclein. In order to 
reconstitute Syb in SDS, protein solubilized in sodium cholate was 
dialyzed against 40x volume of SDS solution (100 mM) at room 
temperature overnight, usually involving 1 or 2 changes of dialysis 
buffer. It is important to keep the temperature above ~18 °C, the Krafft 
point of SDS. However, the formation of protein-detergent complexes 
made it difficult to obtain expected concentrations of SDS and sodium 
cholate, so experiments can be affected by inaccurate or un-matched 
detergent concentrations. The solubilized Syb was then mixed with 
alpha-synuclein dissolved in 100 mM SDS and supplemented with 
10% D2O to make NMR samples. 
In order to reconstitute Syb in SUVs, the appropriate lipids, 
dissolved in chloroform (Avanti Polar Lipids), were mixed and dried 
under nitrogen at 50 °C, followed by drying under vacuum. The dried 
lipid film was resuspended in NMR buffer by pipetting up and down, 
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then vortexing. SUVs were prepared by sonicating the multilamellar 
vesicle suspension in a bath sonicator 4 times for 3 min. During 
sonication, sodium cholate powder was added to a final concentration 
of 25 mM (slightly above the CMC). The detergent is meant to disrupt 
the vesicles. After sonication, the SUV and detergent mixture was 
mixed with Syb dissolved in NMR buffer with 25 mM sodium cholate. 
The detergent was removed by diluting the sample in 3x detergent-free 
buffer, then dialysis overnight. The suspension was finally centrifuged 
at 60,000 rpm (160,000 x g) at 4 °C for 2 hr to remove larger vesicles. 
The Syb-containing SUVs were used as NMR samples, or mixed with 
alpha-synuclein dissolved in NMR buffer. 
For 15N-labeled Syb reconstitution, the final concentrations were 
about 15 mM SUVs and 100 μM Syb. This ratio results in ~75 Syb 
molecules per vesicle, with half facing the vesicle lumen and half 
facing outwards. In order to test alpha-synuclein binding to Syb-
containing SUVs, two samples of SUVs composed of 15% DOPS, 60% 
DOPC, 25% DOPE were produced via the abovementioned 
reconstitution protocol in parallel. One batch was mixed with natural-
abundance Syb dissolved in sodium cholate, while the other with the 
same detergent buffer without protein. To allow for significant 
populations of bound and free alpha-synuclein after mixing with SUVs, 
a lower concentration (3 mM) of SUVs was used, while the Syb 
concentration was kept relatively high (75 μM) to promote potential 
protein-protein interactions. This resulted in higher concentration of 
Syb molecules on the vesicles (~250 per vesicle). As for alpha-
 227 
 
synuclein, NMR experiments were performed at 40 °C on SDS-
containing samples, and at 10 °C on SUV-containing samples. 
 
2c. Results 
 
Isotopically-labeled Syb was solubilized in 100 mM SDS and 
examined via a 1H,15N-HSQC experiment.  The resulting spectrum was 
consistent with a protein containing both helical and disordered 
character (Figure A2.1A, black). Approximately 100 amide cross-peaks 
could be resolved, suggesting that most of the 116-residue peptide 
chain gives rise to signals in SDS. Additionally, two peaks could be 
observed at higher proton and nitrogen field, likely corresponding to 
the indole amides of two tryptophan residues. However, the addition of 
natural-abundance alpha-synuclein (~180 μM Syb, ~90 μM alpha-
synuclein) did not result in any significant spectral changes (Figure 
A2.1A, red). The reverse experiment, consisting of ~60 μM 15N-labeled 
alpha-synuclein in 100 mM SDS with and without ~180 μM Syb also 
showed no significant spectral changes (Figure A2.1B). These results 
argue against a robust interaction between alpha-synuclein and Syb, 
although potentially, higher concentrations of the proteins may be 
required to see evidence of an interaction. While the SDS-bound state 
of alpha-synuclein is thought to resemble at least one of the 
membrane-bound states of the protein that exist in vivo, it is possible 
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that the interaction between the two proteins requires a more realistic 
membrane environment. 
 
Figure A2.1: HSQC spectra of alpha-synuclein and synaptobrevin-2 
in the presence of SDS micelles. (A) 1H,15N-HSQC spectra of 
isotopically-labeled synaptobrevin-2 in the absence (black) and 
presence (red) of unlabeled alpha-synuclein in 100 mM SDS. (B) 
1H,15N-HSQC spectra of isotopically-labeled alpha-synuclein in the 
absence (black) and presence (red) of unlabeled synaptobrevin-2 in 
100 mM SDS. 
To this end, Syb was reconstituted in synthetic SUVs composed 
of 15% DOPS, 60% DOPC, 25% DOPE, meant to mimic the 
composition of synaptic vesicles that normally house synaptobrevin. 
The 1H,15N-HSQC spectrum was different from that observed in the 
presence of SDS micelles, although this difference could be partially 
due to the different temperature. The spectrum of SUV-reconstituted 
Syb contained fewer peaks (~80) and displayed less dispersion along 
the proton axis, suggesting that the helical residues of the 
transmembrane segment (including the tryptophan residues) do not 
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give rise to observable resonances (Figure A2.2). This finding, and in 
fact the entire spectrum, is similar to that for Syb reconstituted in 
phospholipid-containing nanodiscs, in which case the transmembrane 
helix and a few residues proximal to it did not give rise to cross-peaks 
due to their tumbling at the overall rate of the large nanodisc [311]. 
 
Figure A2.2: HSQC spectrum of synaptobrevin reconstituted in 
SUVs. 1H,15N-HSQC spectrum of synaptobrevin-2 reconstituted in 15 
mM 15% DOPS, 60% DOPC, 25% DOPE SUVs. 
In order to test Syb binding to alpha-synuclein, isotopically-
labeled acetylated alpha-synuclein was incubated with SUVs that 
contained natural-abundance Syb and protein-free SUVs, made in 
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parallel, and the extent of alpha-synuclein binding to SUVs quantified. 
While acetylated alpha-synuclein in the presence of protein-free SUVs 
gave rise to a binding profile similar to those observed previously 
(Figure A2.3, black) (compare to Chapter III; [91]), the binding of 
acetylated alpha-synuclein to Syb-containing liposomes was 
significantly reduced in the N-terminal domain while the C-terminal 
tail residues showed decreased peak intensity (Figure A2.3, red). 
 
Figure A2.3: Binding profile of acetylated alpha-synuclein to SUVs 
with and without synaptobrevin. Plot of the ratio of peak intensity in 
the presence of 3 mM 15% PS SUVs with (red) and without (black) 
synaptobrevin to peak intensity in the absence of vesicles versus 
residue number for acetylated alpha-synuclein. 
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There are two possible explanations for the difference in C-
terminal intensities: the samples were not well-matched in 
concentration, or there is an interaction between the C-terminal tail 
and the Syb embedded in the liposomes. The bound populations of 
different alpha-synuclein states can be estimated using both 
interpretations. In the first, acetylated alpha-synuclein shows 
significantly decreased binding to Syb-containing liposomes and an 
increased relative population of N-terminal partly-helical states (0.717 
total bound fraction and 44.2% partly-helical states versus 0.893 and 
27.2%). In the second interpretation, if the C-terminal resonance 
intensities from the protein-free SUV experiment are used to normalize 
the intensities in the experiment with Syb-containing vesicles, the 
fraction of C-terminal tail interacting with Syb is approximately 0.115. 
The normalized bound fractions of different states still show decreased 
total binding and increased proportion of partly-helical states 
compared to the protein-free liposomes (0.750 total bound fraction and 
37.4% partly-helical states versus 0.893 and 27.2%). 
 
2d. Conclusions 
 
The liposome data show that acetylated alpha-synuclein binding 
to 15% PS SUVs is reduced overall when those vesicles contain Syb. 
This could be due to repulsion between the alpha-synuclein and Syb 
molecules, or simply due to crowding, with the large number of Syb 
molecules per vesicle (~250) taking up the surface required for alpha-
 232 
 
synuclein binding. These results are consistent with a previously 
published short report finding that alpha-synuclein has reduced 
affinity for v-SNARE-containing 50% PS SUVs by a factor of 2 [310]. 
The data in the presence of SDS micelles also does not indicate any 
stable interaction between the alpha-synuclein and Syb molecules. On 
the other hand, the decrease in C-terminal tail resonance intensities in 
the presence of Syb-containing SUVs may suggest binding of the C-
terminal tail to Syb, which would be consistent with the model 
proposed by Burré, et. al. [133,234]. 
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A3. Appendix 3: Alpha-synuclein and Hsc70 
 
3a. Introduction 
 
Soon after its categorization as an intrinsically disordered 
protein, alpha-synuclein was proposed to interact with cytoplasmic 
chaperone proteins to mitigate its aggregation potential [312]. Since 
expression of Hsp70, a chaperone that refolds misfolded proteins [313] 
can reduce the toxicity of other aggregation-prone proteins [314], it 
was posited that Hsp70, or its constitutively-expressed homologue 
Hsc70, could do the same for alpha-synuclein. The positive effects of 
Hsp70 on alpha-synuclein-mediated toxicity were shown in several 
cellular and animal models [312,315–318]. However, the exact 
mechanism by which Hsp70 alleviates cytotoxicity induced by alpha-
synuclein is unclear. Since alpha-synuclein overexpression results in 
massive protein aggregation and misfolding, it is reasonable that 
adding more protein refolding activity would ameliorate the negative 
effects. But is there a direct interaction between Hsp70 and alpha-
synuclein, in which alpha-synuclein acts as an unfolded client for 
Hsp70 chaperone activity? 
Hsp70 was shown to inhibit alpha-synuclein fibril formation in 
vitro and to interact preferentially with pre-fibrillar alpha-synuclein 
oligomers (by gel filtration) [319,320]. The inhibition of fibrillation was 
additionally shown to require only the substrate-binding C-terminal 
domain (CTD) of Hsp70 [320]. The highly hydrophobic NAC region of 
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alpha-synuclein was shown to be necessary for this inhibition of fibril 
formation by Hsp70 [321]. These results suggest, though do not 
demonstrate, a model in which Hsc/p70 (via its substrate-binding 
CTD) binds to the hydrophobic and amyloidogenic NAC region of 
alpha-synuclein, likely in oligomeric states, to prevent further 
oligomerization. In a contrasting model, chemical crosslinking studies 
indicate that Hsc70 CTD binds alpha-synuclein in two regions: 
residues 10-45 and residues 97-102 [322]. These two regions flank the 
NAC region (residues 61-95). Yet another model of alpha-synuclein 
interaction with Hsp70 is based on in-cell fluorescence lifetime 
measurements that indicate that Hsp70 reduces intramolecular N- to 
C-terminal contacts in alpha-synuclein molecules [323]. In addition, 
interactions between monomeric alpha-synuclein and full-length 
Hsp70 were ruled out on the basis of lack of chemical shift 
perturbations or resonance intensity decreases [319]. These findings 
do no lead to a consistent and clean understanding of how alpha-
synuclein interacts with Hsp70. 
 
3b. Methods 
 
The CTD of Hsc70 from rat was exchanged into NMR buffer (100 
mM NaCl, 10 mM Na2HPO4, 10% D2O, pH 6.8) and mixed with 15N-
labeled alpha-synuclein, both N-terminally acetylated and unmodified, 
at different stoichiometries. Due to scarcity of Hsc70 CTD protein, 
relatively low concentrations were used (30 μM alpha-synuclein, 0-60 
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μM Hsc70 CTD), requiring long acquisition times for the 1H,15N-HSQC 
spectra. Chemical shifts and intensities of amide cross-peaks arising 
from alpha-synuclein in the absence and presence of Hsc70 CTD were 
compared to find evidence of a direct interaction between the two 
proteins. 
 
3c. Results 
 
 
Figure A3.1: HSQC spectra of acetylated and unmodified alpha-
synuclein in the presence of Hsc70 CTD. 1H,15N-HSQC spectra of 
acetylated (A) and unmodified (B) alpha-synuclein in the absence 
(black) and presence of 0.5:1 (blue), 1:1 (red), and 2:1 (green) 
unlabeled Hsc70 CTD. 
The addition of 1:1 and 2:1 Hsc70 CTD to both unmodified and 
acetylated alpha-synuclein did not result in any significant chemical 
shift changes in the backbone amide peaks as seen in the 1H,15N-
HSQC spectra (Figure A3.1). However, certain peak intensities were 
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decreased. When the intensity ratio to Hsc70-free spectra was plotted 
versus residue number, the majority of intensity decreases for both 
unmodified and acetylated alpha-synuclein were localized to the N-
terminal ~100 residues, with the greatest intensity decrease occurring 
in the very N-terminal 10 or 25 residues (Figure A3.2). These results 
are in contrast to previous NMR studies of unmodified alpha-synuclein 
with Hsp70 [319]. Since the Hsc70 CTD is ~30 kDa in size, the 
combined protein-protein complex should be ~45 kDa, which is not as 
large and slowly-tumbling as a protein-vesicle complex, but 
comparable to a protein-micelle complex. Therefore, the relaxation rate 
would be expected to increase due to somewhat slower tumbling of the 
larger complex, and/or due to loss of the flexible, disordered character 
of the N-terminal region by immobilization on Hsc70 CTD. 
 
Figure A3.2: Binding profiles of acetylated and unmodified alpha-
synuclein to Hsc70 CTD. Plots of the ratio of peak intensity in the 
presence of 0.5:1 (blue), 1:1 (red), and 2:1 (green) Hsc70 CTD to peak 
intensity in the absence of Hsc70 CTD versus residue number for 
acetylated (A) and unmodified (B) alpha-synuclein. 
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The potential interaction of alpha-synuclein with Hsp104, 
another molecular chaperone that works together with Hsp/c70 to 
disassemble protein aggregates was also assayed by NMR. Isotopically-
labeled unmodified alpha-synuclein was incubated with and without 
natural abundance Hsp104 in buffer containing 50 mM HEPES pH 7.5, 
10 mM MgCl2, and 5 mM ATP and 1H,15-HSQC spectra were collected 
as previously described. The spectra of alpha-synuclein in the absence 
and presence of Hsp104 were virtually identical, suggesting that the 
two proteins did not interact under these conditions. 
 
Figure A3.3: HSQC spectra of unmodified alpha-synuclein in the 
presence of Hsp104. 1H,15N-HSQC spectra of unmodified alpha-
synuclein in the absence (black) and presence of 1:1 (red) and 5:1 
(green) unlabeled Hsp104 in aqueous buffer. 
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3d. Conclusions 
 
This interaction can be studied in greater detail by using 
isotopically-labeled Hsc70 to determine the binding site for alpha-
synuclein using reverse titrations. In addition, the alpha-synuclein 
intensity ratio data can be repeated at higher protein concentrations to 
achieve saturation of binding, and the contribution of different types of 
relaxation can be determined using relaxation experiments. 
Additionally, the effects of a full-length Hsc70 protein and the addition 
of ATP on alpha-synuclein binding can be investigated, as well as 
whether transient intramolecular interactions within alpha-synuclein 
are affected. 
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A4. Appendix 4: Alpha-synuclein and TAT fusions 
 
4a. Introduction 
 
The Tat protein from HIV was one of the first proteins discovered 
to be transduced into cells [324,325]. This ability was eventually 
harnessed in the form of fusions of the minimal 11-residue TAT 
peptide (YGRKKRRQRRR) in order to transduce any protein of interest 
into desired mammalian cells [326,327]. To that end, N-terminal and 
C-terminal fusions of the TAT peptide to alpha-synuclein, with 
different linkers, were prepared: TAT-aSyn 
(MRGSYGRKKRRQRRRGGGCGH – [alpha-synuclein 1-140]), aSyn-TAT 
([alpha-synuclein 1-140] – LECRKKRRQRRR), and aSyn-N-TAT ([alpha-
synuclein 1-140] – LEGGGCGHSYGRKKRRQRRR). The latter fusion 
construct made use of the same linker used for the N-terminal TAT 
fusion. Due to the highly positively-charged character of the TAT 
peptide, it may be expected to affect the structure or biophysical 
properties of the fused alpha-synuclein protein, potentially though 
electrostatic interactions. 
While the TAT fusions had no major effect on neither the overall 
disordered conformation of the fusion protein in aqueous buffer nor 
binding to lipid vesicles, the fusion proteins were shown to aggregate 
more readily than the wild-type protein (C. Desobry and H. Lashuel, 
unpublished results). In addition, the TAT-aSyn protein elutes later on 
a size exclusion column, suggesting a more compact structure, while 
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also being more efficiently internalized than the unfused alpha-
synuclein and the aSyn-TAT fusion. The aSyn-N-TAT fusion also elutes 
slightly later than unmodified alpha-synuclein, showing some level of 
compaction as well (C. Desobry and H. Lashuel, unpublished results). 
 
4b. Methods 
 
The alpha-synuclein TAT fusion proteins were produced 
recombinantly in E. coli as previously described. The proteins were 
lyophilized for storage. The three constructs each contained a cysteine 
residue in the linker between the TAT peptide and alpha-synuclein 
sequence to facilitate labeling. This allowed paramagnetic spin-label 
(MTSL) to be conjugated near to the TAT peptide to investigate the 
intramolecular contacts that the peptide may make to the rest of the 
protein. Lyophilized protein was dissolved in NMR buffer and PRE 
samples prepared and analyzed as described in section II.h. 
 
4c. Results 
 
The overall structural characteristics of the different alpha-
synuclein TAT fusion constructs were assessed using NMR 
spectroscopy. In particular, PRE NMR was used to examine the extent 
of potential intramolecular contacts between the highly positively 
charged TAT peptide and different regions along the polypeptide chain. 
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The diamagnetic spectra for all constructs served as a control and 
were very similar to those previously obtained for wild-type alpha-
synuclein (Figure A4.1). Additional cross-peaks arising from the linker 
residues and TAT peptide were seen, as well some peak shifts near the 
N- or C-terminus of the alpha-synuclein sequence. However, the 
majority of the peaks arising from alpha-synuclein were unchaged in 
any of the three fusion proteins, suggesting that no secondary or 
tertiary structure is induced by the addition of the TAT peptide. 
Comparison of the peak intensities in the paramagnetic and 
diamagnetic spectra showed several regions of decreased intensity, 
indicating paramagnetic relaxation enhancement resulting from 
proximity to the spin-label. 
 
Figure A4.1: HSQC spectra of unmodified alpha-synuclein and TAT 
fusion proteins in aqueous buffer. 1H,15N-HSQC spectra of 
unmodified alpha-synuclein (black), TAT-aSyn (green), aSyn-TAT (red), 
and aSyn-N-TAT (blue) in aqueous buffer. 
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The N-terminally-linked TAT construct (TAT-aSyn) shows 
significant PRE effects that are strongest at the N-terminal (centered 
around residue 7) and C-terminal (centered around residue 125) 
regions (Figure A4.2A). These data indicate that the paramagnetic 
spin-label (located at position -3) interacts favorably with both the N- 
and C-terminal regions of the alpha-synuclein polypeptide. The latter 
interaction is most likely mediated by electrostatic attraction between 
the highly positive TAT peptide and negatively-charged C-terminus of 
alpha-synuclein. Notably, the C- and N-terminal regions of wild-type 
alpha-synuclein have previously been shown to interact with each 
other as well [44]. The current PRE data cannot distinguish between 
direct interactions of the TAT peptide with the N- and C-terminal 
regions of alpha-synuclein and indirect interactions mediated by pre-
existing intrinsic intramolecular interactions of unmodified alpha-
synuclein. Nevertheless, the data clearly show that the conformation of 
the TAT-aSyn peptide is likely to be quite compact (Figure A4.3A). 
     The C-terminally linked TAT constructs were made with two 
different linkers: a shorter one, aSyn-TAT; and a longer one identical 
to the N-terminal linker, aSyn-N-TAT. The aSyn-TAT fusion protein 
shows a strong PRE effect at the C-terminus (centered on residue 125), 
as well as a weaker effect on the N-terminus (Figure A4.2B). The C-
terminal PRE could be a local effect due to the proximity of the spin-
labeled cysteine residue (position 143), but also likely reflects some 
interactions between the positively-charged TAT peptide and 
negatively-charged C-terminal tail of alpha-synuclein. The PRE effect 
on the N-terminal region, on the other hand, is unlikely due to direct  
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Figure A4.2: Intramolecular PRE effect for alpha-synuclein TAT 
fusion proteins from a spin-labeled linker. Plots of the ratio of peak 
intensity for samples paramagnetically labeled in the linker to peak 
intensity in unlabeled samples versus residue number for TAT-aSyn 
(labeled at position -3) (A), aSyn-TAT (labeled at position 143), and 
aSyn-N-TAT (labeled at position 147) (C) in aqueous buffer. 
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interactions between the TAT peptide and the N-terminal region, as 
both are overall positively-charged, and instead reflects these two 
regions indirectly coming into proximity, mediated by the well-known 
N- to C-terminal contacts of unmodified alpha-synuclein (Figure 
A4.3B). 
 
Figure A4.3: Diagrams of likely intramolecular contacts for alpha-
synuclein TAT fusion proteins. (A) TAT-aSyn, (B) aSyn-TAT, (C) aSyn-
N-TAT. Positively- (blue) and negatively-charged (red) side-chains are 
highlighted. The green star represents the spin-label position. 
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The aSyn-N-TAT fusion protein was constructed to be more 
comparable to the TAT-aSyn protein, which is more efficiently 
internalized into cells. This fusion construct shows a significantly 
weaker PRE effect than TAT-aSyn, localized to the C-terminal region 
(centered on residue 130) (Figure A4.2C). It is likely that the highly 
positive TAT peptide again interacts with the negatively-charged C-
terminal tail of alpha-synuclein, but this interaction is now more local 
since these two regions are adjacent. There is no evidence of longer-
range intramolecular contacts of the spin-labeled region as with the 
other constructs, suggesting that this peptide is more extended in 
character than TAT-aSyn and aSyn-TAT (Figure A4.3C). 
 
4d. Conlusions 
 
The TAT-fused alpha-synuclein proteins are quite similar to the 
unmodified protein in adopting a set of disordered conformations with 
transient intramolecularcontacts in aqueous solution. While the N-
terminally fused TAT-aSyn construct appears the most compact by 
SEC-MALS and displays the most intense PRE effects at the N- and C-
termini, indicative of significant contacts between the spin-label near 
the TAT peptide and the rest of the polypeptide chain, these contacts 
seem to be very similar or mediated through those that unmodified 
alpha-synuclein exhibits. This fusion protein also shows the greatest 
cell internalization efficiency (C. Desobry and H. Lashuel, unpublished 
results), suggesting that the contacts made by the TAT peptide to the 
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rest of the protein are not inhibitory. In the case of aSyn-TAT, which 
shows decreased internalization efficiency, the contacts are again 
similar to those seen in unmodified alpha-synuclein, although less 
strong that those seen for TAT-aSyn. When the linker between the 
alpha-synuclein sequence and TAT peptide is extended, in aSyn-N-TAT, 
the intramolecular contacts appear the least intense, suggesting that 
this fusion protein occupies the most extended conformations (Figure 
A4.3). 
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